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Sum m ary
The aim of this project was to develop a method for discovery o f biomarkers or a 
protein pattern, as a signature of breast cancer. Early detection o f breast cancer is 
crucial to increase the survival rates of patients. Little was published about 
biomarker discovery from serum using mass spectrometry, so over the course of  
the project each factor o f the methodology was analysed and optimized. It was 
shown that standardisation of sample preparation and handling is critical for any 
quantitative study. The presence o f albumin and other highly abundant proteins in 
serum interferes with proteomic analysis and so depletion techniques were 
investigated. Centrifugal ultrafiltration was optimised and an extensive study 
showed it to be a robust and efficient method to enrich the LMW proteome for 
subsequent biomarker discovery in serum. SELDI-ToF and MALDI-ToF MS 
were compared for intact protein profiling for breast cancer. In contrast to SELDI- 
ToF, MALDI-ToF MS had been little tested for this purpose and therefore new 
software was developed for peak alignment enabling comparison of multiple 
spectra. LMW serum samples from 8 breast cancer and 8 control individuals were 
analysed in each experiment. Here we detected seven potential markers in total 
and gained initial peptide identifications for three markers. This study also tested 
the use of label-free quantitation using LC-MS on serum samples from breast 
cancer patients; one differentially-expressed peptide was discovered. The lack o f a 
software tool for comparison of the resulting spectra limited the detection of 
further markers. The profiling results showed that the use o f replicates all the way 
from starting with the initial serum sample through to data retrieval is crucial due 
to variation between the biological replicates, and also to reduce any variation 
occurring from sample preparation.
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CHAPTER 1
Introduction to Proteomics of Breast Cancer
1.1 Introduction to Breast Cancer
1.1.1 Staging and Histological Typing of Breast Cancer
Breast cancer is a heterogeneous disease, with a UK incidence rate of  
approximately 40,000 women in 2004 [1] and a mortality rate o f 13,000 women in 
2002 [2]. In its early stages, breast cancer is classified as either ductal carcinoma in 
situ (DCIS), arising from ductal epithelium, or lobular cancer in situ (LCIS), arising 
from the epithelium of the lobules. Due to the increasing use of screening 
mammography, these early, non-invasive cancers are more frequently diagnosed and 
now constitute 15-20% o f all breast cancers [3]. DCIS, thought to be a direct precursor 
of invasive breast cancer, is highly curable by surgical removal. Even invasive cancer, 
that has infiltrated the basement membrane, can still be cured in over 90% of patients 
if  detected at stage I (Figure 1.1). Therefore as in other cancers, early detection of 
breast cancer is vital. However, despite surgical removal of early stage tumours, some 
tumour cells may remain (micrometastases) and the cancer could recur locally or in 
distant organs. To reduce the risk o f recurrence, adjuvant treatment is prescribed for 
the majority o f patients in present clinical practice. To avoid unnecessary treatment 
and to help predict response to adjuvant therapies, markers to assist in decisions on 
further therapy are urgently required.
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Figure 1.1: Average survival rate of breast cancer patients. Survival increases with early 
disease discovery and treatment. Data taken from Corporation Imaginis [3],
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Figure 1.2: Female breast cancer incidence and mortality trends in the UK. The incidence of 
breast cancer cases has increased over the past 20 years however due to better treatment the 
mortality has decreased. Data taken from Cancer Research UK [4].
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Recognised prognostic factors for breast cancer include histological subtype, tumour 
size, grade, lymphovascular invasion and axillary node metastases and these allow 
classification o f the tumour (Table 1.1 and Table 1.2). However within each stage of 
disease there are differences in survival so new and better prognostic indictors are 
needed. The aim of this study was to identify potential prognostic markers in serum in 
metastatic breast cancer patients. These markers may enable earlier detection of 
recurrence o f breast cancer disease or define patients at high risk o f metastases.
Table 1.1: TNM Classification o f breast cancer, according to the National Cancer Institute [5].
T - Primary Tumour
TX Primary tumour cannot be a ss e s se d
TO No evidence of primary tumour
Tis Non-infiltrating intraductal carcinoma
Tis (DCIS) Ductal carcinoma in situ
Tis (LCIS) Lobular carcinoma in situ
Tis (Paget's) Paget's d isea se  of the nipple with no tumour.
T 1 Tumour ^ .0  cm in greatest dimension
T2 Tumour >2.0 cm but ^>.0 cm in greatest dimension
T3 Tumour >5.0 cm in greatest dimension
T4 Tumour of any size  with direct extension to chest wall or skin
N - Regional lymph nodes
NX Regional lymph nodes cannot be a ss e s se d  (e.g., previously removed)
NO No regional lymph node m etastasis
N1 M etastasis to movable ipsilateral axillary lymph node(s)
N2 M etastasis to fixed ipsilateral axillary lymph node(s)
N3 M etastasis in ipsilateral internal mammary lymph node(s)
pN - Pathologic classification
pNX Regional lymph nodes cannot be a ss e s se d  (e.g., not removed for pathologic study or previously removed)
pNO No regional lymph node m etastasis histologically
pN1 M etastasis in 1 to 3 axillary lymph nodes, and/or in internal mammary nodes
pN2 M etastasis in 4  to 9 axillary lymph nodes, or internal mammary lymph nodes
pN3 M etastasis in ^ 0  axillary lymph nodes
M - Distant metastasis
MX P resence of distant m etastasis cannot be a ss e s se d
MO No distant m etastasis
M1 Distant m etastasis
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Table 1.2: Breast cancer stage grouping, according to the National Cancer Institute [5],
S ta g e  G rou p in gs
Stage 0 Tis NO MO
Stage 1 T 1 NO MO
Stage 2a T0-T1 N1 MO
T2 NO MO
Stage 2 b T2 N1 MO
T3 NO MO
Stage 3a T0-T2 N2 MO
T3 N1-N2 MO
Stage 3b T4 Any N MO
Stage 3c Any T N3 MO
Stage 4 Any T Any N M1
Table 1.3: World Health Organization Classification o f Carcinoma of the Breast [6]
____________Pathological classifications_________
Noninvasive carcinoma
Ductal carcinoma in situ  
Lobular carcinoma in situ 
Invasive carcinoma 
Invasive ductal carcinoma 
Invasive lobular carcinoma 
Mucinous carcinoma 
Medullary carcinom a 
Papillary carcinoma 
Tubular carcinoma 
Adenoid cystic carcinoma 
Secretory (juvenile) carcinoma 
Apocrine carcinoma
Carcinoma with metaplasia (metaplastic carcinoma) 
Inflammatory carcinoma 
Other (specify)
Paget's disease of the nipple
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1.1.2 Diagnosis and Management
To date, the most commonly used technology for early diagnosis of breast cancer is 
mammography. Although tumours detected by screening are significantly smaller than 
those presenting clinically, specificity and sensitivity of the method can be improved. 
Mammography fails to identify about 10% of cases and also gives a certain number of 
false positive diagnosis [7]. Other imaging techniques (e.g. ultrasound and MRI) have 
been developed to detect small tumour masses; however, the techniques still suffers 
from the lack o f sensitivity to detect small numbers of cells. Therefore a large amount 
of research has focused on looking for biomarkers to detect disease in tissue and in 
serum. A biomarker may be a specific physical trait used to measure or indicate the 
effects or progress o f a disease, illness, or condition [8]. However, the major role of 
current blood markers has been the diagnosis and monitoring of metastatic disease, 
where elevation of established blood tumour markers is correlated with the extent of 
the metastatic breast cancer. In fact, tumour marker measurements are now used, if  not 
routinely, as a complementary test in the diagnosis o f symptomatic metastases [9]. To 
advance early diagnosis and treatment o f breast cancer, more reliable markers need to 
be found.
1.1.3 Tumour Markers of Breast Cancer
A large number o f tumour markers have been proposed over the years for breast 
cancer, some o f which are described below. However, to date, these markers have 
only been used for detection of metastatic disease and/or assessment o f treatment 
response, and have shown little utility for diagnostic purposes.
The most widely-used clinical tumour markers are serum levels o f MUC-1 family of 
mucin glycoproteins (e.g. CA15.3, CA27.29) and onco-foetal proteins such as 
carcinoembryonic antigen (CEA). The clinical data on the current use o f markers is 
controversial, with some studies showing a correlation o f CA15.3 levels in serum with 
disease progression, as high levels of CA15.3 occur in stage IV disease with ~90% 
specificity [10-14]. In combination, CEA, c-erb-2 and CA15.3 have shown a 
sensitivity o f 88% in patients with recurrence o f breast cancer [15]. However, the
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American Society o f Clinical Oncology, as well as the European Group on Tumour 
Markers, chose a cautious policy and state that present data regarding both CA15.3 
and CEA are insufficient to recommend their routine use in the diagnosis o f recurrent 
breast cancer follow-up [16, 17]. Therefore, at present, in the absence o f any 
established alternative, further evaluation o f these markers and new ones is required, 
to provide a much-needed clinical tool to assess response to metastatic cancer therapy.
The growth factor encoding gene, c-erb-2/HER2/«ew, is overexpressed in 20-30% of 
breast cancer patients [18-20] and elevated protein levels have been found in the 
serum of 29% of patients diagnosed with breast carcinoma [15]. The extracellular 
domain o f HER-2/neu is shed from breast cancer cells into the circulation and 
measurable by immunoassay. Serum HER-2/neu receptor protein levels have 
successfully predicted the presence and progression of HER-2/neu -positive breast 
cancer. Collected published studies revealed that more than 80% of patients showed a 
significant correlation between serum HER-2/wew-protein levels and either disease 
recurrence, metastasis, shortened survival or predicting response to chemotherapy and 
hormone therapy [17, 21-24].
Detection of specific antibodies against cancer cells might allow very early detection 
of tumours, before any markers have been released by the tumour, in the same way we 
can diagnose infectious disease based on the humoral immune response at early 
stages. Auto-immunity against cancer proteins, such as p53, heatshock protein 90, c- 
erb-2/HER2/«ew, and mucin-related antigens has been used for detection and 
monitoring of breast cancer [22, 25, 26]. The presence o f p53 has been found in 15% 
of breast cancer patients and is associated with poor prognosis [27]. However, these 
techniques are still being evaluated clinically.
One o f the emerging techniques to improve biomarker detection is proteomics. 
Proteomics is the analysis o f the proteome: all proteins in an organism, tissue or body 
fluid expressed at the time o f interest. The proteome may differ between two samples 
depending on the disease state (e.g. cancer or non-cancer) and this difference may 
give information on what proteins are involved or influenced by tumour formation or 
progression. Proteomics is therefore a critical technique in finding new markers to 
detect tumours in breast cancer.
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1.1.4 The Breast Cancer Proteome
Despite numerous efforts to find a marker to diagnose breast cancer, similar to 
prostate specific antigen (PSA) for prostate cancer, no such protein has been found. 
Hence, it could be hypothesised that the reason for not finding a single reliable 
biomarker, or pattern to detect early breast cancer so far, is due to the heterogeneity of 
the disease. The mammary gland is a cellular ecosystem in which each cell type is 
constantly proliferating and differentiating (Figure 1.3), particularly epithelial cells, 
due to hormonal and growth factor influences [28]. Consequently, most breast cancers 
are carcinomas (malignant epithelial tumours). Furthermore, numerous different 
classifications of breast cancer in the epithelium are found depending on their origin 
and histology. These can be divided into two classes; in situ carcinomas of either 
ducal or lobular origin, which do not invade through the basement membrane; and 
invasive carcinomas, where the basement membrane is damaged or destroyed 
permitting cancer cells to invade surrounding tissue, leading to metastasis [29]. 
Invasive carcinomas are further classified according to the differences in their 
histological appearances. In addition, other cells/tissues, such as blood cells, blood 
vessels and fibroblasts, are usually found within a tumour and cause even greater 
cellular heterogeneity. This makes proteomic analysis o f biopsies very problematic. 
Furthermore, local inflammation (common in breast cancers) and hormonal influences 
cause a constantly developing environment and make serological proteomics 
additionally challenging. It is important to realise that the blood proteome is 
constantly changing as a consequence o f the pathophysiology o f the system, 
subtracting from or modifying the circulating proteome. These disease-related 
differences might be the result of proteins being over-expressed and/or abnormally 
shed and added to the serum proteome. They may also arise from a specific process of 
protein clipping, degradation and/or proteolysis as a consequence o f the disease 
process itself, or may be removed from the proteome due to abnormal proteolytic 
degradation pathway activation [30].
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Figure 1.3: Breast cancer cells are constantly subjected to cellular interactions through 
hormones and growth factors. A + indicates a stimulation and a -  inhibition of breast cancer 
cell growth.
1.1.5 Biomarker Discovery in the Literature
There are two ultim ate goals for proteom ic analysis o f  breast cancer: to identify new 
m arker candidates for diagnosis and profiling disease, and to gain a greater 
understanding o f  the m echanism  o f  cancer and the signalling pathw ays that initiate 
and lead to progression o f  breast tum ours [28]. Surveying the entire proteom e o f  a 
sam ple rather than searching for a specific protein m ay provide a greater chance o f  
identifying m arkers or a diagnostic pattern. The core o f  proteom ics involves the 
com parison o f  two clin ically /b iologically  different sam ples (e.g. cancer vs. non 
cancer), in the case o f  breast cancer this could be tissue, cells or body fluids such as 
plasm a, serum  or n ipple aspirate.
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The first reported study of proteomics appears to have been conducted in 1974 [31] 
comparing clinical samples using 2-dimensional polyacrylamide gel electrophoresis 
(2D-PAGE) from serum, although, no proteins were identified. Mass spectrometry 
was not used for proteomic studies until 1993, where down-regulation of tropomyosin 
1, 2 and 3 in mammary carcinomas was linked to breast neoplasia [32, 33]. Wulfkuhle 
J [34] identified 57 differentially expressed proteins between normal ductal/lobular 
units compared to ductal carcinoma tissue samples, using 2D-PAGE. Even though all 
markers were confirmed by immunohistochemistry in tissue samples, the technique 
lacks reproducibility due to lack of standardisation and the heterogeneity o f the 
biological material. Hence, the data are not yet clinically relevant for diagnosis, 
treatment choice or prognosis. More recent examples of the use of 2D-PAGE include 
a study by Luo [35] where 25 proteins were found to be differentially expressed 
comparing infiltration ductal carcinoma tissue with normal breast tissue. Most 
biomarkers are quantitative and no protein has yet been found to be exclusively 
present or absent in breast cancer versus non-cancer tissue. Nevertheless one example 
where breast cancer proteomics has already identified a potential marker, is the 
molecular chaperone 14-3-3 sigma [36-39]. Using 2D-PAGE and matrix assisted laser 
desorption/ionization time-of-flight (MALDI-ToF) MS, 14-3-3 sigma was shown to 
be down-regulated in primary breast carcinomas and MCF-7 and MDA-MB-231 cell 
lines [39]. This has been confirmed by mRNA studies as an early event in breast 
cancer carcinogenesis [40]. There is also evidence that a loss o f 14-3-3 sigma 
expression through epigenetic silencing or p53 mutations may lead to cancer 
formation. Thus 14-3-3 sigma may have more than one role in cancer formation [41]. 
However a more recent study, looking at the levels o f expression o f 14-3-3 sigma in 
primary breast tumours, using a proteomic approach complemented by IHC analysis 
showed that the loss o f 14-3-3 sigma protein is not a frequent event in breast cancer 
[42], To address the problem of heterogeneity o f cells in the tumour, laser capture 
microdissection (LCM) has been used [43-46], although the technique requires a 
minimum of 100,000 cells for 2D-PAGE [43]. Also the decision on what is considered 
normal breast tissue in the constantly proliferating environment can be challenging. 
Thus, many studies have used cell culture as a starting point to create a homogeneous 
and controlled cellular environment, to identify biomarkers that are later sought in 
tissue biopsies. Westley [47] identified a 46 kDa glycoprotein, secreted from breast 
cancer cells when induced by oestrogen, as the protease cathepsin D. Later it was
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found that norm al and cancerous epithelial cells produce different subgroups o f  
keratin [48-50]. Furtherm ore, from cell culture two new breast cancer prognosis 
m arkers were found to be proteinase inhibitors TIMP1 and PAI-1 [51].
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Figure 1.4: The declining rate o f introduction o f new protein tests data taken from Anderson 
and Anderson [52]
The rate at which new biom arkers have been discovered has declined dram atically  
over the last 10 years (Figure 1.4). Petricoin has described this by saying “The low 
hanging fruit have all been picked.” M ost o f  the estim ated 10,000 serum  proteins have 
not yet been detected by proteom ic analysis, so finding a single b iom arker for breast 
cancer is like searching for a needle in a haystack. Despite the num erous efforts to 
find m arkers for disease in serum  [53-56], to date only potential serum  biom arkers 
have been reported. It is even possible that a single inform ative b iom arker to diagnose 
breast cancer does not exist but we ought to be looking for protein patterns [57]. This 
m ay be due to the fact that cancer is not an infectious disease, hence not a result o f  a 
foreign body entering the blood stream  [58]. It m ay be m ore likely that cancer 
produces a pattern o f  changes, as a consequence o f  abnorm al cellu lar m echanism s and 
the way by which the rest o f  the body reacts to change. Thus, even if  the specific
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protein pattern comprises products that are distant to the actual disease, they can retain 
specificity for the disease because this process can arise from a specific type of 
biomarker amplification. Importantly, recent findings indicate that the tumour-host 
microenvironment can generate cascades o f enzymatic cleavage, shedding and sharing 
of growth factors. This interface could therefore be a source o f low molecular weight 
biomarkers that are ultimately shed and amplified into the serum macro environment to 
bind with carrier proteins, enabling early disease detection and risk, severity and 
response assessment [57].
Recently surface-enhanced laser desorption/ionisation time-of-flight (SELDI-ToF) 
MS analysis has become a popular tool for protein pattern profiling: here the 
identification of the biomarker is secondary if  a protein pattern can be used for cancer 
diagnosis. This technology was especially designed for biomarker discovery and 
possesses high sensitivity. The literature lists many examples o f SELDI-ToF MS 
application in breast cancer [59-63], In a study analysing 169 serum samples o f stage 
O-III breast cancer, healthy volunteers and benign breast cancer, SELDI-ToF analysis 
was able to identify 3 biomarkers (molecular weight: 4.3 kDa, 8.1 kDa and 8.9 kDa) 
[62]. These proteins could successfully distinguish between stage 0-1 breast cancer 
from control sera and could again be used to identify stage II-III cancers. The 
biomarkers had an overall sensitivity o f 85% for breast cancer with a specificity of 
91%. Used in combination the sensitivity was increased to 93% and a specificity o f 
91%. Because o f the multifactorial nature o f breast cancer a combination of 
biomarkers may be beneficial. More recently two o f these three biomarkers were 
validated in a completely independent study [64].
In a different study, using MALDI-ToF MS for identification o f cell membrane 
proteins associated with breast cancer, three novel potential biomarkers (named breast 
cancer membrane protein BCMP11, BCMP84, and BCMP101) were discovered in the 
cell membrane [65]. With thorough validation, these could become diagnostic or used 
in cancer therapy through their membrane receptors. Similarly, candidate markers 
were discovered by 2D-PAGE in laser capture microscope cells from ER-negative, 
HER2/neu-positive tumour cells, which could be the driving force o f more aggressive 
tumour proliferation [44, 46]. One o f these, cytokeratin-19, a marker that has been use 
in immunohistochemistry in the past, has been found to be overexpressed in HER- 
2Ineu positive tumours along with a number of other candidate proteins. This may be
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an important finding to bring proteomics closer to finding markers that could become 
candidates in clinical settings.
1.2 Introduction to Serum Proteomics
1.2.1 Serum Proteins
Serum is a very complex mixture o f proteins, and serum proteins from cancer patients 
may reflect the pathological state o f the tumour as well as the body’s response, and 
therefore provide earlier detection on top of staging o f cancer [52, 6 6 ]. Blood serum 
hosts most major categories o f protein which have been shed from many organs into 
the blood stream, including extracellular and cellular proteins. It has even been 
proposed to contain all human proteins, as well as proteins from other organisms such 
as bacteria, viruses or fungi [67]. The dynamic range of proteins in serum or plasma is 
believed to be one of the greatest o f any biological system (Figure 1.5), ranging from 
< pg/ml level such as prostate-specific antigen, to high abundance proteins such as
albumin or immunoglobulins in the > mg/ml levels [6 8 ]. There also appears to be a
correlation between protein abundance and their biological classification or source 
(Figure 1.5). Sample handling and preparation is critical for proteome research. A 
plasma sample is prepared when blood is drawn in the presence o f anticoagulants 
(EDTA, sodium citrate of heparin) and the red blood cells are removed by 
centrifugation. A serum sample on the other hand is obtained in the absence of 
anticoagulants and the blood is left to clot before centrifugation and removal o f the red 
blood cells. The composition of serum and plasma greatly differs and the debate on 
whether to use serum or plasma for proteomics analysis is ongoing [69].
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Figure 1.5: Reference intervals for 70 protein analytes in plasma. Abundance is plotted on a 
log scale spanning 12 orders of magnitude. Where only an upper limit is quoted, the lower end 
of the interval line shows an arrowhead. The classical plasma proteins are clustered to the left 
(high abundance), the tissue leakage markers (e.g. enzymes and troponins) are clustered in the 
centre, and cytokines are clustered to the right (low abundance). Haemoglobin is included (far 
left) for comparison [52].
1.2.2 Serum Complexity
Serum protein concentration ranges around 60-80 m g/m l, how ever 90%  o f  the content 
is m ade up o f  only 10 proteins [70] (Figure 1.6). H um an serum  album in accounts for 
alm ost 50%  o f  the whole serum  proteom e, o f  the rem aining 10%, further 12 high 
abundance proteins m ake up for 9%, o f  w hich m ost are well characterised (Figure 
1.6). The final 1% o f  the serum  proteom e is com posed o f  proteins that m ay be o f  
clinical or biological interest (Figure 1.7). U nfortunately, the dynam ic range o f  protein 
abundance in serum  leaves com plete characterisation o f  this proteom e nearly 
im possible w ith current analytical m ethods. The high abundance proteins such as 
hum an serum  album in im m unoglobulin G, antitrypsin, IgA, transferrin, and 
haptoglobin [71] m ask the detection o f  the rem aining proteom e during 2D -PA G E and 
m ass spectrom etry. This is a particular problem  because low abundance proteins and
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peptides m ay have higher accuracy than traditional biom arkers for cancer detection 
[72],
Instead the proteom e has to be broken down and analysed in sm aller bits to recover a 
m axim um  num ber o f  proteins, w ith particular focus on the poorly characterised low 
abundance proteins. Serum  and its com ponent low abundance proteins therefore have 
an im m ense diagnostic potential.
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Figure 1.6: Pie chart representing the relative contribution of proteins within serum. Twenty- 
two proteins constitute 99% of the protein content of serum [58].
Chapter I: Introduction to Proteomics and Breast Cancer 15
Hypothetical protein*
Structural protein*, 
nuclear proteins, 
transcription factors, 
oncogene products, etc.
Ckasutels, Receptors, \  
Binding Proteins
Circulating proteins
Coagulation <& 
complement factors
I ransport and
binding prutrins
Protease Inhibitors 
Protcases
Cytokines, Growth Factors, 
Hormones
Figure 1.7: Pie chart representing the relative numbers of proteins identified within the LMW 
serum proteome [58],
1.2.3 Depletion of High Abundance Proteins
Solid phase extraction colum ns are w idely used for depletion o f  high abundance 
proteins from serum and plasm a. A num ber o f  different types o f  colum n are available, 
including, but not lim ited to, those based on ion-exchange, affinity  ligands, dye- 
ligands or antibodies. M any o f  these are com m ercially  available in form  o f  colum ns o f  
cartridges, m icrocolum ns, 96-w ell plates and spin colum ns. B iological affinity 
separation based on antibodies or proteins is m ore specific, for exam ple bacterial 
protein A and G have been show n to be successful at depleting IgGs from serum  [68], 
U sing m ulti-affinity colum ns, w ith polyclonal antibodies for the 6 or 12 m ost com m on 
proteins in serum , has been used to deplete 70-95%  o f  total serum  proteins from 
serum  [73-75]. Rem oval o f  album in and protein G alone depletes only 70%  o f  the 
total serum proteins, how ever only recently  m ulti-affinity  colum ns have becom e 
available. Even the use o f  the M ARS colum ns from Agilent Technology has shown 
that after depleting the six m ost com m on serum  proteins, the next m ost abundant ones 
becom e a problem  and therefore highly selective colum ns depleting even m ore 
proteins are desirable. The S epp ro1M spin colum ns are packed with 12 IgY antibodies 
coupled to m icrobeads [76]. High reproducibility  and m aintenance o f  the separation 
capacity has been observes. O ver tim e these form s o f  depletion should im prove 
protein identification and quantitation in serum.
Chapter 1: Introduction to Proteomics and Breast Cancer 16
1.2.4 The Low Molecular Weight (LMW) Proteome
As an alternative to affinity depletion, molecular weight cut-off (MWCO) centrifugal 
filters have also been used to remove high molecular weight proteins, such as albumin 
and Igs. The MWCO filters are used to separate the high and low molecular weight 
proteins by centrifugation. The use o f denaturing acetonitrile (ACN) enables the 
release o f proteins/peptides bound to larger proteins. Centrifugal ultrafiltration has 
been performed using a number o f different MWCO filter sizes (10 - 50 kDa) and 
centrifugation speeds for 1000 -  12000 xg (Table 1.4). The technique has been 
demonstrated in a number o f studies [30, 58, 77-80]. From the LMW fraction, 
Tirumalai et al. [58] identified 341 human serum proteins including a very low 
abundance protein, vasoconstrictor peptide endothelin-1 , and remarkably no peptides 
originating from human serum albumin were identified. It is worth noting that ultra­
filtration does not exclude all high molecular weight species from later analysis, 
peptides from proteins larger than the cut-off mass may also be identified. This may 
be for three reasons: one the filter has been ruptured and the filtration was 
unsuccessful, secondly due to its elliptical shape, a protein managed to slip through 
the filter or lastly the peptide is from a proteolytic fragment naturally occurring in 
serum [79].
Fractionation of the LMW fraction with ion-exchange-LC before subsequent RPLC- 
MS/MS has been used to successfully reduce the complexity o f the resulting fraction 
and increase the number o f protein identifications [58]. Harper et al. [81] used RPLC- 
MS/MS alone on the LMW fraction and identified 262 proteins from serum, including 
cytokines and other circulatory proteins. Proteins with higher masses than the cut-off 
filter were detected; however 75% of the identified proteins fell within the range of  
below 50 kDa.
In a similar way to albumin depletion, LMW ultrafiltration can also lead to the 
removal o f bound proteins and peptides, since many LMW species are covalently 
bound to carrier proteins such as albumin and therefore may be found within the high 
molecular mass fraction o f the serum proteome. In a paper, Zhou et al. [82] identified 
63 proteins associated with albumin alone, and altogether 210 proteins, mapped from 
378 peptides, were bound to the six most abundant proteins in serum. Only 6 % of 
these identified proteins have previously been studied as biomarkers, the remainder 
may still have potential. Depletion of albumin and IgGs could result in loss o f these
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proteins. To get around this problem, a number of different denaturing conditions, to 
disrupt protein-protein interactions, have been used prior to centrifugal ultra-filtration 
(Table 1.4). Tirumalai et a l  [58] showed that under the right denaturing conditions, 
protein-protein interactions between carrier proteins, such as albumin, and their cargo 
could be disrupted thus enabling greater enrichment. Denaturing o f the protein-ligand 
bonds with 25mM NH4 HCO3 and acetonitrile (ACN) buffer enriches the sample with 
proteins and peptides formerly bound to carrier proteins such as albumin. Acetonitrile 
is crucial in the LMW enrichment [58]. The importance o f ACN in protein separation 
was further shown by a proof o f principle study precipitating HMW proteins with 
ACN to gain access to the LMW proteins before centrifugal ultra-filtration [83].
Table 1.4: Centrifugal ultrafiltration in the literature for high molecular weight protein 
depletion. Denaturing conditions and use of MWCO filters varies in different studies. The 
dilution factor, type of denaturing buffer, centrifugation speed and time, filter type and pre- 
and post-procession are shown.
Reference Dilition
(v/v)
Denaturant Before filtration Ultra-filtration
(xg)
Time Filter type After filtration
Morris 2004 3:2 20% ACN heat for 15m in @ 40C; 
centrifuge; condition filters 
with 0.1 M NaOH
2000 90 min Microcon
Tirumalai 2003 1:5 25mM NH4HC03, 
20%ACN, pH 8.2
3000 until 90% 
passed
Centricon 2DLC-MS/MS 
30kDa
Johnson 2004 1:4 25mM NH4HC03, vortex 
20%ACN, pH 7.6
12,000 20min Microcon
10kDa
Zhou 2004 
Yeo 2004
1:3
1:1
H 20
saline solution
Albumin depletion, elute 
HSA 0.2% v/v FA + ACN 
1:1, boil for 10min, dilute 
1:2
1000 Centricon
30kDa
Centricon
50kDa
Kaiser 2004 1:50 4M urea, o.1M 
NaCI, 0.0125% 
ammonia
3000 until 4/5 
passed
Centricon C2 cartridge, 
30kDa 50%ACN, 
0.5%FA
Harper 2004 3:2 20% ACN heat for 15min @ 40C; 
centrifuge; condition filters 
with 0.1M NaOH
2000 90 min Microcon
50kDa
20p of 88% Formic acid, 2pL of 
5pmol/pL mellitin, and 2pL of
Merrell 2004 
Mehta 2003
1:2 100% ACN 
50% ACN
vortex 5 sec,stand at RT 
for 30 min
30ul serum sepadex G25 
or G50 mol sieve column 
for 3m in a t 3000xg
12,000
1000
10min 5pmol/pL Glu-fibto lyophilized 
sam ples. Brought to 40pL with 
H20.
Microcon
30kDa
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Enrichment of LMW species by releasing them from their molecular carriers is 
furthermore important for protein recovery from a physiologic perspective, as free 
phase LMW molecules should be rapidly cleared through the kidney, and this may 
significantly reduce the concentration o f free-phase low molecular mass biomarkers to 
a level below detection. The abundant high molecular mass carrier proteins (such as 
albumin) exist above the cut-off for kidney clearance, and hence possess a half-life 
that is many orders o f magnitude greater than small molecules [30]. Analysis o f the 
LMW proteome may provide extra information that is not available from crude serum.
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1.3 Introduction to Chromatography
To isolate proteins for analysis, samples from any source have to be fractionated. 
Optimally the separation should be so efficient that each fraction contains only one 
protein, which would make identification by mass spectrometry very simple, however 
in practice, complex mixtures are difficult to separate and fractions can contain many 
hundreds o f proteins. Polyacrylamide gel electrophoresis was the first method for 
protein separation, several thousands o f proteins could potentially be separated [84]. 
However this method has limitations, and more recently HPLC has been optimized for 
more high-throughput separation o f proteins. The use o f different chromatography 
columns allows a greater range o f protein coverage, although not necessarily in one 
step. Both techniques are discussed in more detail below.
1.3.1 2D Gel Electrophoresis
In 1930, Tiselius [85] introduced the moving boundary method for electrophoresis of  
proteins. Since his pioneering work, various forms o f electrophoresis have been used 
for the separation of protein mixtures. The steady increase in resolution can be 
accredited to the introduction o f acrylamide gels, stacking systems, isoelectric 
focusing (IEF) and a variety of 2D gel electrophoretic separations [8 6 ]. The uses of 
ID sodium dodecyl sulphate (SDS) and subsequent 2D-PAGE have made it possible 
to compare the proteome o f two complex mixtures in a single separation step (Figure 
1.8). Intact proteins are separated first along a pH gradient according to their 
isoelectric point by IEF. Then the IEF strip is laid on top o f a SDS gel where the 
proteins are separated by molecular mass through electrophoresis. Next the gel is 
stained to visualise the proteins for quantitation, before they are excised for 
identification. The excised gel spots are digested with trypsin and the resulting 
peptides analysed by MS for identification from the database.
However there are limitations to the utility o f gel electrophoresis, it has been shown 
that 2D-PAGE does not separate all proteins: acidic, basic, very large or small 
proteins are not separated well by 2D-PAGE. Furthermore, although 2D-PAGE is able
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to resolve thousands o f  proteins, Gygi et al. [87] showed that only the m ost abundant 
proteins are v isualised by staining and can be identified by MS. H ence 2D -PA G E is a 
useful tool for identification o f  less com plex sam ples and tissue [88], but its use is 
problem atic in serum  analysis. Not only do all proteins not separate and stain in the 
gel, but serum  is so com plex that m any proteins m igrate to the sam e spot and are hard 
to identify. P re-fractionation o f  the sam ple before loading it onto the gel can be 
em ployed to im prove resolution, for exam ple C hem okalskaya et al. [89] used 
centrifugal ultrafiltration for a m ore thorough proteom e analysis o f  different m olecular 
w eight fractions prior to 2D -PA G E separation. This w ay the group identified m ore 
than 340 serum proteins.
Spot
excision
=> M SM S
Isoelectric focusing SDS PAGE
Figure 1.8: 2D Polyacrylamide Gel Electrophoresis (PAGE). Proteins are separated according 
to their pH by IEF and then in the second dimension depending on their molecular weight by 
gel electrophoresis. Protein spots are then visualized for comparison with Coomassie Blue or 
silver staining.
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Figure 1.9: 2D-PAGE: Individual proteins separate isoelectrically along a pH gradient across 
the top of the gel and then dependent on their molecular weight vertically through the gel. 
Two gels can be compared for expression levels and spots identified by mass spectrometry.
1.3.2 High Performance Liquid Chromatography (HPLC)
M ultidim ensional high perform ance liquid chrom atography (H PLC ) separation can 
provide higher resolution and greater separation pow er than 2D -PA G E. HPLC 
fractionation can be perform ed on proteins and peptides (as well as o ther m olecules), 
to achieve separation due to their chem ical properties such as charge, polarity, size or 
certain affinities. The analytical colum n is packed with a stationary phase that binds 
the protein/peptide after injection. W hen the sam ple is loaded, the equilibrium  is 
towards binding to the stationary phase. The m obile phase, a solvent or buffer that 
increases in concentration (salt, organic solvent or pH buffer), slow ly shifts the 
equilibrium  away from binding to the stationary phase and the m olecules start to m ove 
into the m obile phase than bind to the colum n. Over time, different m olecules are 
pulled o ff  the colum n and collected in separate fractions, therefore separating them 
out. D uring 2D-LC separation, the eluted fractions are either collected and 
individually (offline) loaded on a second colum n or directly injected (online) onto 
another colum n as they elute from the first. To identify the proteins or peptides in the
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fractions, they can then be analysed by MS. A commonly used form of multi­
dimensional HPLC-MS is to use an ion-exchange column, a strong cation exchange 
(SCX) for peptides or weak anion exchange (WAX) for proteins, as a first step and 
then to separate the peptides/proteins further on a reverse phase (RP) column. Intact 
proteins may also be enzymatically digested before loading the second column.
In the analysis o f peptides, trypsin digestion is a critical step. Prior to trypsin 
digestion, solubilisation and alkylation steps have been described as crucial to ensure 
good recovery o f peptides [90-92]. Additionally, Qian et al. [93] described that 
alkylation o f proteins may provide better coverage o f cysteine-containing peptides and 
hence an increase in protein identifications.
For peptide mass fingerprinting, trypsin is the most widely used digestion enzyme, 
however other enzymes (e.g. chymotrypsin or Endo Arg N) or chemicals (e.g. 
cyanogens bromide) have been used [94]. Protein identifications can be maximised 
through offline pre-fractionation of the serum sample by size, polarity or charge prior 
to digestion to reduce the complexity. It is important to digest and analyse the 
fractions separately. However 2D-LC fractionation o f peptides online has also been 
used as well as multidimensional peptide identification technology (MudPit) 
separation [95, 96]. Washburn et a l  (2001) detected and identified a total o f 1,484 
proteins in the yeast proteome using a MudPit column, where SCX and RP LC 
separation are performed on the same column (Figure 1.10). Nevertheless offline 
separation of proteins followed by digestion o f the fractions before additional RP 
separation appears to be more useful, as the complexity of the sample is reduced 
before enzymatic digestion.
Chromatographic columns are commercially available but to reduce costs and for 
more customized applications can be packed by hand using a high pressure pump. The 
use o f pulled-tip columns as a part of the electrospray source allows direct spray into 
the mass spectrometer (Figure 1.10).
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Figure 1.10: Multi-dimensional protein identification technology (MudPIT). Ion-exchange 
and reverse-phase chromatography is performed on the same column. Peptides are separated 
in two dimensions before MS analysis. Picture taken from [96],
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1.4 Introduction to Mass Spectrometry (MS)
After sufficient separation, the molecules can be identified, quantitated or their 
structure and chemical composition elucidated by mass spectrometry. This powerful 
analytical technique can detect compounds at minute quantities (as little as 1 0 ' 12 g or
10' 15 moles for a compound of 1000 Dalton (Da) mass). This means that compounds
1 0can be identified at very low concentrations (one part in 1 0  ) in chemically complex 
mixtures, which is important for identification of low abundance proteins.
The technique of mass spectrometry had its beginnings in J .J. Thomson's vacuum tube 
where, in 1897, he demonstrated the existence of electrons and "positive rays" [84]. In 
his 1906 Nobel Prize-winning experiment, he discovered the electron and determined 
its mass-to-charge (m/z) ratio. However, the primary application o f mass spectrometry 
remained in the realm of physics for nearly thirty years. Today, for molecule analysis 
after separation, a HPLC instrument can be coupled to the MS, so that ions are 
directly sprayed into the source.. This was first established in 1974 by P.J. Arpino 
[97]. Alternatively the fractionated proteins/peptides can be spotted on a solid plate or 
chip for analysis by MALDI-ToF MS or SELDI-ToF MS.
The mass spectrometer is an instrument that measures the masses of individual 
molecules that have been converted into ions, i.e., molecules that have been ionized. 
The molecular weight of an ion is not measured directly, but rather the mass-to-charge 
ratio (m/z) o f the ions formed. The charge on an ion is denoted by z, and m/z therefore 
represents Da per unit of charge. In many cases, the ions encountered in mass 
spectrometry have just one charge (z = 1 ) so the m/z value is numerically equal to the 
molecular (ionic) mass in Da, as generally for MALDI-ToF MS.
For peptide identification the ion can be further fragmented in a second mass analyser 
using collision induced dissociation or a second ToF tube (Figure 1.11). The m/z ratio 
of the fragment ions represents fragments that have lost one or several residues. For 
MALDI-ToF MS, a ToF/ToF consists o f two successive ToF accelerations. The first 
acceleration selects, isolates, and fragments (usually by collision with a neutral gas) a 
precursor ion o f interest. The second acceleration reaccelerates the precursor ion and 
fragments, then measures the masses and intensities o f the fragment ions.
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Figure 1.11: Tandem mass spectrometry. The first MS selects the precursor ions for 
fragmentation in the collision cell and the second MS then produces the mass spectrum of the 
fragment ions; diagram taken from ASMS website [98].
During tandem  MS the peptide is fragm ented into ions, that have lost one or several 
amino acids. The types o f  fragm ent ions observed in an M S/M S spectrum  depend on 
m any factors including prim ary sequence, the am ount o f  internal energy, how  the 
energy was introduced, charge state, and the type o f  MS instrum ent used. An ESI-M S 
using collision-induced dissociation for exam ple produces m ainly b and y  ions, as it is 
uses low energy for fragm entation [99].
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Figure 1.12: Main fragmentation path of peptides in CID/MS/MS. (Diagram was taken from 
Matrix Science website http://www.matrixscience.com/help/fragmentation_help.html)
Fragm ents w ill only be detected i f  they carry at least one charge. If  this charge is 
retained on the N term inal fragm ent, the ion is classed as either a, b or c. I f  the charge 
is retained on the C term inal, the ion type is either x, y  or z. The subscript indicates the 
num ber o f  am ino acids in the fragm ent (Figure 1.12).
In addition to the proton(s) carrying the charge, c ions a n d y  ions abstract an additional 
proton from the precursor peptide. The structures o f  the six singly charged fragm ent 
ions produced through cleavage in the peptide chain are show n in Figure 1.13. The 
m ass difference betw een the consecutive ions with in a M S/M S spectrum  is used to 
determ ine the peptide sequence o f  the precursor ion.
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Figure 1.13: Sequence ions produced by fragmentation using a mass analyser. The structures 
include a single charge carrying a proton. (Diagram was taken from MatrixScience website 
http://www.matrixscience.com/help/fragmentation_help.html.)
For protein identification, the fragment ion pattern obtained from MS/MS can be 
compared to the sequence predicted for all the proteins contained in a database. In 
May 2007 the human UniProt database contained 468,000 protein sequences; the 
databases are constantly updated by the European Bioinformatics Institute (EBI) for 
redundancy and protein annotations [100]. Several algorithms have been developed 
for interpretation of MS/MS spectra from peptides [84]. For the work in this thesis, the 
Sequest algorithm was exclusively used to compare the observed masses with those 
expected from a known sequence in the database [101]. Sequest uses a unique 
approach to correlate the fragmentation spectrum to the peptide sequence contained in 
the database. The database is searched for peptides with the same mass as the 
precursor ion in the MS/MS spectrum. Then the observed fragmentation spectrum is 
compared to the predicted spectrum in the database and a similarity score is 
calculated. The peptides identified from the same protein are combined to predict a 
protein and provide a protein probability score. The more peptides from one protein 
are identified, the more confidence is in the protein match. Some studies claim to 
confidently match a protein from only one peptide; others use at least two or more 
peptides to identify a protein. Often the number of proteins identified in a sample 
depends on the search and filter stringency criteria used.
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For this thesis four different types of MS were used. Two time-of-flight instruments 
(MALDI-ToF and SELDI-ToF MS) and two electrospray (3D-linear ion trap and Q- 
ToF MS), these are described in more detail below.
1.4.1 Matrix-Assisted Laser Desorption/Ionization Time-of-Flight 
(MALDI-ToF) MS
In 1987, Hillenkamp and co-workers [102] discovered that molecular ion species can 
be produced from large proteins by laser desorption, without much fragmentation, if  
these molecules are mixed with small organic compounds that serve as matrices. The 
requirements of a matrix are that it has a strong absorbance at the laser wavelength 
and is o f low enough mass to be sublimated [103]. This process is now called matrix- 
assisted laser desorption/ionization mass spectrometry. The typical preparation 
protocol for MALDI-ToF MS is to prepare the sample in liquid form, and then to 
prepare a matrix solution that contains small organic compounds such as a-cyano-4- 
hydroxycinnamic acid or sinapinic acid. The analyte and the matrix are mixed and a 
small amount of solution is placed on a metal plate to dry. After the matrix 
crystallises, the sample plate is analysed inside the MALDI-ToF mass analyser. 
During the analysis process, the matrix material strongly absorbs the laser energy and 
quickly becomes vaporised (Figure 1.14). The proteins/peptides are embedded in the 
matrix and carried along in the fast vaporisation process. The molecules pick up a 
positive charge and travel down the time-of-flight tube, where they are analysed on 
basis of their m/z ratio (Figure 1.15).
MALDI-ToF MS can potentially obtain masses for numerous biopolymers including 
oligosaccharides, gangliosides, peptides and proteins that range from -500 to 100,000 
Daltons [84]. Under optimum conditions, the limit o f sensitivity o f tryptic peptides 
(below 5,000 Da) is approximately 10-50 fmol. Because o f interference from the 
matrix, the lower limit o f the mass range is about 500 Da, below this, matrix adducts 
dominate the spectrum.
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Figure 1.14: Schematic of MALDI-ToF plate and matrix vaporisation. A nitrogen laser (red 
line) is fired at the matrix/analyte deposited in the plate in a vacuum and the excited ions 
move down the time-of-flight (ToF) tube to the detector. (Diagram reproduced from 
University o f Bristol website [104])
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Figure 1.15: Schematic o f a MALDI-ToF mass analyser. Ions travel down the ToF tube where 
they hit the detector (linear) or are reflected to another detector (reflectron) for more accurate 
mass measurements.
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To enable the charged ions to move down the flight tube in the mass spectrometer, 
after laser excitation, they are accelerated in an electric field (i.e., 25 kV). MALDI- 
ToF MS can be done either in positive or negative ion mode but positive ion mode is 
more commonly used in proteomics experiments. MALDI-ToF MS analysis o f 
peptides is suitable for the purpose o f identification; however it is not (absolutely) 
quantitative, as there can be large differences in how well different proteins/peptides 
ionize.
For protein analysis, MALDI-ToF MS analysis is mostly performed in linear mode. 
The ions travel down a linear flight path and their mass/charge ratio is determined by 
the time it takes for them to reach the detector (Figure 1.15). Hence, this instrument is 
called a time-of-flight instrument. Because all the ions are exposed to the same 
electrical field, all similarly charged ions will have similar energies; therefore ions 
that have a larger mass have lower velocities and hence will require a longer time to 
reach the detector. MALDI-ToF is probably the most used MS technique for 
identification o f proteins in 2D-PAGE spots.
1.4.2 Surface-Enhanced Laser Desorption/Ionization- (SELDI) ToF MS
SELDI-ToF MS is a form of soft ionization, patented by Ciphergen Biosystems Ltd. 
for rapid analysis of peptides, proteins and other molecules. The technique, originally 
described in 1993 [105], again relies on time-of-flight MS for the accurate 
measurement of the m/z ratio o f peptides and proteins (Figure 1.16) but SELDI-ToF 
MS involves the binding of proteins and peptides present in complex biological 
samples, such as serum, cell lysates, tissue homogenate or culture supernatants, to 
ProteinChip® arrays. These arrays have certain chromatographic surfaces, similar to 
the interior o f a HPLC column, and proteins bind to the surface. Many types of 
samples can be applied directly to the ProteinChip® arrays, without the need for prior 
removal o f salts or detergents which typically interfere with other types o f MS 
methods. An advantage o f SELDI-ToF MS is that it only requires very small sample 
volumes [106]. Proteins and peptides in the sample bind non-covalently to the surface 
of the arrays depending on their biochemical properties, (e.g., acidic proteins can bind 
to cationic surface arrays). Unbound peptides and proteins, as well as salts, detergents 
and other contaminants, are then washed away from the surface o f the arrays.
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ProteinChip* arrays are available w ith a variety o f  chrom atographic surfaces, such as 
reversed phase or ion-exchange, or w ith pre-activatcd surfaces (e.g. antibody capture
(R)or protein-protein interactions). A fter preparation o f  the ProteinChip the arrays are 
read in the m ass analyser. The MS is essentially  a M A LD I-ToF, a m atrix is used for 
laser desorption/ionization. The softw are provided with com m ercially  available 
SELD I-ToF system , allow s peak alignm ent, norm alisation and sem i-quantitative 
com parison o f  two sam ple cohorts. The protein peaks can be visualised as peaks or gel 
bands and individual peaks can be highlighted for statistical analysis w ith in the 
software (Figure 1.17) or the data can be exported and further analysed using Excel or 
another statistical analysis program .
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Figure 1.16: SELDI ProteinChipR array and time-of-flight mass spectrometry [106].
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Figure 1.17: Mass spectrometry can show protein expression differences between two 
samples. Protein levels are quantitated as maximum peak height.
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1.4.3 Electrospray Ionization Mass Spectrometry (ESI-MS)
Probably the m ost com m only used form o f  peptide identification and m apping o f  
protein is electrspray ionization (ESI)-M S/M S. E lectrospray for ESI-M S was 
developed in 1988 by J. Fenn where he show ed the detection o f  a spectrum  from 
proteins even above 20,000 Da [84], Electrospray coupled to a HPLC system or 
directly injected produces ionized peptides in the liquid, by applying a voltage, as they 
exit the colum n. The ions are repulsed by the high voltage (as they carry the same 
polarity) and are attracted by the low er voltage o f  the M S. This w ay the droplets 
becom e sm aller until only  a fine m ist enters the MS (Figure 1.18). As the droplets 
pass through a heated m etal capillary, the solvent evaporates, and the droplets become 
over-charged and fission into ever-sm aller droplets until only single, usually m ultiply- 
charged peptide ions (e.g., 2+, 3+ for tryptic peptides) are left (as opposed to M ALDI- 
ToF MS, which only produces single charged ions from peptides).
Vacuum
interface
Figure 1.18: Electrospray ionization and mass spectrometry.
Even though intact proteins can be analysed, accurate m ass m easurem ents are not 
possible. It is further im portant to recognise that for large m olecular w eight m olecules, 
such as proteins, the m ass m easured is the average m ass and that the peak envelope 
extends over isotopic m asses.
Glass Sample 
capillary solution
Mass
spectrometer
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Figure 1.19: LC-M S/M S analysis. The diagram  shows the transition betw een the 
basepeak chrom atogram  o f  the LC separation and the first stage o f  MS where parent 
ions are selected through to the second M S producing fragm ent ions in the M S/MS 
experiment.
In com plex m ixtures, the recovery o f  M S/M S scans and hence peptide identifications 
from ESI-M S/M S is low, due to the large num ber o f  peptides that have to be analysed 
and fragm ented at one time. Hence optim ising the separation by extending the elution 
gradient becom es im portant to spread m olecular ions out. ESI-M S spectra o f  peptides 
are alm ost always recorded in positive ion mode. ESI- tandem  M S analysis can be 
perform ed in “data-dependent m ode” , w here the m ost intense m/z peaks are selected 
for subsequent M S/M S but then ignored for a certain am ount o f  tim e (Figure 1.19). 
During “data-dependent m ode” no peaks are analysed for MS w hile M S/M S is in 
process, this is called the “exclusion tim e” . A lternatively, peaks are scanned for 
M S/M S in “selective ion fragm entation” , where certain, chosen m/z precursors are 
selected by the software for M S/M S analysis. This becom es useful to identify a 
peptide o f  known m/z. ESI-ion trap m ass spectrom eters also record the m ass-to-charge 
ratio, typically producing a spectrum  in the m ass range o f  500-2000 Da for peptides. 
For peptide sequencing the m/z peak is further fragm ented and am ino acid loss is used 
to identify the amino acid com position; which are then used to m ap proteins from a 
database com m only using Sequest as described above [101].
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1.4.4 Serum Protein Profiling using LC-MS/MS in the Literature
Attempts at serum protein identification first started in the 1970s when Anderson and 
Anderson [107] discovered 40 proteins in un-depleted blood serum by 2 D-PAGE. 
Thirty years later still only 490 proteins from immunoglobulin and albumin depleted 
serum were identified in 1992 [108] and again in 2002 [6 8 ] by 2D-PAGE (Figure 
1.20). However serum is estimated to contain many thousands of proteins, based on 
genomic data [6 8 ]. With the use o f multidimensional HPLC separation techniques, 
Shen et a l  [109] showed that, from un-depleted serum, they could conservatively 
identify 800 serum proteins (including all serum proteins). Using multidimensional 
HPLC-separations, trace components with a dynamic range o f > 8  orders o f magnitude 
were detected. In a similar approach, using more conservative identification criteria, 
Qian et a l  [93], confidently identified 804 different plasma proteins (not including 
immunoglobulins) covering a dynamic range o f 6-7 orders o f magnitudes. 
Nevertheless this is still far less than the total number o f estimated plasma proteins. 
These studies, from different laboratories, used increasingly more conservative 
filtering criteria during their database searches, to minimise the number of false 
positive identifications. A Sequest database search can be performed at different 
stringency levels which determine the number o f proteins identified. For example, to 
eliminate false positives Tirumalai et al. [58] searched all spectra against the human 
FASTA database without removing viral proteins, and each protein that also identified 
a virus was then removed from the protein identifications. Furthermore, proteins that 
were identified by only one peptide were analysed manually for their signal-to-noise 
ratio; and the presence o f at least 3 consecutive fragment ions. Other search methods 
include increasing the search criteria for different charge states and reverse sequence 
database searching [110]. The idea is if  two different peptides can be found from the 
same raw file and the exact same scan number then it is possible for a false positive. 
The data is first searched with one sequence database and then the reverse sequence 
database to see if  there are any MS/MS scans that are mapped back to two different 
peptide sequences.
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Figure 1.20: Protein Markers over 70-year penod. The increase in protein species resolved 
and identified in plasma. Squares show the number of peaks, bands, or spots resolved based 
on literature. Diamonds show the number of proteins identified [52].
The use o f  m ore stringent criteria has slowed the increase in num ber o f  identifications 
greatly. So when Shen et al. [109] used the less stringent search criteria than A dkins et 
al. [68] had in their study, they identified 1600 instead o f  800 (stringently  searched) 
different proteins. This em phasises the need for powerful bioinform atics tools and 
stringent search criteria to confidently map proteins. It further suggests that these 
criteria need to be conserved and standardised across laboratories to com pare results. 
N onetheless, Shen et al. [109] identified low abundance proteins in ng/m l quantities 
such as hum an growth factor activator and alpha-fetoprotein confidently  in the 
presence o f  serum  album in in the m ore stringent search. A lthough, to identify 
cytokines and other inflam m atory m ediators such as in terleukin-1 and -6 (IL-1, IL-6), 
present in pg/m l levels, in serum  or plasm a, further developm ents are necessary. At 
the m om ent rare proteins are often only identified by a single peptide and few am ino 
acid peaks, and only offers low confidence identification [96].
The use o f  different proteom ic approaches results in identification o f  different 
proteins. A paper by A nderson et al. [67] com pared protein identifications from 
different m ethods across laboratories. One o f  the m ain conclusions draw n is that with 
a dynamic range and com plexity  greater than that o f  any other biological m aterial and 
w ith the technology available today, none o f  the m ethods were able to d iscover
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anyw here near the protein distribution o f  the whole proteom e. M ore concerning they 
could only find a sm all overlap o f  protein identifications betw een the different studies 
(Figure 1.21). As the data was collected from independent laboratories, the differences 
in identification m ay have resulted from either the presence o f  different proteins in the 
sample, or different sam ple preparation and separation m ethods, or from different M S 
analysis and searching tools and criteria [67]. M ost likely, different technologies are 
capable o f  detecting proteins w ith different properties; hence a m ulti-technology 
approach has the greatest potential at discovering the m axim um  num ber o f  proteins.
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Figure 1.21: Diagram of Proteins Found in Multiple Datasets. All overlaps are shown (2-way, 
3-way and 4-way) for all four input data sets: Literature search (dotted line); 2D-PAGE MS 
(dashed line); LC-MS (solid line) and LC-MS/MS (double solid line). Numbers represent the 
number of shared accessions in the respective overlapping areas. Diagram taken from [67],
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1.5 Serum Protein Quantitation and Biomarker Discovery
Mass Spectrometry has its strength in the qualitative analysis and identification of 
molecules and not for relative quantitation of molecules in complex mixtures such as 
serum. Relative quantitation o f comparisons o f protein expression between two 
sample cohorts is therefore challenging and with the exception for SELDI-ToF MS 
data little published. In fact at the start o f this project MALDI-ToF MS and LC-MS 
were untested for protein or peptide quantitation from clinical serum samples.
In a traditional proteomics study, proteins are first resolved by 2D-PAGE, and their 
expression levels are monitored by the intensities o f stained spots on gels. However 
2D-PAGE is not suitable for serum quantitative analysis, because low molecular 
weight molecules exist below the lower limit of effective resolution achieved by 
conventional 2D-PAGE [8 6 ]. Furthermore the large amount of albumin can mask the 
detection o f low abundant proteins. Consequently, investigators have turned to HPLC 
coupled with MS. Separation methods such as multidimensional LC can provide 
separation power superior to that o f 2D-PAGE. Mass spectrometry actually has its 
optimal performance in the low mass range [111]. Especially SELDI-ToF MS, 
analysing intact proteins, performs best on proteins below 30 kDa [112].
Mass spectrometry dominates the field o f proteomics as an analytical tool. In the past 
few years, a number o f methods based on isotopic labelling for proteins and peptides 
have been reported for comparing the relative abundance o f proteins in two different 
biological groups [67, 80, 113-116].
The basis of labelling approaches for proteomic studies is the generation of two 
proteome pools, one unlabelled, the other isotopically tagged (now up to 8  samples 
can be labelled using the new iTRAQ reagents (Applied Biosystems, UK)) that 
behave indistinguishably during separation. In principle, isotope tags can be 
incorporated into proteins during cell growth [117] or after cell lyses as well as in 
biofluids, or even in intact animals. In a study monitoring individual protein turnover 
rates, Doherty et al. [118] fed chicken a deuterium-labelled valine diet. The use of 
isotopically labelled amino acids in animals however is complicated by the fact that 
some amino acids are already present in the organism and so only partially labelling is 
possible. Alternatively, proteins can be isotopically labelled at the C-terminal of the 
tryptic peptides using 160 / 180  labelled water [119-121]. However with most o f these 
methods only two samples can be compared, therefore often the samples and
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replicates from two cohorts are often pooled for analysis. For comparison using MS, 
the labelled and unlabelled samples are combined during sample preparation, which 
allows minimal variation during separation and analysis and, thus, more accurate 
quantitation o f the expression levels of proteins in the counterpart proteomes [1 2 2 ]. 
Most commonly the labelled peptides are separated using RP-LC-MS/MS couples to 
ESI-MS and MS/MS. Quantitation follows peptide identification using specialized 
software such as Bioworks or other commercially available programs. MALDI-ToF 
MS has also been used for quantitation using isotopically labelled peptides [123]. This 
has the advantage o f singly charged peaks and being able to perform MS/MS 
fragmentation on peptides that showed abundance changes.
1.5.1 Peak Intensity Quantitation and Internal Standards
Although isotope labelling is a relatively sophisticated technique, it is associated with 
a number o f problems, such as labour- and time-intensive labelling steps and high cost 
of the reagents, just to name a few. There are a number o f approaches o f label-free 
quantitation, in which no addition of a isotopic or chemical tag is necessary. For 
quantitation using an internal standard, a protein o f known concentration is added to 
control and disease samples as an internal standard. Optimally a protein is used that 
does not naturally exist in the mixture. Then the mixture including the internal 
standard is enzymatically digested according to the standard protocol and analysed by 
RPLC-MS/MS. Chromatographic peptide peaks from one protein can then be 
combined to calculate the overall peak area or height. This way, Yeo et al. [124] used 
bovine insulin to compare plasma peptides from control and chronic asthma mice. 
Bondarenko et a l  [125] claimed that the peak area of the peptide is directly 
proportional to the abundance o f a protein in a mixture. Conversely it was noticed by 
[126] that different peptides ionize at different rates although from the same peptides.
Quantitation o f small molecules by integration of the LC-MS extracted ion 
chromatogram (XIC) peaks has been used commonly in analytical chemistry. The 
same method can be applied to proteolytic protein digests for biomarker discovery 
[127, 128]. A large amount o f data is produced in these experiments and the 
complexity o f the samples analysed requires automated data analysis tools. In contrast
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to pattern-based, difference based [129], or identification-based [130, 131] 
approaches, an analytical tool for integration o f all peaks in each spectrum was 
designed by Higgs et al. [132]. However none o f these papers report a comparison o f  
real samples for marker discovery but study the methodology and evaluation o f  
respective statistical tools.
Wiener et al. [129] for example used an approach to devise an algorithm that 
compared peptide peak intensities at each time and m/z ratio. The computational 
analysis takes into account that peak intensity measurements are variable. This has 
allowed the method to take into account small but significant intensity changes in low 
abundance peptides but ignore large but statistically insignificant changes in peptides 
at much greater concentrations. The method uses a /-test to compare the peak intensity 
at each time and m/z ratio, to compare two conditions. The experiment was carried out 
in tryptic digests of 19 proteins. Visual inspection o f the base peak chromatogram did 
not show any differences between the samples. The algorithm however, was able to 
distinguish differences between samples that could not be detected by visual detection 
alone. After significantly different m/z peaks have been detected in a full MS analysis, 
“markers” can be further analysed in a second experiment where they are specifically 
selected by the MS for fragmentation to avoid loss in the exclusion time.
Similarly, Yeo et al. [124] used 3D Excel® (Windows, Microsoft) plots to visualise 
elution time, m/z and peak area. The bubble graphs identify peaks that are more 
intense in one sample than in the other (Figure 1.22). This may be a technique 
worthwhile exploring.
Chapter I : Introduction to Proteomics and Breast Cancer 40
23 ik
T
V
&
3
3
Figure 1.22: Excel 3D bubble plot depicting peptide intensities. On the x-axis the m/z ratio 
and on the y-axis elution fraction. The peak intensity is visualised in form of the size o f the 
bubble [124],
1.5.2 Intact Protein Profiling
It could be argued that com paring peptide changes betw een different sam ples is 
problem atic due to the fact that different peptides from the sam e protein m ay ionize 
differently  and therefore the extrapolation back to the protein is challenging [126]. 
The use o f  intact proteins provides a m ore realistic m easure o f  the actual change in 
protein intensity. SELD I-ToF MS has been specifically designed for high throughput 
detection o f  biom arkers. The use o f  the ProteinChip technology has enabled detection 
o f  a num ber o f  potential m arkers from serum in different diseases [62, 1 12, 133-135]. 
U sing SELD I-ToF technology, biom arkers can be detected as w ell as m ore 
com plicated protein patterns can be identified for further validation. The great 
advantage to using SELD I-ToF MS is the “easy” and fast application and subsequent 
analysis and interpretation o f  the data. As part o f  the softw are “norm alization” , peak 
alignm ent and data analysis tools are available and relative easy to use. A lthough 
SELD I-ToF MS suffers from low accuracy M S, the practicality  has facilitated m any 
studies w ith the necessary speed o f  analysis to analyse relatively large sam ple sets and 
publish a vast am ount o f  data. M A LD I-ToF MS on the other hand, although the m ass 
accuracy is m uch higher and the MS technology relatively sim ilar has not been used to 
the sam e extend for global quantitative studies from serum. For M A LD I-ToF M S a
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serum sample has to be fractionated for improved peak recovery by removing high 
abundance proteins as well as removing the high amounts o f salt from serum [136, 
137]. The presence of hotspots in the matrix where some proteins ionize better and 
produce higher peaks causes MALDI-ToF to be less reproducible than SELDI-ToF 
MS. However this can be overcome by accumulating a large number o f spectra from 
each spot as well as analysing each sample in replicates, and the use o f better 
matrix/analyte application [138]. But finally and possibly the most likely reason for 
the limited use o f MALDI-ToF for quantitative protein profiling is the lack o f readily 
available peak alignment tools and algorithms supporting high-throughput data 
analysis and interpretation of the data to elucidate potential markers.
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1.6 Objectives of the Study
On the basis o f the information gathered, the use o f the following protocols to look for 
serum biomarkers of breast cancer is proposed. The use o f LMW ultrafiltration for 
serum separation seems a good method as the first dimension o f separation. It involves 
a single step and produces only one fraction of a sample with much reduced protein 
complexity. Fortunately many o f the high abundance proteins are also o f relative high 
molecular weight. The UF protocol will be investigated for reproducibility and 
efficiency to establish an optimised method for comparing breast cancer serum and 
no-cancer controls. In more detail, the application o f intact protein profiling will be 
evaluated using SELDI-ToF MS. Furthermore, I aim to develop a robust protocol for 
quantitation o f protein peaks using MALDI-ToF, including the programming o f a 
peak alignment software for comparison of large sample sets. Identification of 
differential markers will be attempted using a MALDI-ToF/ToF as part o f a 
collaboration formed with Applied Biosystems in Germany. The use o f LC-MS for 
peptide quantitation will be demonstrated in a small study and the options for 
identification o f discriminating peaks explored.
In order to maximise the chances o f identifying a biomarker pattern indicative of 
breast cancer, the initial study group will be composed of patients with advanced 
metastatic breast cancer, who have not received chemotherapy. Patients with 
metastases to the liver were excluded. By carefully matching the control and case 
cohorts for factors such as age and menopausal status, we can focus on a single 
variable to find robust breast cancer-specific markers. Blood samples will be obtained 
from selected patients at Singleton hospital, and subject to standard protocols for 
consent and ethical approval. Issues related to sample collection, handling and storage, 
standardisation o f protocols, availability o f normal controls, access to bio-banks, 
clinical information, as well as ethical considerations are critical, and have been 
considered and dealt with from the beginning. Since sample preparation is such a key 
variable and concern in these types of studies, we have a standard sample collection 
and storage protocol, which will be adhered to strictly. In addition as a second control 
measure any deviation from the protocol is recorded to allow us to do post-hoc outlier 
identification at a later stage.
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CHAPTER 2
General Materials and Methods
2.1 Materials and Chemicals
All centrifugal filters and Zip-Tips were purchased from Millipore UK Ltd (Watford, 
UK). Tricine, glycine, tris, sinapinic acid (SA), and HPLC grade acetonitrile (ACN) 
were purchased from Fisher Scientific UK Ltd (Loughborough, UK), and ammonium 
bicarbonate (NH4 HCO3 ), B-mercaptoethanol, trifluoroacetic acid (TFA), Formic acid 
(FA), cytochrome C, bovine serum albumin (BSA), lysozyme, vitamin B12 and 
ubiquitin from Sigma-Aldrich Company Ltd. (Gillingham, UK). The BCA assay kit 
was purchased from Pierce (Perbio Science UK Ltd, Cramtington, UK) and 
ProteinChip® Arrays from Ciphergen Biosystems Ltd., (Guildford, UK). Sequence- 
grade trypsin was purchased from Promega (Southampton, UK) and acrylamide/ 
bisacrylamide and all protein standards came from Bio-Rad® (Hemel Hempstead, 
UK).
2.2 Serum Preparation and Handling
Human blood samples were obtained from healthy female volunteers and from female 
patients with metastatic breast cancer. Patients with breast cancer metastatic to the 
liver were excluded from the study. The project was approved by the Local Research 
Ethics Committee and written informed consent was obtained from all participants. 
The Ethics approval is shown in the Appendix (F). Human blood was collected by
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venepuncture into Vacuette, gold-top serum separator tubes. Blood was allowed to 
clot at room temperature for 30 min and was centrifuged at 3000 x g for 5 min after 
which serum was collected. Serum was aliquoted into 500 pi and stored at -80°C until 
analyzed. Each breast cancer sample was matched with a control sample o f similar age 
and the pair was processed simultaneously.
2.2.1 Determination of Protein Concentration
The protein concentration o f all samples and fractions was determined with the Pierce 
BCA™ assay; here a dilution series of BSA (0.025 -  2 mg/ml) to generate a standard 
curve was prepared. For the mirco-assay, 10 pi o f each sample and standard was 
mixed with 200 pi o f the working reagent (50:1) in a 96-well plate. The plate was 
incubated floating on a water bath for 30 min at 37°C. Absorbance was measured at 
550 nm in a Multiskan Ascent plate reader (Thermo Labsystems, UK). The protein 
concentration of each sample was read against the standard curve of BSA 
concentrations.
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2.3 Serum Protein Pre-Fractionation
2.3.1 SDS Polyacrylamide Gel Electrophoresis (PAGE)
All protein gel electrophoresis experiments were performed using Mini-Protean II 
cells (Bio-Rad®, Hemel Hempstead, UK). All buffers were prepared as stock 
solutions prior to casting the gel. The first step was to prepare the acrylamide gel, for 
LMW proteins the gels are composed o f 3 layers modified slightly from Schagger and 
von Jagow [1]. The bottom layer of acrylamide (the separating or resolving gel) 
comprised o f about 50% o f the gel height. The acrylamide concentration o f the 
separating gel was 17% and pH 8.9. The middle layer was the Spacer gel which is 1-2 
cm thick and contains 10% of acrylamide, and was buffered at pH 8.9. The top-most 
layer is referred to as the stacking gel, and comprised about 10% o f the gel height. The 
stacking layer contains 4% o f acrylamide and is buffered at pH 6 .8 . The difference in 
pH and acrylamide concentration at the stacking and spacer gel interface functions to 
compress the sample at the interface and provides better resolution and sharper bands 
in the separating gel. The acrylamide gel solutions for each layer were prepared with 
the compositions given in Table 2.1 and ammonium persulphate and TEMED were 
added just before pouring. Each layer was left to polymerize and, to provide a smooth 
surface and interface at the top o f the separating gel, H2 O was placed above the gel 
during polymerization.
Table 2.1: Composition of separating, spacer and stacking gels.
Separating Gels
Stacking Gel Spacer Gel
(4%) (10%) 12% 17%
19:1 acrylamide:bis-acrylamide - 0.33 ml - 0.84 ml
37.5:1 acrylamide:bis-acrylamide 0.2 ml 0.35 ml 1.2 ml 1.9 ml
Gel Buffer
1 M Tris HCI pH 8.4, 0.1 % SDS - - 3.3 ml 3.3 ml
3 M Tris HCI pH 8.9, 0.3 % SDS - 1.6 ml - -
1 M Tris HCI pH 6.8 1.25 ml - - -
ddiH20 3.5 ml 2.3 ml 1.4 ml 4.3 ml
10%  SDS 0.025 ml - - -
50 % Glycerol - - 2.8 ml 2.2 ml
25 % ammonium persulphate 0.01 ml 0.068 ml 0.036 ml 0.013 ml
TEMED 0.005 ml 0.0017 ml 0.01 ml 0.0033 ml
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Each sample was incubated for 5 min at 100°C in 5 pi of sample loading buffer (0.3% 
SDS, 12% glycerol, 50mM Tris HCI pH 6 .8 , 2% B-mercaptoethanol and 0.05% 
bromophenol blue) and then loaded onto the gel. The samples were run with a two 
buffer system, comprising o f a lOx cathode buffer (1M Tris HCI pH 8.3, 1M tricine 
and 0.1% SDS) and lOx anode buffer (2M Tris HCI pH 8.9). The lOx stock solutions 
were diluted with dd i^O  before use and the electrophoresis run at a constant current 
of 50 mA until the dyefront reached the bottom of the gel. A broad range and a low 
molecular weight protein standard marker were included.
The protein bands were fixed in a solution containing 40% methanol and 10% acetic 
acid for 30 min. After two 5 min ddiH2 0  washes, the gels were stained with blue- 
silver colloidal Coomassie G-250 staining solution (added in order 20% ddi^O , 10% 
phosphoric acid, 10% ammonium sulphate, 0.12% Coomassie G-250, 60% H2 O and 
20% methanol) for 12-24 hours. Gels were de-stained for 24 hours in dd i^ O  and 
images taken using a UVP BioDoc-It Imaging system (Cambridge, UK).
2.3.2 Centrifugal Ultrafiltration
All sample preparation and centrifugation was performed on ice or in a refrigerated 
Legend™ T/RT swinging bucket centrifuge (Sorvall, Langenselbold, Germany) at 
4°C. The centrifugal filter membranes were washed in 0.1 N NaOH and then rinsed 
with ddiH2 0  by centrifugation for 3 min each. A serum sample was diluted with 
denaturing buffer (25 mM NH4 HCO3 , 20% ACN (v/v)) and incubated on ice for 60 
min, with frequent shaking. The filters were then centrifuged until a minimum of 70% 
volume had passed through the filter. (Later into the project the HMW retentate was 
re-suspended to the original volume and centrifuged again until 70% of the volume 
had passed.) The filtrate was recovered and aliquoted into 1 ml tubes before it was 
lyophilized and stored at -80°C.
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2.3.3 Protein Precipitation
Serum samples were precipitated using ACN, ethanol and TCA/acetone protocol for 
comparison. For each of the methods 20 pi of crude serum were used and the protocol 
performed in triplicate.
The ACN precipitation was the same as previously described [2], briefly two volumes 
of 100% ACN were added to 1 volume of serum and vortexed for 5 sec. The mixture 
was then incubated for 30 min at room-temperature and then centrifuged for 1 0  min at 
1 2 , 0 0 0  xg.
The ethanol precipitation was performed according to the protocol described by 
Villanueva J. [3], here equal volumes o f 100% E t O H  were mixed with the serum by 
vortex for 1 min and then centrifuged for 10 min at 15,000 xg. The pellets (albumin) 
and supernatants were retained and brought to dryness in a speed vacuum centrifuge. 
For further analysis the supernatant was re-suspended in 20 pi o f 25 mM N H 4 H C O 3  
and the pellet in 70 pi o f 7M urea, 2M thiourea and 4% C H A P S .
For TCA/acetone precipitation a protocol published by Chen et al. [4 ] was used and 20 
pi of serum were rapidly mixed with 80 pi of ice-cold acetone and 1 0 % trichloroacetic 
acid (TCA) (v/v), and mixed gently by vortexing immediately. The mixture was then 
incubated for 90 min at -20°C and centrifuged at 15,000 xg for 20 min in a 
refrigerated centrifuge (4°C). The supernatant was removed and collected; the 
precipitated pellet (proteins) was washed with 1 ml o f ice-cold acetone and incubated 
on ice for 15 min. Then the precipitate was centrifuged again at 15,000 xg for 20 min 
at 4°C and the supernatant removed and collected and the pellet lyophilized. The 
pooled supernatants (albumin) were precipitated again by adding 1 ml o f ice-cold 
acetone/ TCA to the supernatant. The new pellet contains albumin. Both pellets were 
re-suspended in 100 pi o f 7M urea, 2M thiourea and 4% CHAPS. All fractions from 
above were analysed by SDS-PAGE as described above.
2.3.4 Affinity Chromatography for Albumin and Protein G removal
A Vision™ BioCAD Family Perfusion Chromatography Workstation (Applied 
Biosystems, Warrington, UK) was used for human serum albumin (0.2 ml volume, 4 
mm I.D. x 15 mm) and protein G (0.2 ml volume, 4 mm I.D. x 15 mm) depletion from 
serum. Before first use the Poros® anti-HSA and anti-Protein G cartridges affinity
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depletion cartridges (Applied Biosystems, Warrington, UK) were equilibrated with 10 
cartridge volumes (CV) of PBS (pH 7.2) at a flow-rate o f 1 ml/min. For depletion the 
two cartridges were used in tandem, 50 pi of 10% diluted serum (in ddi^O ) were 
injected on the anti-protein G cartridge and eluted onto the anti-HSA cartridge at a 
flow-rate o f 0.5 ml/min. The cartridges were then washed with 30 CV (3-6 ml) of 
PBS (pH 7.2), before bound HSA and protein G were eluted with 10 CV of 12 mM 
HC1 at a flow-rate o f 1 ml/min. Fractions were collected automatically every minute. 
Finally the anti-HSA cartridge was cleaned with 10 CV o f 1 M NaCl and the anti­
protein G cartridge with 10 cartridge volumes CV of 2 M urea in 1 M NaCl at a flow- 
rate of 1 ml/min
2.3.5 Weak Anion Exchange (WAX) for Intact Protein Separation
Neat serum proteins were separated by ion exchange chromatography using a 100 mm 
x 4.6 mm I.D., 1000 A PolyLC WAX column (PolyLC, Maryland, USA). The 
separation was performed using the Vision™ BioCAD Family Perfusion 
Chromatography Workstation (Applied Biosystems, Warrington, UK). After the 
column was equilibrated with two repeat 90 min gradients, 100% A (5% ACN in 
water) to 100% B (5% ACN in 0.6 M NH4 acetate), 2x 40 pi o f serum were injected 
and eluted at a flow-rate o f 1 ml/min. 1.5 ml fractions were collected and for salt 
removal and drying, speed vacuum centrifuged, using a low vacuum concentrator 
Heto Vacuum Centrifuge (Jouan, Alterod, Denmark) for approximately 24 hours. 
Some fractions were pooled for SDS-PAGE analysis.
2.4 Trypsin Digestion
For subsequent LC-MS/MS peptide identification, serum proteins were digested with 
trypsin in solution. As a first step, protein disulphate bridges were reduced by adding 
10 mM dithiothreitol (DTT) and boiling it for 10 min. The proteins were then 
digested, overnight at 37°C, with a protein:enzyme ratio o f 50:1 trypsin (prepared at a 
1 pg/pl concentration with 25 mM N H 4 H C O 3 ) .  The enzyme reaction was stopped by 
lowering the pH to 0.1% TFA and the samples were dried and frozen in -80°C for 
storage.
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For protein identification from SDS-PAGE gels, gel pieces were first completely de­
stained with 1 ml o f 50% A C N  in 25mM N H 4 H C O 3 , pH 8.4 by vortexing it three 
times, each time the solution was re-applied fresh and removed. Next the gel slices 
were dehydrated with 50 pi o f 100% A C N  for 5 min and dried completely in a speed- 
vacuum centrifuge for 10-20 min. For proteolysis the gel pieces were covered with 
trypsin solution (15-20 ng/pl trypsin in 25 mM N H 4 H C O 3  pH 8.4) and allowed to 
swell for 45 min on ice. The trypsin solution was removed and the gel slices covered 
with 25 mM N H 4 H C O 3 ,  pH 8.4 and incubated at 37 °C overnight with rocking. In the 
morning the supernatant was recovered and later combined with tryptic peptides 
extracted 3x with 50 pi o f 70% A C N ,  5% FA with 5 min sonication. Peptides were 
stored at -80°C or processed to Zip-Tip clean-up.
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2.5 Protein and Peptide Clean-up and Concentration
Empore™ cartridges and Zip-Tips were used with the same protocol. First the CIS- 
material was conditioned with 60% MeOH and washed with ddiF^O. The sample was 
loaded by pipetting up and down through the Zip-Tip and washed with ddiFbO, before 
the proteins/ peptides were elute with 80% ACN, 0.1% TFA. For storage at -20°C and 
further analysis the peptides were concentrated to dryness in the vacuum concentrator 
5300 (Eppendorf AG, Hamburg, Germany).
2.6 SELDI-ToF MS
2.6.1 Pre-Fractionation of Intact Proteins: Using WAX Separation
To increase the number of protein peaks visualized, an anion exchange fractionation 
procedure was performed in which the LMW serum was separated into six different 
fractions (flow through, pH 9, pH 7, pH 5, pH 4, pH 3, and organic wash). For this, 
40pl o f LMW serum (5 mg/ml concentration) was denatured with 30 pi of U9 buffer 
(9 M Urea, 2% CHAPS, and 50 mM Tris-HCl, (pH 9)) by vortexing for 20 min. Two 
additional samples, one of all cancer and the other o f all control sera were pooled, and 
added to investigate the effect o f pooling on peak as well as biomarker discovery. The 
QHyper DF resin (Ciphergen, Guildford, UK) was prepared by washing three times 
with 5 bed volumes o f 50 mM Tris-HCl (pH 9). A 50/50 slurry of resin (180 pi) in 50 
mM Tris-HCl (pH 9) was then aliquoted on a 96-well filter plate and equilibrated with 
3 washes of 200 pi U1 buffer (1 M Urea, 0.22% CHAPS, and 50 mM Tris-HCl (pH 
9)) on a vacuum manifold (Beckman Coulter Inc., High Wycombe, UK). The whole 
volume of the serum/U9 mix was then added to the resin in each well o f the filter 
plate. For use of columns the sample was added to a column each and prepared the 
same way as for the 96-well plate. Plates were then vortexed for 30 min to bind the 
serum to the anion exchange resin. Consecutively, 100 pi of wash buffer was added to 
each well, vortexed for 1 0  min, at room temperature and the eluted fraction collected 
via a vacuum manifold. For the pH 9.0 fractions, only one 100 pi wash was 
performed. For each subsequent fraction, two 100 pi washes were performed. For 
fraction 1, the 100 pi flow through and 100 pi pH 9.0 wash are combined into one 200
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pi fraction. The wash buffers for the different fractions were 50 mM Tris-HCl, 0.1% 
octyl glucopyranoside (OGP), (pH 9; FI), 50 mM HEPES, 0.1% OGP (pH 7; F2), 100 
mM Na-Acetate, 0.1% OGP (pH 5; F3), 100 mM Na-Acetate, 0.1% OGP (pH 4; F4), 
50 mM Na-Citrate, 0.1% OGP (pH 3; F5), and 33.3% isopropanol/ 16.7% ACN/ 0.1% 
TFA (F6 ). All of the pipetting steps a Biomek 2000 laboratory workstation (Beckman 
Coulter Inc. High Wycombe,UK) was used. Collected fractions were stored at -20°C 
until final analysis.
2.6.2 Binding of LMW Proteins to ProteinChip® Arrays
Each WAX fraction was then applied to two biochemically distinct ProteinChip® 
array surfaces (Ciphergen, Guildford, UK). The immobilized metal affinity capture 
coupled with copper (IMAC-Cu2+) and weak cation exchange (WCX, CM 10) arrays 
were chosen to increase the proportion of the serum proteome represented on the 
arrays for mass spectrometric analysis. Additionally the WCX array was also analysed 
under stringent as well as low stringency conditions. Each cancer sample was 
processed together with its age-matched control sample on the same chip.
LMW serum samples were analysed on four different ProteinChip arrays to define the 
best to use. The IMAC-Cu2+ chips were preloaded with 50 pi o f 100 mM CuSC>4 per 
spot on a bioprocessor module, which allows simultaneous processing o f 1 2  
ProteinChip® arrays, vortexed for 5 min and rinsed with H2 O. All arrays were then 
equilibrated twice with 200 pi of the appropriate binding buffer (Table 2.2). Ten pi of 
each fraction or sample and 90 pi o f the respective binding buffer were then added on 
each spot and vortexed for 30 min. After discarding the remaining sample, the arrays 
were washed three times with 200 pi of binding buffer for 5 min and two brief water 
rinses. All samples were analysed twice; that is, complete SELDI-ToF MS profiles o f 
the LMW filtrates were obtained from duplicate LMW serum samples, to minimize 
the effects of intra-assay variation. This was performed for Q10 and CM 10 arrays.
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Table 2.2: Binding and washing buffers for different chromatographic chip surfaces.
Array Types: Binding and Washing buffers:
H50 10% acetonitrile, 0.1% TFA
Q10 low: 50mM Tris-HCl, pH 9
high: 100mM Sodium acetate, pH 6
CM10 low: 100mM Sodium acetate, pH 4
high: 50mM Tris-HCl, pH 7
IMAC 30 0.1 M sodium phosphate, 0.5 M NaCl pH 7
2.6.3 ProteinChip Analysis, Peak Detection and Data Analysis
Sinapinic acid solution as energy absorbing matrix was prepared according to the 
manufacturer’s instructions (Ciphergen Biosystems Inc.); 12 mg/ml in 50% ACN/ 5% 
TFA, and 0.6 pi of the saturated solution applied twice to each spot on the chip. 
ProteinChip arrays were air dried and stored at room temperature in the dark until 
further use. Arrays prepared in Guildford were read on the ProteinChip Reader 
PCS4000 model and the data analyzed with Ciphergen Express software (Ciphergen 
Biosystems). Later in Cardiff, these arrays and all others were read on the Protein 
Biological System II ProteinChip reader and analysed using the ProteinChip software 
Ver. 3.1 (Ciphergen Biosystems Inc., Guildford, UK). All arrays were analysed in 
linear mode using the following settings: 150 shots/spectrum collected in positive ion 
mode, laser intensity 215, detector sensitivity 10 and focus mass 7500 Da. The mass 
spectrometer was externally calibrated using the “All-in One” peptide mass standard 
(Ciphergen Biosystems Ltd., Guildford, UK) which contains vasopressin (1084.2 Da), 
somatostatin (1637.9 Da), bovine insulin /5-chain (3495.9 Da), human insulin 
recombinant (5807.6 Da), and hirudin (7033.6 Da). Data analysis was performed 
using the Ciphergen ProteinChip® software 3.1 after baseline subtraction, peak 
clustering and standardisation.
Peak detection was performed using the ProteinChip Biomarker software version 3.1 
(Ciphergen Biosystems Inc.). All o f the spectra were compiled, baseline subtracted 
and normalized to the total ion current o f all peaks. The part of the spectrum with m/z 
values < 1 , 0 0 0  was not used for analysis, as the energy absorbing matrix signal 
generally interfered with peak detection in this area. Peaks between 1,000 and 100,000 
m/z ratios were auto-detected with a S/N ratio o f >3 and the peaks clustered using
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second-pass peak selection with S/N ratio >2 and a 0.3% mass window. Mass-to- 
charge values that were within the 0.3% mass accuracy window were considered to be 
identical between replicates. The resulting peak intensity values were analysed for 
differences using a Mann-Whitney U  test within the software and also exported to 
Excel for Student’s Mest analysis.
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2.7 MALDI-ToF MS
2.7.1 Sample Preparation and Peak Detection
Protein samples were analysed using MALDI-ToF MS after mixing lp l o f protein in 
0.1% TFA with 1 pi o f matrix (either sinapinic acid 10 mg/ml in 70% acetonitrile, 
0.1% TFA in H2 O (w/v); or a-cyano-4-hydroxycinnamic acid 10 mg/ml in 50% 
acetonitrile, 0.1% TFA in H2 O (w/v)). Spectra were acquired in linear mode for 
positive ions using a Voyager DE-STR (Applied Biosystems, Warrington, UK) after 
external calibration using either calibration mixture 2 (angiotensin I: m/z 1297.51 
ACTH (clip 1-17): m/z 2094.46 ACTH (clip 18-39): m/z 2466.72; ACTH (clip 7-38): 
m/z 3660.19 and insulin (bovine): m/z 5734.59 ) or calibration mixture 3 (insulin 
(bovine): 5734.59; thioredoxin (E. coli): m/z 11674.48 and apomyoglobin (horse): 
m/z 16952.56) from Applied Biosystems (Warrington, UK) depending on the 
molecular weight range acquired. Settings for spectra acquisition were as per 
Table 2.3. Typically 400-800 shots were accumulated per spectrum and all spectra 
were basepeak normalized, 2  standard deviations o f noise removed and a noise filter 
with a correlation factor o f 0.7 applied. The spectra were analysed using Data 
Explorer 4.0 (Applied Biosystems, Warrington, UK) and peak lists were exported for 
data analysis.
Table 2.3: MALDI-ToF instrument settings for spectra acquisition.
Mode of operation 
Extraction mode 
Polarity
Accelerating voltage 
Grid voltage 
Extraction delay time 
Number of laser shots 
Laser Rep Rate 
Input bandwidth
400 nsec 
60/spectrum
Linear 
Delayed 
Positive 
25000 V 
90%
20.0 Hz 
25 MHz
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2.7.2 Peak Alignment and Data Analysis
The code for a peak alignment tool was written in Visual Basics for Excel, the 
software produces a reference peak list from across all spectra in the experiment. Next 
the program “aligns” peak intensity values in one spreadsheet combined from all 
spectra in the experiment. The aligned intensity values for replicate spectra from the 
same sample for each mass peak were they combined by calculating an average. The 
data from the breast cancer and control samples was compared by means o f a £-test in 
Excel (as described below: section 2.9.2). Furthermore, variations within and between 
the two cohorts was visualized by principal-component-analysis (PCA) described 
below (section 2.9.3).
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2.8 Protein Profiling using LC-MS/MS
2.8.1 Column Packing
For all peptide identification work, in-house packed pulled-tip C l8 reverse-phase 
columns (10 cm x 75 pm I.D., 3 pm, 300 A) were used. For packing an approximately 
20 cm long piece of fused silica was heated approximately 5 cm from one end using a 
Bunsen burner. By gently pulling until the silica came apart, a tapered tip was formed 
at one end. The tip was then opened by cutting the very fine end off. The fused silica 
was attached to a reservoir containing C l8 silica-bonded stationary phase (PepMap, 
Dionex, Camberley, UK) suspended into a slurry with isopropanol, which in turn was 
connected to a high pressure pump. In order, first the pressure was raised to 2000 psi 
and then the solvent (methanol) turned on. Then the pressure was increased to 5000 
psi, packing of the material against the narrow tip opening could be observed visually 
against a dark surface. After at least 12 cm were packed the pressure and solvent were 
turned off and the column depressurized by loosening the pump-to-reservoir 
connection. The packed column was then “re-packed” and equilibrated for at least 30 
minutes by HPLC with 2% ACN and 0.1% TFA in ddiH20 at a flow-rate o f 200 
nl/min.
Using the column holder at the front of the source allows fine tuning of the 
positioning and distance of the column. In order to attach a 10 cm or longer column 
and to allow direct spray into the source the manifold where the column is attached 
had to be changed. A devise was build (by myself in the metal workshop) made of 
aluminium, consisting of a track that was attached to the front o f the nano-source and 
a sliding manifold, where the column holder is mounted on. The construction can be 
seen in Figure 2.1.
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Figure 2.1 Sliding column holder for use of longer pulled-tip columns. Four isometries are 
shown to display the structure and use of the extension. The extension enables use o f columns 
in variable lengths with the LCQ-Deca.
Column position 
30  fin«-control
Figure 2.2: Picture of the nano-source, showing the sliding column holder attachment and the 
way it was attached to the nano-source.
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2.8.2 LC-MS/MS Peptide Identification
For peptide identification, all serum samples analysed were first digested with trypsin 
described in section 2.4 and de-salted using Zip-Tips (section 2.5) or a Cl 8-trap 
column. The peptide samples were injected made up in 0.1% FA in ddiH20. For 
nano-LC-MS/MS experiments, after Zip-Tip desalting, an Ultimate HPLC Pump (LC- 
Packing, Dionex, Netherlands) was coupled to the LCQ Deca XP Plus quadruple ion 
trap MS (ThermoElectron, Hemel Hempstead, UK) equipped with an electrospray 
source. The column was connected to the Famos switch valve with a 50 pm I.D fused 
silica tubing via a gold tee-piece (Nanospray accessory kit, Thermo Finnigan, UK), 
the voltage was applied directly to the column through a gold-covered connection 
(Figure 2.2 and Figure 2.3). The Famos autosampler (LC-Packing, Dionex, 
Camberley, UK) was used to inject 8 pi o f sample through a 10 pi injection loop 
directly onto the separation column. The autosampler was refrigerated to 10°C during 
the analysis. The flow-rate was 200 nl/min starting with a 15 min wash o f 98% buffer 
A (2% ACN, 0.1% FA in H2 O) and then peptides were eluted using a stepwise 
gradient of 2% solvent B (0.1% FA in ACN) to 98% solvent B in 100 min. The 
column was then re-equilibrated for 10 min with 100% A. The electrospray voltage 
was held at 1.6 kV with a capillary temperature o f 160°C. The mass spectrometer was 
operated in a data-dependent mode where each full MS scan was followed by three 
MS/MS scans, in which the three most abundant peptide molecular ions were 
dynamically selected for collision-induced dissociation (CID) using a normalized 
collision energy o f 38%. The LC-MS/MS analysis was performed over a parent ion 
m/z range of 475-2000 Da. For online desalting using a Cl 8-trap column (5 cm x 300 
pm I.D. Dionex, Netherlands) the set-up and conditions described above were the 
same, except for here the sample was loaded onto the trap at a flow-rate o f 30 pl/min 
for 3 min, using the Switchos pump and then eluted after column switching straight 
onto the C18-analytical column at a flow-rate o f 200 nl/min.
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Electrical Contact int0 MS
with Liquid (1.6 kV)
Figure 2.3: Schematic diagram of a pulled-tip C l8 RP-column attached to the HPLC for 
online LC-MS/MS of peptides.
2.8.3 Sequest Searches for Peptide Identification and Protein Mapping
Tandem  MS .raw files acquired by X calibu rlvl 1.4 S R I, were searched against the 
hum an FASTA database with TurboSequest within the Bioworks Brow ser Ver. 3.2 
(Thenno Finnigan, Hemel Hem pstead, UK). The settings for Sequest searching were 
set as seen in Table 2.4. The amino acid sequences and peptide identifications were 
then filtered and the peptide results exported into Excel.
Table 2.4: Bioworks Browser settings for TurboSequest searching.
D a t a b a s e h u m a n . f a s t a  (d a te )
Instrument LCQ Deca XP
Enzyme Fully Tryptic (KR)
Precursor mass Monoisotopic using AMU
Fragment mass Monoisotopic using AMU
Intensity threshold 50000 AMU
Missed cleavage sites 2
Precursor tolerance 1.4 AMU
Peptide tolerance 2 AMU
Fragment tolerance 1 AMU
Mass range 500.00 - 3500.00
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2.8.4 Q-ToF Tandem MS for Peptide Identification
For tandem MS fragmentation of peptide peaks for amino acid sequencing, a LMW 
serum protein digest was separated by capillary HPLC separation using a in-house 
packed C l8 reverse-phase column (15 cm, 300 pm I.D., 3pm, 300 A) PepMap 
(Dionex, Camberley, UK). The peptides were eluted over 60 min from 98% A (2% 
ACN, 0.1% FA in water) to 100% B (0.1% FA in ACN) at a flow-rate o f 4 pl/min and 
analysed online in a Q-ToF Ultima (Waters, UK). For tandem MS analyses the 
parameters were as follows: capillary voltage was set to 3.5 kV, the cone voltage to 35 
V, with the cone gas flow to 40 litres/ hr. The source and desolvation temperature
were set to 100°C and 120°C, respectively. MS/MS was performed by collision with
argon gas (pressure 20 psi) with a collision energy of 32 eV at a scan time for 1 s and 
a scan range between 50 -  1600 Da. All spectra were analysed using MassLynx 
Version 4 (Micromass Ltd, Walters, UK).
2.9 General Data Analysis
2.9.1 Standardisation
Before statistical analysis the data was standardised using the same method as used by 
the “normalization factor method” as calculated as part of the Ciphergen ProteinChip® 
software 3.1. Standardisation compensates for varying levels o f total protein in the 
samples or spectra intensity variations. It was assumed that on average, the number of 
proteins being expressed is the same across all samples being standardized. Also, the 
number of proteins whose expression levels change is few relative to the total number 
of protein peaks in the spectra. The method uses the “Total Ion Current” 
standardization which uses the area under the spectrum for standardization.
First the average o f all peak intensities (TIC) in the standardization range was 
calculated by dividing the total intensity o f all peaks by the number of peaks in the 
spectrum. Secondly a “normalization coefficient” (NC) was calculated which takes an 
average across the TIC of all selected spectra. Finally the “normalization factor” (NF) 
for each spectrum was calculated by dividing the NC by the TIC for each spectrum. 
The NF for each spectrum was used to multiply each peak intensity value within the 
standardization range. For the SELDI-ToF MS data this was performed as part of the
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ProteinChip® software. For MALDI-ToF MS data this was manually calculated in 
Excel.
2.9.2 Unpaired Student’s f-test
The Student’s /-test calculates the difference between the means o f the breast cancer 
sample group and the control samples for every peak in the spectrum. To determine 
whether the breast cancer and control samples have an equal variance an F-test was 
performed in Excel. When the variance was found to be significantly different (p- 
value <0.05) a type III /-test was performed, otherwise a type II /-test used. The 
difference between the two tests is the degrees o f freedom used to determine whether 
the /-test result is significant or not. In excel the data from one group was compared to 
the data of the other group, selecting an unpaired /-test o f either type II or type III, 
dependent on the result o f the F-test calculated before.
2.9.3 Principal Component Analysis (PCA)
Principal component analysis is a multivariate projection method designed to extract 
and display the systematic variation in a data set. Even data characterised by 
thousands of variables can be reduced to just a few information rich plots. For this 
study, the multivariate analysis package SLMCA-P 10 (Umetrics, Umea, Sweden) was 
used. The peak intensities and m/z value for every sample (including each replicate) 
were transposed and imported into SIMCA-P, here the primary (m/z value) and 
secondary (sample name) observer were defined. An un-supervised PCA analysis was 
performed and the scatter plot for PCI and PC2 was exported in from of a 3D-plot.
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CHAPTER 3
Serum Sample Preparation and Pre-Fractionation
It has been established that of all the proteomes, particularly in relation to cancer 
development, serum or plasma may provide the greatest source o f biological or 
medical information [1-4]. Chan et al [5] reported that the majority o f lower 
abundance proteins identified in serum represent species secreted or shed by cells as a 
result o f signalling, necrosis, apoptosis, and haemolysis. This great variety o f proteins 
present makes serum the most informative proteome for clinical applications. Most 
cells interact with serum or shed their content into the serum after they have been 
damaged or following cell death and so the protein content o f serum is thought to 
reflect the overall profile of an individual. The serum protein concentration ranges 
from 60-80 mg/ml, however 99% o f the content is made up o f only 22 proteins [6]. 
Despite these highly abundant proteins the semm proteome is one o f the most 
complex, as the semm proteome exhibits a dynamic range of protein concentrations of 
up to eight orders of magnitude. The vast majority o f such proteins are at such low 
abundance that they make up a small percentage o f the entire protein content o f semm
[4]. The complexity o f the semm proteome however may not only provide a vast 
amount of information about the disease state but also complicates the analytical 
process.
The highly abundant proteins such as human semm albumin (>50% total protein 
concentration), immunoglobulin G, antitrypsin, immunoglobulin A, transferrin, and 
haptoglobin [7] mask the detection o f the remaining proteome during 2D gel 
electrophoresis and mass spectrometric analysis. To study the semm proteome, 
proteins such as immunoglobulin G (IgG) and albumin are often eliminated as the first 
step in the analytical protocol [1, 7-12]. Removal o f some semm proteins can be 
achieved either by affinity chromatography, precipitation, magnetic beads or 
centrifugal ultrafiltration (UF). Many o f these techniques have been utilised for
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albumin removal. However, this step has been hypothesised to concomitantly remove 
potentially informative proteins/peptides associated with these highly abundant 
proteins targeted for depletion [12, 13]. Albumin and o2-macroglobulin especially act 
as molecular sponges, binding the low molecular weight (LMW) species and 
transporting them through serum [13, 14]. Nonetheless, under denaturing conditions, 
through addition of acetonitrile or isopropanol, protein-protein bonds are broken and 
LMW species released [4, 15, 16]. An important initial step in this project was to 
optimise a practical and reproducible pre-fractionation protocol after evaluating 
different techniques (albumin depletion, precipitation, weak anion exchange (WAX) 
separation and centrifugal ultrafiltration). This is described in this first result chapter.
3.1 SDS Gel Electrophoresis for Protein Visualisation
SDS-PAGE was used for visualisation purposes and quality control o f the pre­
fractionation results; here this method was optimised for LMW proteins. Glycine- 
SDS-PAGE, also known as Laemmli-SDS-PAGE [17], and tricine-SDS-PAGE [18] 
are based on glycine-Tris and tricine-Tris buffer systems, respectively, and are 
commonly used for separating proteins. The acrylamide gels used, are characterised 
by the total percentage concentration of both monomers (acrylamide and the 
crosslinker bisacrylamide) and the ratio of the concentration of the crosslinker relative 
to the acrylamide concentration (37:1 or 19:1). Together, Laemmli-SDS-PAGE and 
tricine-SDS-PAGE cover the protein mass range 1-500 kDa. However, the more 
commonly used Laemmli-SDS-PAGE is optimal for proteins >30 kDa whereas 
tricine-SDS-PAGE enables separation of proteins <30 kDa [18]. A direct comparison 
of the resolution capacity of a 17% acrylamide tricine-SDS-PAGE and Laemmli- 
SDS-PAGE in the low molecular mass range is shown in Figure 3.1. The tricine buffer 
enables better resolution of the LMW proteins forming sharper bands. The different 
separation characteristics of the two techniques are directly related to the strongly 
differing pK values o f the functional groups of glycine and tricine in the 
electrophoresis buffer, that define the electrophoretic mobilities o f the trailing ions 
(glycine and tricine) relative to the electrophoretic mobility o f proteins [18].
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Figure 3.1: Comparison of SDS-PAGE with 17% acrylamide gels using a glycine and tricine 
running buffer. Shown is the resolution of the same concentration of LMW proteins by 
separation using glycine (lane 3) and tricine (lane 4) running buffer. Lanes 1 and 2 show 
molecular weight markers separated with the tricine running buffer.
A uniform acrylam ide tric ine-S D S gel covers a narrow  m ass range, for exam ple a 
16% gel covers the range 1-70 kD a and offers high resolution, especially for the small 
protein and peptide range. These uniform  acrylam ide tric ine-S D S  gels are alm ost 
exclusively used to separate very small proteins and peptides. Uniform  high- 
acrylam ide Laem m li gels cannot be used to access the small protein range, because 
the stacking lim it in the Laemm li system  is too high, and small proteins usually appear 
as sm earing bands near the gel front. In a less convenient way, how ever, the small 
protein and peptide range can be accessed by m aking use o f  gradient gels that 
continuously de-stack proteins according to decreasing m ass during electrophoresis. 
Laem m li-type gradient gels, for exam ple, 8 -16%  acrylam ide gels for the range 6 -250  
kDa, cover a w ide range o f  m asses [18]. To sim plify gel casting, in the absence o f  a 
gradient gel pourer, a “ layer” gel w as designed, as described in the m aterials and 
m ethods (section 2.3.1). The separating gel, approxim ately  2/3 o f  the gel, consists o f  a 
17% acrylam ide/bisacrylam ide at a 19:1 ratio and on top a “ spacer” layer o f  10% 
acrylam ide/bisacrylam ide which separates larger proteins betw een 70-200 kDa. And 
the up m ost layer a regular 4% stacking gel. This optim ised SD S-PA G E gel used in 
com bination w ith a tricine-Tris buffer could separate LM W  proteins very well and 
was useful for visualisation and control purposes throughout the thesis.
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3.2 Serum Pre-Fractionation Methods for MS Analysis
3.2.1 Affinity Chromatography
One o f the most commonly cited methods of depleting highly abundant proteins from 
serum samples is affinity removal [8, 9, 19]. At the time when this project was started, 
very little information was available on depletion kits and their effectiveness. 
Although with hindsight, the Poros® cartridges were not the best kit to use, as only two 
proteins are removed, we tested them for serum albumin and protein G removal. The 
cartridges were used as described by the manufacturer, except for the addition of 20% 
ACN to break protein-protein interactions, and detailed in the Materials and Methods 
(section 2.3.4). A crude serum sample was injected onto the cartridges and washed 
with PBS. The antibodies immobilised on the cartridges bind HSA and protein G, 
which were eluted after 15 minutes with 12 mM HC1. Fractions from the flow-through 
(FT) and the eluted fractions were collected and analysed using SDS-PAGE and 
MALDI-ToF MS. The Poros® depletion cartridges showed little specificity for 
albumin and protein G, all lanes showed gel bands for albumin, including lane 3 
(Figure 3.2 b) which should have contained proteins of the FT only. It was first 
suspected that the large amount o f albumin in the FT caused the lane to be smeared. 
However, MALDI-ToF MS analysis showed that relatively little HSA was present in 
the FT (Figure 3.2 c). Hence the smearing may have been due to the high salt content 
from the PBS, which despite Zip-Tip concentration may have interfered with SDS- 
PAGE. More importantly, very few protein peaks were shown in the MALDI-ToF 
mass spectrum of the FT, in fact most o f the peaks appear to be related (Figure 3.2 c). 
The major protein peak at m/z 14132.40 appears to be singly charged, forming a dimer 
at m/z 28280.07 and a doubly changed peak at m/z 7058.01 o f the same protein. 
Besides these three peaks the spectrum contains very few peaks o f significant 
intensity.
The eluted fraction in lane 7 should contain mainly albumin and protein G but also 
clearly shows many other protein bands in the gel o f a range o f molecular weights 
(Figure 3.2b). The same was observed by MALDI-ToF MS (Figure 3.2c).
Chapter 3: Serum Sample Preparation and Pre-fractionation 76
FT
1 1 2i 1—*-
wash
eluted 
y ' fraction
10 15
min
20
wash 1 wash 2 wash 3 eluent
\
Flow  th ro u g h
2 8 2 8 0 .0 78 7 6 .0
40
19834.20
E lu ted  frac tio n
17379.1060
,9050.41
1 3 9 1 3 .4 6
3 6 1 5 .9 6
:283 3 .1 2
1999.0 17599.6 33200.2 48800.8 64401.4 80002.0
Figure 3.2: Immunoaffinity depletion of HSA and protein G from serum. (A) HSA and protein 
G bind to the anti-HSA and protein G cartridges, while un-bound proteins were washed onto 
the flow-through (FT) shown at 3 min. The bound proteins eluted after 17 min with HC1. (B) 
Protein fractions were collected and separated on a 17% tricine-SDS-PAGE. In lanes 1 and 2 
molecular weight markers are shown, in lane 3 and in lanes 4-6 proteins from the FT and 
proteins that wash of the cartridges later are separated, respectively. In lane 7 proteins that 
were eluted from the cartridges are shown. (C) The MALDI-ToF MS spectrum shows proteins 
from the FT fraction and proteins that bound to the cartridges in the eluted fractions.
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These findings suggest that, despite diluting the semm to account for the capacity of 
the affinity cartridges, albumin was still present to a large degree in the "depleted" FT 
fraction and that many other proteins were removed, as they non-specifically bind or 
were removed alongside HSA. This is in accordance with other reports using 
immunoaffinity, where it was clearly reported that many proteins bind to these carrier 
proteins and are concomitantly removed [13, 20]. Trying to improve specificity in 
removing albumin, different buffers, PBS with and without 20% ACN and NH4 HCO3 
with and without 20% ACN, were tested. The results showed that PBS with 20% ACN 
to break protein-protein interactions returned the most proteins in the depleted 
fractions. None o f the other buffers tested improved the recovery o f LMW and low 
abundant proteins (data not shown). The high salt concentrations of PBS and HC1 
caused down-stream problems with MS and SDS-PAGE which make the method 
impractical and not very high-throughput. Additionally, at the time, there was little 
data available on longevity and reproducibility o f these affinity depletion systems. By 
now more accounts of immunoaffinity depletion using the Multiple Affinity removal 
System from Agilent can be found [8 , 11, 21]. The multi-affinity depletion cartridge 
appears to successfully remove the 6  most abundant proteins from serum, however the 
FT also requires desalting and treatment prior to further analysis [19, 22].
3.2.2 Protein Precipitation
Protein precipitation with trichloroacetic acid (TCA)/acetone, acetonitrile or ethanol 
has also been useful for removal o f albumin and other highly abundant serum proteins 
without the loss of the remaining peptides and proteins. The goal was that albumin 
remains soluble while the other proteins precipitate in the case o f TCA/acetone or 
albumin precipitates while the other proteins and peptides remain soluble for ethanol 
and acetonitrile precipitation. Organic solvents are miscible and reduce the water 
activity around the protein and the dehydrated hydrophobic areas make it less soluble. 
As the water is displaced, oppositely-charged areas o f different proteins become 
attracted and aggregate together. Albumin precipitation in serum relies on the “Cohn 
process” [23], where albumin is extracted and recovered from blood plasma. The 
process is based on the differential solubility o f albumin and other plasma proteins
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based on pH, organic solvent concentration, temperature, ionic strength, and protein 
concentration. Albumin has the highest solubility and lowest electric point o f all the 
major plasma proteins. This makes it the final product to be precipitated in 40% 
ethanol, or separated from its solution as a paste [23], This may be due to its size and 
isoelectric point; large proteins aggregate earlier as they have more surface area to 
interact with and their surface can be oppositely charged [24]. Using our method of 
albumin precipitation, one commonly used for removal o f albumin, albumin actually 
specifically precipitates using 100% ethanol. Although that is the reverse to what was 
described by the Cohn process, the process still applies as albumin appears to have 
specific characteristics and behaves differently to the other serum proteins. For 
albumin removal TCA appears to bind to albumin and render it soluble in organic 
solvents [25], so that all other proteins precipitate and albumin remains in the solution. 
It is not clear why albumin in particular remains soluble in organic solvents while 
other proteins do not. It may be due to the degree o f TCA binding to the protein, as 
albumin may have a large number o f TCA binding sites. Chen et a l  [25] tested the 
effect o f different organic solvents and acids to optimise the protocol and showed 
convincing results. Three different methods o f precipitation were tested as they were 
described in the literature and in the Materials and Methods (section 2.3.3). A 20 pi 
sample of human serum was precipitated as previously described using acetonitrile 
[20], ethanol [26] and TCA/acetone [25]. Although differences between the 
precipitation methods were observed, none o f them showed sufficient removal o f high 
abundant proteins (Figure 3.3). Albumin was still present in all the depleted fractions 
and further many other bands are visible in the fraction that should contain removable 
proteins only. In addition, very few proteins remained in the depleted fraction. 
TCA/acetone precipitation was most specific towards removing albumin from serum 
(Figure 3.3, lanes 6-7), similar to the results found by Chen Y. et a l  [25]. However 
strong denaturing agents were necessary to re-solubilise the precipitated proteins, 
which results in down-the-line complications such as protein quantification and MS 
compatibility.
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Figure 3.3: Serum preparation to reduce the protein complexity studied using 17% tricine SDS 
PAGE gels, stained with colloidal Coomassie blue. Proteins in the precipitate and the 
supernatant after solid-phase extraction using acetonitrile (albumin pellet: AP and protein 
supernatant: AS) are shown in lanes 5 and 9, ethanol (albumin pellet: EP and protein 
supernatant: ES) in lanes 4 and 8, and TCA/acetone (protein pellet: TP and albumin 
supernatant: TS) in lanes 6 and 7. Neat serum was run in lane 3 for comparison.
3.2.3 Weak Anion Exchange (WAX) Chromatography
W eak anion exchange chrom atography is a w idely used m ethod for separating 
proteins prior to enzym atic digestion and MS analysis [24, 27, 28], Ionic exchange 
separates proteins by their different net charge at a specific pH. The stationary phase 
inside the colum n binds proteins by electrostatic interactions. A nion exchange 
colum ns have a positively charged m atrix, where a single positively charged nitrogen 
atom is im m obilised on a chrom atography support. Proteins are ionized in solution, 
depending on the pH o f  the buffer and the pi o f  the protein. W hen the pH o f  the buffer 
is greater than the p i o f  the protein, this will becom e negatively charged and bind to 
the anion exchange colum n. G enerally proteins with a pi <8 will bind to an anion 
exchange colum n; for exam ple album in has a pi o f  4.6. As described in m ore detail in 
the M aterials and M ethod (section 2.3.5), serum was loaded onto the colum n and as 
the salt concentration (am m onium  acetate) increased w ith the gradient, m ore proteins 
eluted from the colum n. Fractions w ere collected and separated by SD S-PAG E. The 
m ajority o f  proteins bound to the colum n with great affinity and required a higher 
concentration o f  am m onium  acetate (Figure 3.4, lanes 11, 13 and 14). Some highly 
abundant proteins (such as album in) were eluted in single fractions (Figure 3.4, lanes 
6, 7 and 10). SD S-PA G E analysis o f  the fractions collected showed that, despite
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desalting, the fractions that were pooled had a much higher salt concentration and 
caused smearing in the gel (Figure 3.4, lane 12). Although WAX separation was able 
to fractionate the serum proteins successfully, it was decided that this form of pre- 
fractionation is not optimal for preparing a large amount of samples. There are at least 
10 fractions that would have to be collected and desalted for trypsin digestion and LC- 
MS/MS analysis. Desalting o f the fraction was a critical step as the high salt 
concentrations used in the elution gradient interfered with trypsin digestion and MS 
analysis. It was later discovered that desalting is possible using a high vacuum 
centrifugal concentrator (Jouan, Alterod, Denmark), however without this instrument 
desalting is a limiting factor for subsequent analysis. As the endpoint of this 
experiment, removal o f albumin, was shown using SDS-PAGE, no further 
investigations testing precipitation, affinity depletion or WAX were carried out.
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Figure 3.4: WAX separation (4.6 mm I.D x 100 mm, 1000 A) 90 min gradient 5% ACN, 0.6 
M NH4 Acetate) of neat serum proteins (A). Fractions were collected and pooled for 
visualisation by tricine-SDS-PAGE. Some of the fractions appear smeared due to an increased 
protein and salt concentration (B).
3.2.4 Centrifugal Ultrafiltration (UF)
U ltrafiltration is a sieving m echanism  creating two fractions. A retentate and a filtrate 
are formed, separating larger from sm aller proteins, respectively. UF has no absolute 
cu t-o ff point as som e larger proteins pass through the m em brane and som e sm all ones 
stay behind. As proteins are not tru ly  spherical, contain bound w ater w hen in serum  or 
are engulfed by a sheath o f  fluid, their actual size can be changed w hen passing 
through the m em brane. The shape especially  affects the diffusion coefficient o f  
individual proteins [29]. As soon as the trans-m em brane pressure is exposed by 
centrifugation, the solvent flux starts and the solvent is pushed tow ards the m em brane 
surface. The local solute concentration increases causing a concentration polarisation
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effect. Concentration can be taken to the extent that larger proteins aggregate and form 
a thixotropic gel (also called gel layer or filter cake). UF is a dynamic process and 
formation of the gel layer reduces the amount o f proteins passing through the 
membrane. The surface charge increases due to higher concentrations o f protein and 
electrostatic interactions cause particle-particle bonds, which reduce the passage of 
smaller proteins. However protein aggregation is reversible and by re-diluting the 
proteins in the retentate, interactions can be broken. This can be explained by a 
reduction of Gibbs free energy as the solute is dispersed. Prior to ultrafiltration 
acetonitrile was added to the sample in order to release proteins and peptides bound to 
albumin [4, 15, 20]. As the majority of highly abundant proteins are of higher 
molecular weight, they could be removed using UF (Figure 1.6 in the Introduction and 
Table 3.2). The process is not very labour intensive as only one fraction is produced 
with a relatively small subset of serum proteins. After lyophilisation and desalting, 
this fraction can be used directly for MS analysis. SDS-PAGE can be performed on 
the fraction without any further preparation. Figure 3.5 shows a good separation of 
high and low molecular weight proteins. For comparison crude serum was run in lane 
3 and to show reproducibility the filtrate and retentate o f two different UFs are shown. 
The UF fractions showed no loss of LMW proteins to the HMW fraction and no 
HMW proteins passing through the membrane (Figure 3.5). UF is shown to be more 
efficient for the removal o f HMW proteins such as albumin and immunoglobulins 
than Poros® affinity chromatography or precipitation. And furthermore this pre- 
fractionation method is higher-throughput as up to 24 filters can be prepared at one 
time in a large bench top centrifuge. It was therefore decided to use UF for further 
preparation of serum samples in MS biomarker discovery. The rest o f this chapter will 
deal with the evaluation and optimisation of UF to ensure the use o f the most effective 
and reproducible conditions for centrifugal UF for removal o f highly abundant 
proteins.
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Serum  LMW filtrate HMW fraction
Figure 3.5: Serum samples separated by centrifugal ultrafiltration. Lanes 1 and 2: molecular 
weight markers, lane 3: unfiltered serum (25 jug), lanes 4 and 5: LMW serum filtrate (50 pg) 
and lanes 6 and 7: HMW retentate (25 pg).
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3.3 Optimisation of UF for Biomarker Discovery
3.3.1 Evaluation of Different Centrifugal Filters
Following discussion with Millipore, a number of MWCO membranes were tested and 
compared. All filters were used according to the manufacturer’s specification. The 
aim o f the filtration was to either completely remove or sufficiently reduce the levels 
of albumin and IgG in the semm sample, and to amplify the LMW protein 
concentration. Additionally, as blocking of some filters had been observed, minimal 
blocking and easy use o f the filters was studied.
For semm fractionation Millipore recommended Amicon® Ultra-15 and Centriprep® 
centrifugal units. Centricon® Plus-20 and Centriplus® centrifugal filters were not 
recommended, as they were apparently designed for samples with low protein 
concentration (Figure 3.6). Nevertheless, the two latter filter types are the most 
commonly used in the literature for semm UF for proteomics studies [4, 14, 30-33].
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Figure 3.6: Millipore centrifugal ultrafiltration devices. The filtration mechanism of each filter 
is shown. (A) The Amicon Ultra filters are cross-flow membranes so that residue collecting at 
the bottom of the tube during centrifugation cannot block the membrane and the solvent 
passed tangentially. (B) In Centricon Plus filters the membrane is located in the middle of the 
device and the serum collects around the filter. Again this is a cross-flow membrane. (C) 
Centriprep filters work by a reverse centrifugal mechanism. The serum sample is in the lower 
tube; another tube with a dead-end filter at the end is placed close to the bottom and during 
centrifugation the LMW fraction is pushed directly through the filter up into the inner tube. 
(D) Centriplus devices have a dead-end membrane in the bottom of the upper tube; by 
centrifugal force small proteins are pushed directly through the membrane in to the lower cup. 
(Diagrams were taken from Millipore manuals.)
For com parison o f  the filters, the centrifugation speed and duration recom m ended by 
the m anufacturer w as used as shown in Table 3.1; assum ing that these conditions 
would be optim al. The m em branes w ere prepare as recom m ended by the m anufacturer 
and described in the M aterials and M ethods (section 2.3.2). Each filter was processed 
in duplicate. An aliquot o f  the same serum  sam ple was used for all filters.
Additionally to the different filters a new  centrifugation protocol w as also tested in an 
attempt to achieve better protein recovery using Centriplus* filters only. The serum
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sam ple was diluted and filtered tw ice to increase the recovery  o f  LM W  species 
especially those bound to album in and other HM W  proteins. The concentration o f  the 
serum w as reduced to avoid blocking o f  the filters and the centrifugation speed 
lowered to 750 xg. The protein concentration o f  each LM W  filtrate, from each filter 
type, was determ ined using a BCA assay and the filtrate w as further analysed using 
tricine-SD S-PA G E and M A LD I-ToF MS. Except for the A m icon U ltra (30 kDa) 
filters, all protein concentration recoveries were reproducible (Table 3.1).
Table 3.1: Running conditions used for each of the different UF membranes, also shown is the 
expected recovery o f cytochrome C (cyto C) and protein concentration recovered in the LMW 
filtrate with standard errors across 2 replicates.
Filter MWCO dilution sp e e d tim e
ex p e c te d  
cy to  C 
retention
LMW filtrate standard  
recovery  (%) error
Amicon A10 10 kDa 1 1 x2 2000 xg 40 min 95 3.4 0.95
Amicon Ultra 30 kDa 1 5x2 3000 xg 38 min 35 3.0 1.40
Amicon Ultra 50 kDa 1 5 3000 xg 38 min 35 1.6 0.10
Centricon Plus 30 kDa 1 20 x2 2000 xg 36 min 2.9 0.35
Centriprep 30 kDa 1 5 1500 xg 38 min 15 1.5 0.00
Centriplus 30 kDa 1 5 2000 xg 16 hours 75 2.4 0.19
Centriplus 50 kDa 1 5 2000 xg 16 hours 10 2.3 0.00
Centriplus 30 kDa 1 20 x2 750 xg 16 hours 75 2.6 0.41
Centriplus 50 kDa 1 20 x2 750 xg 16 hours 10 2.8 0.95
Tricine-SD S-PA G E and M A LD I-ToF MS analysis showed that m ost o f  the filters 
allowed som e album in to pass through the m em brane (Figure 3.7 and Figure 3.9). 
However, the results also showed that the filters recom m ended by M illipore (Am icon 
Ultra A30 and A50, Centriprep®  and A m icon®  U ltra A 10) w ere perm eable to 
album in and other proteins larger than the m olecular cu t-o ff value. Centriprep®  
colum ns showed no proteins at all in the LM W  fraction. The Centriplus®  filters on the 
other hand m anaged to retain the m ajor portion o f  album in and, when analysed by 
tricine gel electrophoresis, LM W  protein band intensities w ere increased com pared to 
neat serum and the filtrates from the other UF m em branes (Figure 3.7 and Figure 3.9). 
Although not recom m end for sam ples as concentrated as serum , the Centriplus®  
filters perform ed significantly better than the other filters tested. M ost convincingly, 
M ALD I-ToF MS show ed the superiority o f  the Centriplus®  filters in recovering
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LMW proteins m/z <6000 (Figure 3.9). Many more LMW peaks are shown in the 
spectrum and no peaks >10 kDa. In comparison, the spectra from the other filters 
show less LMW peaks and the Amicon filtrates contain may HMW proteins including 
albumin. As the LMW region was the main region o f interest, Centriplus® filters with 
a MWCO level of 50 kDa were chosen to be used for further analysis. Furthermore 
using the new protocol, higher concentrations o f LMW proteins were obtained o f a 
greater number of proteins.
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Figure 3.7: SDS-PAGE separation of the filtrate and retentate for comparison of the 
performance o f different centrifugal ultrafiltration membranes. ( A )  LMW filtrates, lane 1 and 
2: molecular weight markers; lanes 3-4: Amicon Ultra (30 kDa), lanes 5-6: Amicon Ultra (50 
kDa), lane 7-8: Centriprep (30 kDa) and lane 9-10: Centriplus (50 kDa). (B) HMW retentate 
of the same membranes as in A.
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Figure 3.8: SDS-PAGE separation of the filtrate and retentate for comparison of the 
performance of different centrifugal ultrafiltration membranes continued. (C) LMW filtrate 
from other filters: Lane 1-2: Amicon Ultra (30 kDa) spin 1; lanes 3-4: Centricon Plus (30 
kDa) spin 1, lane 5: Amicon Ultra (10 kDa) spin 1; lanes 7-8: Amicon Ultra (30 kDa) spin 2; 
lanes 6 and 9: Centricon Plus (30 kDa) spin 2, and lane 10: Amicon Ultra (10 kDa) spin 2. (D )  
Comparison o f Centriplus filters with different MWCO 30 and 50 kDa. Lanes 1 and 2: 
molecular weight markers; lanes 3-4: spin 1 of 30 kDa, lanes 5-6: spin 1 of 50 kDa filters, 
lanes 7-8: spin 2 of 30 kDa filters; lanes 9-10: spin 1 of 50 kDa filters.
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Figure 3.9: MALDI-ToF analysis of LMW filtrates form different Millipore membranes 
tested. Two mass ranges (A) 1000-10000 Da and (B) 6000-70000 Da are shown.
3.3.2 Centrifugation Speed and Protein Concentration
For m axim um  recovery o f  LM W  proteins 50 kD a M W CO  filters were used 
throughout the rem aining study, as according to the m anufacturer these allow the 
m ajority o f  LM W  proteins to pass through the m em brane w hilst efficiently retaining 
high m olecular w eight proteins. Earlier experim ents, using serum  sam ples at a 
concentration o f  12 m g/m l, resulted in the form ation o f  a gel layer and protein loss.
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This gel layer has previously been described to contain albumin and fibrinogen [34, 
35]. However, to resolve this, the serum sample was diluted to a concentration o f 3 
mg/ml and the retentate re-diluted for a second round o f filtration. The centrifugation 
speed during UF influences the recovery and retention o f proteins. The recommended 
centrifugation speed is 3000 xg, however it has been hypothesised that a lower speed 
may allow more time for small proteins/peptides to be released from larger molecules. 
In a report by Georgiou [30] the filters were used at very high centrifugation speeds, 
which resulted in insufficient retention o f high abundance proteins, 64% of proteins 
passed through the filter into the filtrate [30]. Another report, using UF for LMW 
proteome purification used the recommended centrifugation speed of 3000 xg; here 
0.2% LMW proteins o f the total serum proteome were isolated [4], however it was 
also estimated that the LMW proteome should make up at least 1% of all serum 
proteins. In this study, lowering the centrifugation speed from 3000 xg to 750 xg 
increased the recovery of LMW proteins by 0.7% (determined by BCA protein assay). 
Using a more dilute starting material, lower spin speed and multiple filtrations, we 
were able to recover 2.8% of the total protein content. The SDS-PAGE analysis 
confirmed that proteins isolated were of LMW as no bands were visible in the upper 
region of the gel (Figure 3.6).
To investigate whether the lower centrifugation speed would benefit protein 
identification, each filtrate was analysed by LC-MS/MS. For this, un-filtered crude 
serum and the LMW filtrates from UF at 3000 xg and 750 xg were analysed by 1D- 
LC-MS/MS after enzymatic digestion with trypsin. The MS/MS spectra were searched 
and analysed against the UniProt human FASTA database using TurboSequest 
through Bioworks 3.2 [36] as described in the Materials and Methods (section 2.8). 
The results shown are all from fully tryptic peptides amd filtered within the Bio works 
Browser for peptide probability (P = 0.001), for higlh stringency cross correlation 
(Xcorr) 1+, 2+, 3+ = 1.9, 2.5, 3.2 and delta correlation (deltaCn) = 0.08. For increased 
confidence in the proteins mapped from identified pepttides, the result filters were set 
relatively stringent, so only fragmentation spectra with good b and y  ion sequences 
were identified from the database (Figure 3.10). As a result some proteins may have 
been lost from the identification list. To increase protein identifications each protein 
digest was analysed by LC-MS/MS in duplicate and the results combined.
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Figure 3.10: Tandem MS analysis of the precursor m/z 554.94, all h and y ions were 
accounted for. This peptide was matched to plasma retinol binding protein 
(RETBP_HUMAN), which occurs at relatively low serum concentrations (3.17 pg/ml).
The proteins m atched by TurboSequest are listed in Table 3.2. W hile 27 proteins were 
detected in crude serum , 13 were album in or im m unoglobulin. In addition, h a lf  (13) o f  
the proteins w ere m atched by only 1 peptide. As shown, 17 o f  the 24 proteins with 
inform ation on serum  concentration levels w ere from high abundance proteins [37]. 
Only 4 low abundance proteins were detected and the dynam ic range o f  protein 
concentrations covered 4 orders o f  m agnitude w ith pregnancy zone protein precursor 
the lowest reported protein concentration o f  8.4 pg/m l. The m ost abundant protein 
detected, as expected, w as serum album in identified with 45 unique peptides.
In com parison, after UF the lowest abundant protein detected was prothrom bin 
precursor which has a reported serum concentration o f  1.2 ng/m l. The dynam ic range 
o f  protein concentrations in the LM W  filtrate (750 xg) was show n to be over a range 
o f  7 orders o f  m agnitude. Peptide m ass fingerprinting further em phasised the need for 
album in depletion and protein pre-fractionation prior to further analysis.
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Identification o f  proteins in the LM W  filtrate after 750 xg com pared to 3000 xg 
show ed an increase o f  22%  m ore proteins in the 750 xg LM W  filtrate. Further, 
com parison o f  the LC-M S/M S results from the LM W  filtrates with those o f  un-filtered 
crude serum  show ed m any proteins w ere rem oved from the LM W  filtrate, including 
12 im m unoglobulins (Figure 3.11). In conclusion, a spin speed o f  750 xg, lower 
sam ple concentration and m ultiple filtrations were found to be the optim al UF 
conditions for an efficient serum sam ple preparation and were used for future analysis.
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Figure 3.11: The Venn diagrams illustrate the overlap of protein identifications after LC- 
MS/MS analysis from different processing procedures. Comparing neat serum and two 
different centrifugation speeds (3000 xg and 750 xg). An increase in protein identifications 
was observed in UF filtrates using the lower spin speed protocol. Additional proteins were 
identified that are usually masked during proteomic analysis of neat serum.
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Table 3.2: Proteins detected by RP-LC-MS/MS in crude serum and serum UF at 3000 x g and 
750 x g in comparison. Highly abundant proteins in serum are highlighted in bold (the 
information on serum abundance was taken from Polanski and Anderson [ 3 7 ]  and high and 
low levels from Tanaka et al. [ 3 8 ] ) .
A cc e ss io n
no Protein Sw issP rot ID
Protein
probability
M olecular Matched 
m a ss p eptides
Abundance
(pg/ml)
c ru d e  s e ru m
P02768 Serum  album in precursor ALBUJHUMAN 1.47E-12 69322 45 4.10E+10
P02787 Serotransferrin precursor TRFE_HUMAN 8.44E-14 77000 15 4.00E+09
P01009 A lpha-1-antitrypsin precursor A1AT_HUMAN 3.20E-07 46707 6 1.40E+09
P01023 Alpha-2-m acroglobulin precursor A2MG_HUMAN 4.75E-09 163174 6 1.80E+09
P02647 A polipoprotein A-l precursor APOA1_HUMAN 1.30E-10 30759 6 1.40E+09
P01857 Ig gam m a-1 chain  C region IGHG1_HUMAN 1.82E-11 36083 6 high
P00738 H aptoglobin precursor HPT_HUMAN 2.37E-07 45177 4 1.25E+09
P01876 Ig alpha-1 chain  C region IGHA1_HUMAN 4.08E-08 37631 4 high
P01842 Ig lambda chain  C regions LAC_HUMAN 2.26E-10 11230 4 high
P02774 Vitamin D-binding protein precursor VTDBHUMAN 1.41E-08 52929 3 ?
P01877 Ig alpha-2 chain  C region IGHA2_HUMAN 4.08E-08 36485 2 high
P01859 Ig gam m a-2 chain C region IGHG2_HUMAN 1.37E-06 35862 2 high
P01861 !g gam m a-4 chain C region IGHG4_HUMAN 1.82E-11 35918 2 high
P01834 Ig kappa chain  C region KAC_HUMAN 3.33E-08 11602 2 high
P01011 Alpha-1 -antichymotrypsin precursor AACT_HUMAN 1 04E-04 47621 1 ?
P02765 Alpha-2-HS-glycoprotein precursor FETUA_HUMAN 5.71 E-06 39300 1 6.10E+08
P01019 A ngiotensinogen precursor ANGTHUMAN 1.45E-07 53121 1
P 04114 Apolipoprotein B-100 precursor APOB_HUMAN 1.27E-07 515242 1
P02656 Apolipoprotein C-lll precursor APOC3_HUMAN 4.22E-05 10846 1 1.20E+08
P01024 C om plem ent C3 precursor C 03H U M A N 1.49E-04 187045 1 high
P01766 Ig heavy chain  V-lll HV3E_HUMAN 1.17E-08 13218 1 high
P01597 Ig kappa chain  V-l KV1E_HUMAN 7.17E-07 11654 1 ?
P01620 Ig kappa chain  V-lll KV3B_HUMAN 1.26E-10 11768 1
P01625 Ig kappa chain  V-IV KV4A_HUMAN 1.61E-05 12632 1 ?
P01871 Ig mu chain C region MUCJHUMAN 1.95E-04 49526 1 -
P19823 Inter-alpha-trypsin inhibitor ITIH2_HUMAN 7.16E-04 106370 1 low
P20742 P regnancy zone protein precursor PZP_HUMAN 1.27E-08 163732 1 8.36E+06
U F  a t 3 0 0 0  xg
P06727 Apolipoprotein A-IV precursor APOA4_HUMAN 5 65E-13 45372 11
P02671 Fibrinogen alpha chain precursor FIBA_HUMAN 1.97E-09 94914 8 high
P02647 A polipoprotein A-l precursor APOA1_HUMAN 3.07E-08 30759 6 1.40E+09
P01024 C om plem ent C3 precursor C03_HUMAN 3.13E-11 187045 3 high
P02768 Serum  album in precursor ALBU_HUMAN 1.85E-08 69322 3 4.10E+10
P02765 Alpha-2-HS-glycoprotein precursor FETUAJHUMAN 8.22E-14 39300 2 6.10E+08
P02656 Apolipoprotein C-lll precursor APOC3_HUMAN 2.58E-09 10846 2 1 20E+08
P00734 Prothrombin precursor THRBHUM AN 3 28E-07 69992 2 1.20E+03
P02652 Apolipoprotein A-ll precursor APOA2HUM AN 1.91E-04 11168 2 2.44E+08
P02775 Platelet b asic  protein precursor SCYB7_HUMAN 4.40E-09 13885 1 5.94E+09
014791 Apolipoprotein-L1 precursor APOL1_HUMAN 1 37E-07 43900 1
P01009 A lpha-1-antitrypsin precursor A1AT_HUMAN 2.33E-09 46707 1 1.40E+09
P0C0L5 C om plem ent C4-A precursor C04A_HUMAN 7 84E-06 192672 1
P01042 Kininogen-1 precursor KNG1_HUMAN 8.62E-05 71900 1
P61769 Beta-2-microglobulin precursor B2MGHUMAN 1 49E-07 13706 1 2.05E+06
U F  a t 750  x g
P06727 Apolipoprotein A-IV precursor APOA4 HUMAN 5.69E-12 45372 13
P02647 A polipoprotein A-l precursor APOA1_HUMAN 1.21E-10 30759 11 1.40E+09
P02671 Fibrinogen alpha chain precursor FIBA_HUMAN 1.01E-08 94914 7 high
P01024 C om plem ent C3 precursor C03_HUMAN 1.30E-09 187045 5 high
P02765 Alpha-2-HS-glycoprotein precursor FETUA_HUMAN 1 88E-12 39300 3 6 10E+08
P02656 Apolipoprotein C-lll precursor APOC3_H U M AN 1.20E-12 10846 3 1.20E+08
P01009 Alpha-1-antitrypsin precursor A1AT_HUMAN 8.54E-10 46707 3 1.40E+09
P02652 Apolipoprotein A-ll precursor APOA2HUM AN 3.43E-06 11168 3 2.44E+08
P02775 Platelet basic protein precursor SCYB7_HUMAN 9.48E-10 13885 2 5.94E+09
P00734 Prothrombin precursor THRBJHUMAN 2.05E-10 69992 2 1.20E+03
P02766 Transthyretin precursor TTHY_HUMAN 4.60E-09 15877 2 3.00E+08
P02768 Serum  albumin precursor ALBU_HUMAN 1.22E-04 69322 1 4.10E+10
P00751 C om plem ent factor B precursor CFABHUMAN 1.39E-07 85479 1
P01842 Ig lam bda chain  C regions LAC_HUMAN 9.88E-09 11230 1 high
P02655 Apolipoprotein C-ll precursor APOC2_HUMAN 1.65E-05 11277 1
014791 Apolipoprotein-L1 precursor APOL1_HUMAN 1.02E-06 43900 1
P02753 Plasm a retinol-binding protein precursor RETBP_HUMAN 7.18E-05 22995 1 3.17E+07
P08697 Alpha-2-antiplasm in precursor A2AP_HUMAN 2.17E-05 54531 1
P01042 Kininogen-1 precursor KNG1_HUMAN 8.09E-05 71900 1
P02654 Apolipoprotein C-l precursor APOC1JHUMAN 9 52E-04 9326.1 1 6.10E+07
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The num ber o f  detected proteins in the LM W  filtrate w as relatively low and since the 
m agnitude o f  protein concentrations is large it w as assum ed that the filtrate is still too 
com plex for 1D-LC-M S/M S. Therefore the LM W  serum  sam ple was first separated 
by tricine-SD S-PA G E and all bands were excised and trypsin digested (Figure 3.12). 
The extracted peptides were then analysed by LC-M S/M S and identified against the 
hum an FA STA database using Biow orks v. 3.2 as described above. This m ay give a 
m ore com prehensive account o f  what is actually present in the LM W  filtrate.
15-20
Figure 3.12: SDS-PAGE of LMW serum proteins run in two lanes. The individual MW bands 
were excised and individually digested for peptide mass fingerprinting by LC-MS/MS. Bands 
15-20 were excised every 2mm across both lanes for increased recovery of proteins.
In total, 47 proteins w ere detected from all the bands excised. In each band an obvious 
protein was detected w ith a high num ber o f  peptides and the “correct” m olecular 
weight, highlighted in bold (Table 3.3). Som e low abundance proteins not detected in 
crude serum w ere identified including prothrom bin precursor, as before. A bove, to 
increase the num ber o f  identifications from the LM W  filtrates, the peptide results 
from two independent 1D-LC-M S/M S runs were com bined. This was not possible for 
the gel bands; otherw ise even more proteins with higher confidence m ay have been 
detected. Proteins w ith a very high m olecular w eight were detected in some o f  the
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lower gel bands. It is possible that these proteins originate from split o f subunits or 
fragments during the UF in the denaturing buffer. Moreover, the presence o f a much 
reduced proportion of some highly abundant HMW proteins in the filtrate was to be 
expected as UF is a dynamic process and the shape o f a molecule can cause it to slip 
through the pores of the membrane. However, albumin and other HMW proteins were 
removed satisfactorily, allowing the detection of other less abundant proteins during 
MS or electrophoresis (Table 3.2 and Figure 3.12).
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Table 3.3: Proteins detected from gel bands of LMW serum by LC-MS/MS. 47 unique 
proteins were detected, proteins that match the molecular weight of the gel band are marked in 
bold, abundance levels in serum were taken from www.plasmaproteome.org [37] and 
high/low indicators from [38]. High abundance proteins (> 1.0 xlOl) pg/pl) are marked in 
bold.
A cc e ss io n
no Protein S w issP ro t ID
Protein
probability
M olecular
m a ss
M atched
p ep tid es
ab u n d an ce
(pg/m l)
Protein gel ban d  1
P01042 K ininogen-1 precursor KNG1_HUMAN 9.12E-04 71900.1 1
P02768 Serum  album in precursor ALBU_HUMAN 1.03E-09 69321.6 17 4.10E+10
P02790 H em opexin  precursor HEMO_HUMAN 2.45E-06 51643.3 2
P01009 A lpha-1-antitrypsin p recursor A1AT_HUMAN 7.45E -11 46707.1 3 1.40E+09
P06727 Apolipoprotein A-IV precursor A POA4HUM AN 1.33E-08 45371.5 1 high
P02647 Apolipoprotein A-l precursor APOA1_HUMAN 4.16E-09 30758.9 2 1.40E+09
Protein gel ban d  2
Q5TAX3 Zinc finger CCHC dom ain-containing protein 11 ZCH11_HUMAN 7.36E-04 185015.3 1
P02768 Serum  album in p recurso r ALBUJHUMAN 7.38E-08 69321.6 1 4.10E+10
P14136 Glial fibrillary a cid ic  protein, astrocy te GFAP_HUMAN 7.49E-08 49849.7 1
P06727 A polipoprotein  A-IV precursor APOA4_HUMAN 8.37E-12 45371.5 18 high
P25311 Zinc-alpha-2-glycoprotein p recursor ZA2GJHUMAN 5.99E-08 33850.9 3
P02647 Apolipoprotein A-l precursor AP0A1_HUMAN 1.62E-08 30758.9 2 1.40E+09
Protein gel ban d  3
P01024 C om plem ent C3 precursor C 03H U M A N 1 53E-05 187045.3 1 high
Q 14624 Inter-alpha-trypsin inhibitor heavy chain H4 p recursor ITIH4JHUMAN 3.38E-12 103294.1 6 low
P02671 Fibrinogen alpha chain precurso r FIBAJHUMAN 4.11E-07 94914.3 1 2.72E+09
P00751 C om plem ent factor B precurso r CFAB HUMAN 3.33E-07 85478.6 2 high
P01042 Kininogen-1 p recu rso r (Alpha-2-thiol p ro te inase KNG1_HUMAN 8.25E-04 71900 1 1
P01009 A lpha-1-antitrypsin precursor A1AT_HUMAN 1.42E-10 46707.1 1 1.40E+09
P06727 A polipoprotein  A-IV precursor APOA4_HUMAN 4.69E-07 45371.5 5 high
P02760
AMBP protein p recursor [C ontains: Alpha-1- 
m icroglobulin AMBP_HUMAN 7.79E-07 38974.0 1
P02647 A polipoprotein  A-l precursor APOA1_HUMAN 2.58E-12 30758.9 13 1.40E+09
P00915 Carbonic an h y d ra se  1 CAH1JHUMAN 1 80E-06 28721.3 1 low
P24592 Insulin-like growth factor-binding protein 6 p recursor IBP6_HUMAN 4.76E -11 25306.2 1
P02753 P lasm a retinol-binding protein p recursor RETBP_HUMAN 5.55E-07 22995 3 1 3.17E+07
P41222 P rostaglandin-H 2 D -isom erase precursor PT GDS_H U MAN 1 30E-07 21015.4 1
P02766 Transthyretin  precurso r TTHY_HUMAN 4.03E-08 15877.1 4 3.00E+08
Protein gel ban d  4
Q 14624 Inter-alpha-trypsin inhibitor heavy chain H4 p recursor ITIH4_HUMAN 3.67E-06 103294.1 1 low
P06727 A polipoprotein  A-IV precursor APOA4_HUMAN 1.48E-08 45371.5 11 high
P02647 A polipoprotein  A-l precursor APOA1_HUMAN 9.83E-09 30758.9 7 1.40E+09
P00915 C arbonic an hyd rase 1 CAH1_HUMAN 1.07E-06 28721.3 4 low
P 02753 P lasm a retinol-binding protein p recursor RETBP_HUMAN 3.90E-05 22995 3 1 3.17E+07
P 41222 Prostaglandin-H 2 D -isom erase precursor PTGDSJHUMAN 8.96E-08 21015.4 2 3.00E+08
P 02766 Transthyretin  precursor TTHY_HUMAN 5.88E-08 15877.1 3 3.00E+08
P 01842 Ig lam bda chain C regions LAC_HUMAN 1.32E-08 11229.5 1 high
Protein gel band 5
B asem en t m em brane-specific hepa ran  sulfate 
P98160 proteoglycan core protein p recursor PGBM_HUMAN 2.87E-04 468528.2 1
P02671 Fibrinogen alpha chain p recursor FIBAJHUMAN 8.72E-06 94914.3 2 2.72E+09
P 01009 A lpha-1-antitrypsin precursor A1ATJHUMAN 1.52E-09 46707.1 1 1.40E+09
P 06727 A polipoprotein A-IV precursor AP0A4_HUMAN 7.90E-12 45371.5 2 high
P 02649 Apolipoprotein E p recursor APOE_HUMAN 4.73E-09 36131.8 1 ?
P02647 A polipoprotein  A-l precursor AP0A1_HUMAN 3.46E-11 30758.9 18 1.40E+09
P00746 C om plem en t factor D precursor CFAD_HUMAN 2.49E-05 26986.8 1 high
P22352 G lutathione p erox id ase  3 precursor GPX3_HUMAN 1.82E-08 25489.0 4
P02753 Plasm a retinol-b inding protein precursor RETBP_HUMAN 5.68E-07 22995.3 3 3.17E+07
P02766 Transthyretin precursor TTHY_HUMAN 2.99E-12 15877.1 4 3.00E+08
P02775 P latele t basic  protein precursor SCYB7_HUMAN 6.06E-06 13885 4 1 low
P01623 Ig kappa chain V-lll region WOL KV3E_HUMAN 9.34E-08 11738.9 5 high
P01842 Ig lam bda chain C regions LAC_HUMAN 7.55E-09 11229.5 2 high
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A ccess io n
no Protein S w issP rot ID
Protein
probability
M olecular
m a ss
M atched
p ep tid es
ab u n d an ce
(pg/rnl)
Protein gel band 6
B asem en t m em brane-specific hep a ran  sulfate 
P98160 proteoglycan core protein precursor PGBM_HUMAN 4.77E-07 468528.2 1
P02671 Fibrinogen alpha chain p recursor FIBAJHUMAN 1.54E-10 94914.3 2 2.72E+09
P01042 Kininogen-1 p recurso r KNG1JHUMAN 1.34E-05 71900.1 1
P02768 Serum  album in p recursor ALBUJHUMAN 9.70E-06 69321.6 1 4.10E+10
P01009 Alpha-1-antitrypsin precursor A1ATJHUMAN 1.59E-10 46707.1 2 1.40E+09
P 06727 Apolipoprotein A-IV precursor APOA4_HUMAN 1.88E-10 45371.5 18 high
P 02647 Apolipoprotein A-l precursor APOA1_HUMAN 7.64E-10 30758.9 8 1.40E+09
P22352 G lutathione p erox id ase  3 precursor GPX3 1.57E-05 25489.0 3
P16035 M etalloproteinase inhibitor 2 precursor TIMP2_HUMAN 7.66E-12 24383.1 1 3.40E+04
P02753 P lasm a retinol-b inding protein precursor RETBP_HUMAN 3.06E-08 22995.3 6 3.17E+07
P02766 Transthyretin precursor TTHY_HUMAN 3.23E-11 15877.1 5 3.00E+08
P02775 Platelet basic  protein precursor SCYB7_HUMAN 1.29E-08 13885.4 1 low
P02656 Apolipoprotein C-lll p recursor APOC3_HUMAN 1.16E-08 10845.5 1 1.20E+08
Protein gel band  7
Q9H8L6 Multimerin-2 p recursor MMRN2JHUMAN 1.53E-08 104352.1 1
P02671 Fibrinogen alpha chain p recursor FIBAJHUMAN 3.14E-06 94914.3 2 2.72E+09
P01042 Kininogen-1 precurso r KNG1JHUMAN 2.27E-06 71900.1 2
P06727 Apolipoprotein A-IV precursor APOA4_HUMAN 1.65E-08 45371.5 7 high
P02647 Apolipoprotein A-l precursor APOA1JHUMAN 6.46E-08 30758.9 2 1.40E+09
P02753 P lasm a retinol-b inding protein precursor RETBP_HUMAN 4.93E-08 22995.3 6 3.17E+07
P02766 Transthyretin precursor TTHYJHUMAN 1.02E-08 15877.1 6 3.00E+08
Protein gel band 8
P02787 Serotransferrin  precursor TRFE_HUMAN 7.39E-07 76999.7 1 4.00E+09
P02768 S erum  album in p recurso r ALBUJHUMAN 7.17E-08 69321.6 4 4.10E+10
P01857 Ig gam m a-1 chain C region IGHG1JHUMAN 1.57E-10 36083.2 1 high
P02647 Apolipoprotein A-l precursor _HUMAN 5.37E-07 30758.9 3 1.40E+09
P02766 Transthyretin precursor TTHYJHUMAN 6.29E-09 15877.1 4 3.00E+08
Protein gel band 9
P 02768 Serum  albumin p recurso r ALBUJHUMAN 4.93E-06 69321.6 3 4.10E+10
P06727 Apolipoprotein A-IV precursor APOA4_HUMAN 1.17E-04 45371.5 1 high
P01857 Ig gam m a-1 chain C region IGHG1HUM AN 1.64E-11 36083 2 1 high
P02647 Apolipoprotein A-l precursor APOA1JHUMAN 6.75E-04 30758.9 1 1.40E+09
P02766 Transthyretin precursor TTHY_HUMAN 6.53E-08 15877.1 6 3 00E+08
P02656 Apolipoprotein C-lll p recursor APOC3 JHUMAN 3.17E-09 10845.5 1 1.20E+08
Protein gel band 10
P02671 Fibrinogen alpha chain precursor FIBA JHUMAN 5.07E-07 94914.3 1 2.72E+09
P01009 Alpha-1-antitrypsin precursor A1 AT JHUMAN 6.72E-09 46707.1 1 1.40E+09
P06727 Apolipoprotein A-IV precursor APOA4_HUMAN 1 49E-07 45371.5 3 high
P02766 Transthyretin precursor TTHYJHUMAN 3.84E-09 15877.1 5 3.00E+08
P01034 C ystatin C precursor CYTC_HUMAN 5.05E -11 15789.1 3 3.20E+05
P07737 Profilin-1 PROF1_HUMAN 2.46E-06 14913.5 1
P02775 P latelet basic  protein precursor SCYB7HUM AN 5.47E -11 13885.4 1 low
P02655 Apolipoprotein C-ll p recursor APOC2 HUMAN 3.49E-07 11276.8 1
P02656 Apolipoprotein C-lll p recursor APOC3_HUMAN 5.50E-07 10845.5 1 1.20E+08
Protein gel band 11
P 06727 Apolipoprotein A-IV precursor APOA4_HUMAN 3.86E-08 45371.5 1 high
P02766 Transthyretin  p recursor TTHYJHUMAN 1.46E-06 15877.1 1 3.00E+08
P02775 Platelet b a sic  protein precursor SCYB7JHUMAN 1.16E-08 13885.4 2 low
P61769 B eta-2-m icroglobuiin  precursor B2MG_HUMAN 3.98E-05 13705.9 1 2.05E+06
P02655 Apolipoprotein C-ll precursor APOC2 JHUMAN 1.86E-04 11276.8 1
P02656 Apolipoprotein C-lll p recursor APOC3_HUMAN 4 45E-10 10845.5 1 1.20E+08
Protein gel band 12
P01042 Kininogen-1 p recurso r KNG1JHUMAN 4.64E-05 71900.1 1
P02775 Platelet b asic  protein precursor SCYB7_HUMAN 5.94E-09 13885.4 2 low
P02656 Apolipoprotein C-lll precursor APOC3_HUMAN 2.76E-09 10845.5 1 1 20E+08
Chapter 3: Serum Sample Preparation and Pre-fractionation 99
A cc e ss io n Protein M olecular M atched ab un d an ce
no Protein S w issP ro t ID probability m a ss p ep tid es (pg/ml)
Protein gel ban d  13
P02656 A polipoprotein  C-lll precursor APOC3_HUMAN 3.80E-09 10845.5 1 1.20E+08
Protein gel ban d  14
P02671 Fibrinogen alpha chain precurso r FIBAJHUMAN 3.82E-06 94914.3 4 2.72E+09
P 01042 Kininogen-1 p recurso r KNG1JHUMAN 5.00E-04 71900.1 1
P48677 Glial fibrillary acidic protein homolog GFAP_HUMAN 2.92E-06 41824.5 1
P02649 Apolipoprotein E p recursor APOE_HUMAN 1.26E-07 36131.8 1 ?
P02647 Apolipoprotein A-l precursor APOA1_HUMAN 1.51E-09 30758.9 4 1.40E+09
P 02775 P latelet basic protein precursor SCYB7 JHUMAN 4.02E-08 13885.4 2 low
P02655 A polipoprotein  C-ll precursor APOC2 JHUMAN 6.08E-06 11276.8 4
P02652 A polipoprotein  A-ll precursor APOA2_HUMAN 1.35E-04 11167.9 1 2.44E+08
P02656 A polipoprotein  C-lll precursor APOC3_HUMAN 6.92E-10 10845.5 3 1 20E+08
P02776 Platelet factor 4 precursor PLF4_HUMAN 4.25E-05 10837.9 1 9 70E+03
Protein gel ban d  15
P02647 Apolipoprotein A-l precursor APOA1JHUMAN 5.49E-09 30758.9 1 1.40E+09
P02652 A polipoprotein  A-ll precursor APOA2_HUMAN 8.74E-04 11167.9 1 2 44E+08
P02656 A polipoprotein  C-lll precursor APOC3JHUMAN 4.49E-10 10845.5 1 1.20E+08
P02654 A polipoprotein  C-l precursor APOC1_HUMAN 7.77E-05 9326.1 1 6.10E+07
Protein gel band 16
P02671 Fibrinogen a lpha chain p recursor FIBAJHUMAN 3.45E-05 94914.3 1 2.72E+09
P00734 Prothrom bin p recurso r THRB JHUMAN 6.05E-05 69992 2 3 1.20E+03
P06727 Apolipoprotein A-IV precursor APOA4 HUMAN 3.86E-04 45371.5 1 high
P02647 Apolipoprotein A-l precursor
Secretory  granule proteoglycan core protein
APOA1JHUMAN 1 03E-08 30758.9 2 1.40E+09
P10124 precursor PGSG_HUMAN 7.99E-06 17612.6 1
P02766 T ransthyretin p recursor TTHY HUMAN 1.40E-08 15877.1 2 3.00E+08
P02775 Platelet basic protein precursor SCYB7_HUMAN 1.28E-04 13885 4 1 low
P02652 A polipoprotein  A-ll precursor APOA2_HUMAN 1.54E-07 11167.9 2 2.44E+08
P02656 A polipoprotein  C-lll precursor APOC3_HUMAN 6.04E-10 10845.5 1 1.20E+08
P02654 A polipoprotein  C-l precursor APOC1JHUMAN 6.29E-06 9326.1 2 6.10E+07
Protein gel ban d  17
P01042 Kininogen-1 p recurso r KNG1JHUMAN 5.23E-05 71900.1 1
POO734 Prothrom bin p recurso r THRB JHUMAN 1 92E-05 69992.2 1 1.20E+03
P02765 Alpha-2-H S-glycoprotein p recursor FETUA_HUMAN 1.32E-07 39299 7 2 6.10E+08
P02655 A polipoprotein  C-ll precursor APOC2_HUMAN 1.34E-04 11276.8 1
Protein ge l ban d  19
P01024 Com plem ent C3 precurso r C 0 3  JHUMAN 6.61 E-07 187045.3 1 high
P01042 Kininogen-1 precurso r KNG1JHUMAN 3.30E-04 71900.1 1
P02765 Alpha-2-H S-glycoprotein precurso r FETUA_HUMAN 4.79E-06 39299.7 2 6 10E+08
Protein gel band 20
P20742 P regnancy  zone  protein precursor PZP_HUMAN 1 08E-04 163732.1 2 8.38E+06
P01023 Alpha-2-m acroglobulin p recursor A2MGJHUMAN 1 88E-07 163174.3 7 1.80E+09
P01876 Ig alpha-1 chain C region IGHA1JHUMAN 1.31E-06 37630.7 2 high
P01857 Ig gam m a-1 chain C region IGHG1JHUMAN 9.49E-10 36083.2 3 high
P01781 Ig heavy chain  V-lll region HV3T_HUMAN 3.52E-06 12722.2 2
P01597 Ig kappa chain  V-l region KV1E_HUMAN 7.72E-10 11653.8 8
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3.3.3 Investigation of Possible Contamination from the Filter Material
It has been hypothesised that the centrifugal filters could contaminate the serum 
sample with foreign molecules (e.g. glycerine) that would be detectable during 
MALDI-ToF MS or in a SDS-PAGE gel. To test this, and to ensure the UF process 
does not interfere with subsequent analysis, the denaturing buffer was filtered 3x and 
collected each time. This was then lyophilised, loaded on a gel and analysed by 
MALDI-ToF MS highly concentrated. Neither tricine-SDS PAGE nor MALDI-ToF 
MS analysis detected any contaminants in the buffer. This was important when 
identifying MS peaks to make sure all peaks originate from the serum sample.
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3.4 Discussion and Conclusions
In this chapter some fundamental decisions on pre-fractionation of serum samples 
were made. This was important so that sample preparation could be efficient during 
biomarker experiments. It was established that un-filtered crude serum is too complex 
for analysis of all proteins in one step. Pre-fractionation is necessary to remove high 
abundance proteins such as albumin and IgGs. For visualisation o f the proteins, SDS- 
P AGE for LMW proteins was optimised and it was found that a combination o f high 
percentage separating gels with a spacer layer and tricine-Tris electrophoresis buffer 
can significantly improve resolution o f LMW bands compared to Laemmli gels run 
with glycine-Tris buffer. For removal o f high abundance proteins UF was compared to 
albumin depletion, protein precipitation and WAX separation. Centrifugal UF was 
found to be superior compared to alternative depletion methods. Depletion was 
possible in a single step, producing one fraction without the need for high salt buffers. 
However all methods suffered from non-specific removal o f other proteins and 
incomplete removal of albumin. Optimising UF membranes were tested and the 
centriplus filters were found to be most effective. Here an optimised UF protocol 
using 50 kDa MWCO filters, at a reduced centrifugation speed (750 xg), collecting 
two successive filtrates was proposed. The use o f UF enabled detection o f proteins 
with a range of serum concentrations over 7 orders o f magnitude. Low abundance 
proteins of ng/ml were detected in LMW filtrates, 3 orders o f magnitude lower than 
detected in crude serum. Hence we established that UF is a good method for removal 
of albumin and that the LMW sub-proteome has a small enough complexity for 
proteomic analysis. As a next step the reproducibility of UF has to be validated to test 
their usefulness for biomarker discovery.
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CHAPTER 4
Centrifugal Ultrafiltration: Reproducibility and 
Efficiency
Despite the wide use of ultrafiltration (UF) for serum proteome fractionation [1-8], 
this approach has not been studied for efficiency and reproducibility in detail, only 
one report [9] testing the reproducibility o f protein recovery from centrifugal 
membranes has been published. At the time the work for this chapter was carried out, 
Tammen et al. [9] had not published their data and also a completely different 
approach had been taken. It is particularly important to use a robust and reproducible 
sample preparation protocol for protein profiling and biomarker discovery.
The optimised UF protocol for sample preparation significantly improved detection of 
low molecular weight proteins from complex mixtures compared to manufacturer’s 
recommendations (results were shown in Chapter 3). The results further emphasised 
the need for multiple consecutive filtrations. In the present chapter the performance of 
the UF membranes and whether they pose a potential source o f variation was 
investigated. The aim was to show that UF is suitable as a pre-fractionation method 
for biomarker discovery protein profiling purposes. Three experiments, as outlined in 
Figure 4.1, were carried out to assess in detail how markers o f different molecular 
weight and whole serum can be separated by the optimised UF process. First a simple 
mixture o f standard markers with varying masses was separated by ultrafiltration. This 
allowed estimation o f protein concentrations passing through the filter without the 
interference o f complex mixtures and the high total protein concentrations present in 
biological samples. Secondly, human serum samples were spiked with standards in the 
filtrate for recovery analysis by absorbance quantitation. This enabled monitoring of 
the filter performance under “genuine” conditions. Finally, the reproducibility of
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recovery o f  serum  proteins naturally  occurring in the sam ple was studied by SDS- 
PAGE, LC-M S/M S and M A LD I-ToF M S. All three m ethods w ere used because, as 
shown, the results from each m ethod w ere com plem entary and support the argum ent, 
show ing reproducibility  across filtrations.
SDS-PAGE
HPLC Quantitation
LC-MS/MS
MALDI-ToF
Marker Serum  (B  Serum Whole
Mixture Cytochrom eC  Vitamin B12 serum
LMW 1
LMW 2
SOkDa centrifugal 
ultra-filtration
HMW re-diluted
i
50kDa centrifugal 
ultra-filtration
1
HMW re-diluted
i
50kDa centrifugal 
ultra-filtration
LMW 3
i
HMW
Figure 4.1: A schematic description of the experiment setup. (A) A simple mixture of standard 
markers, (B) human serum spiked with either cytochrome C or vitamin B12 and (C) neat 
human serum were all separated by centrifugal ultrafiltration. Each HMW retentate was made 
up to the original volume in denaturing buffer and filtered again, this was repeated twice. All 
the LMW filtrates and the final HMW retentate were collected and analysed by SDS-PAGE 
for successful separation, HPLC for protein recovery and LC-MS/MS for serum protein 
identification.
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4.1. The Marker Mixture
A simple mixture o f 5 markers, containing 235 nmol/ml ubiquinin, 1481 nmol/ml 
vitamin B12, 121 nmol/ml BSA, 161 nmol/ml cytochrome C and 142 nmol/ml 
lysozyme (final concentration) was prepared in denaturing buffer (25mM NH4HCO3 
and 20% ACN (v/v)) and pre-ffactionated by UF. Each marker was prepared as a 2 
mg/ml concentration except for BSA, which was at a concentration o f 8  mg/ml to 
mimic the excess of albumin in human serum. For direct comparison the markers were 
prepared in the same denaturing buffer as used for serum. For subsequent quantitation 
of each marker in the marker mixture, the mixture was separated by reverse-phase 
chromatography, using an in-house packed Poros 20 R2 reverse-phase separation 
column (100 mm x 4.6 mm I.D, 20 pm particle size) (Applied Biosystems, 
Warrington, UK) at a flow rate o f 5 ml/min, on a Vision™ BioCAD Family Perfusion 
Chromatography Workstation (Applied Biosystems, Warrington, UK).
The HPLC chromatogram in Figure 4.2 b shows that baseline separation o f each of 
the components in the marker mixture was achieved, so that the individual markers 
could be quantified individually without contamination from the other markers. 
Standard curves o f UV absorbance versus a serially diluted marker mixture o f known 
concentration were prepared for each marker, and to avoid introduction o f variation 
during the chromatography o f the standards, each dilution was separated in triplicate. 
The standard curves for each o f the markers are shown in Figure 4.2 a.
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Figure 4.2: Standard curves generated from the UV detector response of the marker mixture 
diluted in series by HPLC separation. (A) Each marker was diluted to produce a standard 
curve for subsequent quantitation. The S.E bars illustrate the accuracy of the separation and 
peak area analysis. (B) Each of the markers elutes from the reverse phase column at a 
different retention time, a good separation was observed. Three replicate HPLC separations of 
the same sample were overlaid in the graph to demonstrate reproducibility.
The concentration o f  each m arker w as estim ated by  calculating it from the standard 
curves. Each m arker achieved a high squared correlation coefficient (R greater than 
0.98), indicating a high degree o f  accuracy in form ing the standard curves (Table 4.1). 
The C.V. o f  each dilution in each m arker across 3 replicate RP-separations was 
calculated and show ed good consistency (Table 4.1).
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Table 4.1: The coefficient of variance (C.V.) across the three replicates of each dilution step in 
the calibration curve for each marker was calculated as well as the square correlation 
coefficient (R2) for the best fit of the standard curve to ensure accurate estimation of the 
marker concentration.
Average 
Mw (Da) C.V. (%) R2
vitamin B12 1350 14 0.997
albumin 67000 25 0.985
cytochrome C 12300 13 0.997
lysozyme 14100 12 0.995
ubiquitin 8500 13 0.998
From these standard curves the sam ple recovery in each fraction, after UF, was 
determ ined and it was noted that consecutive spins o f  UF can significantly  increase 
the protein recovery (Figure 4.3 a). A fter one round o f  UF a m axim um  o f  only 50% 
(o f the total amount in the com bined LM W  fractions) o f  each m arker was recovered in 
the filtrate. For exam ple, a total o f  85% o f  the original am ount o f  ubiquitin was 
recovered after three rounds o f  UF. However, only 45%  o f  ubiquitin was pushed 
through the m em brane during the first filtration. The second filtration step 
considerably im proved the overall recovery o f  LM W  proteins, yet protein recovery 
did not significantly benefit from a third filtration step. The requirem ent for m ore than 
one round o f  UF is explained by the fact that during UF the concentration o f  a 
com pound in a m ixture rem ains the same, e.g. as 1/3 o f  the m ixture volum e is 
retained, 1/3 o f  vitam in B12 rem ains above the m em brane. How ever, as the 
concentration in the HM W  retentate increases som e proteins m ay form aggregates or 
be forced through the m em brane. To re-dissolve the proteins the retentate was re­
suspended and filtered again.
Com bining the successive filtrates, the recovery o f  the proteins in the centrifuged 
m arker m ixture was shown to be highly reproducible although dependent on 
m olecular weight (Figure 4.3 b).
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Figure 4.3: Recovery of the markers in each fraction, subjected to ultrafiltration. (A) The 
marker recovery in each individual filtrate is shown. Standard error bars are shown for each 
filtrate. (B) The individual LMW filtrates were combined and recovery in each fraction (i.e. 
LMW filtrate and HMW retentate) was recorded by HPLC. From this the marker loss of each 
marker was calculated. The variation between the replicate filtration runs is shown as ± SE.
The C.V.s o f  recovery across the replicate filtrates o f  each m arker was calculated and 
is shown in Table 4.2. As expected, vitam in B12 and ubiquitin, passed through the 
m em brane readily. Despite cytochrom e C and lysozym e having a m olecular w eight
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below the pore size of the filters, neither passed through the membrane as efficiently 
as vitamin B 12 or ubiquitin (Figure 4.3 b).
However, MALDI-ToF MS analysis of the whole marker mixture showed that 
lysozyme forms a dimer, with a molecular weight o f 28,193 Da (Figure 4.4). The 
literature confirmed that lysozyme exists as a dimer even under denaturing conditions 
[10, 11]. Hence protein recovery is dependent on a number o f factors additional to 
molecular weight, which may include pH, tertiary shape and solubility.
Table 4.2: Marker recoveries from the mixture. The yield of markers in the filtrate was 
dependent on molecular weight, the CV of recovery across three replicate filtrations showed 
high reproducibility.
Source/ Marker Marker Mixture
Filtrate yield (%) Replicate CV (%)
Vitamin B12 85 1.8
Ubiquitin 85 2.3
Cytochrome C 55 13
Lysozyme 9 1.7
BSA 0.5 0.4
Furthermore, although cytochrome C has a molecular mass o f 12.4 kDa, it did not 
pass through the filter completely, whereas ubiquitin, which has a mass o f 8.5 kDa 
passed through the filter with almost 90% efficiency. Additionally, the reproducibility 
of the recovery for cytochrome C was not as good as the other markers (Table 4.2). 
However, cytochrome C is amphiphilic and due to the water binding to the molecule 
when in solution it may be variable in shape and size during filtration [12]. 
Furthermore, amphiphiliates can bind to biological membranes by burrowing their 
hydrophobic part into them. This could be an explanation for the variable behaviour of 
cytochrome C during the UF. As explained in Chapter 3 (section 3.2.4) polarisation of 
concentrated molecules at the membrane can block filtration of concentrated proteins. 
Passage of proteins depends on more than MW and so certain proteins may pass with 
more difficulty than others.
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Figure 4.4: MALDI-ToF analysis of the marker mixture. Dimerisation of lysozyme at 28,193 
Dalton is evident.
4.2. Markers Spiked into Serum
4.2.1. Choice of Markers for UF Evaluation
Reproducible recovery o f  serum proteins can not necessarily be extrapolated from the 
results using a sim ple m ixture, as the com plexity o f  serum  m ay influence the 
perform ance o f  the M W CO  m em branes. To investigate the reproducible recovery o f  
proteins from serum, standards (m arkers) can be spiked into the sam ple prior to UF. 
Insulin is a native protein in serum and at a M W  o f  5.6 kD a it was expected to be 
filtered successfully. To quantify its recovery, insulin w ith a fluorescent FITC tag was 
purchased and spiked into hum an serum. Since 1 m ole o f  FITC equates 1 m ole o f  
insulin, it should have been directly  correlated. The results how ever were very 
inconsistent and high am ounts o f  the fluorescence were detected in the HM W  
retentate. To investigate the quality and M W  o f  the insulin-FITC it was analysed by 
M A LD I-ToF MS. The insulin was suspended in NH 4 H C O 3 at a concentration o f  175 
pm ol/pl and then desalted using M illipore filter disc for 30 m inutes. M A LD I-ToF MS 
analysis showed 2 peaks at m/z 6125 and m/z 6513, these have a m ass difference o f  
390 Da and 778 Da com pared to unlabelled insulin (Figure 4.5). A single peak for 
insulin-FITC tag at m/z 6125 was expected. M A LD I-ToF MS in reflectron m ode
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revealed that the FITC tag could be removed by fragmentation (Figure 4.5 b). The 
major peak in the spectrum was insulin without the tag, however there were two more 
peaks indicating that possibly two tags are attached to FITC labelled insulin. It was 
therefore concluded that two FITC-tags were attached to some insulin molecules. 
Later it was confirmed that our particular batch o f FITC labelled insulin had an 
average of 1.6 mol o f FITC per mol of insulin (Sigma-confirmed). However, the 
complex with two FITC tags could be still small enough to pass through the filter. To 
explain the retention o f FITC fluorescence above the filter, it could be assumed that 
the FITC tag became detached in the denaturing solution during UF and re-bound to a 
HMW molecule within serum. Chemical bonds are dynamic and N-H and N-C bonds 
(bond between FITC and insulin) break and reform readily in solution; hence the 
insulin-FITC was not suitable for testing o f the UF reproducibility.
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Figure 4.5: MALDI-ToF MS analysis of FITC-labelled insulin. (A) Shown is FITC-labelled 
insulin analysed in positive linear mode. (B) The same spot was analysed in positive 
reflectron mode to break the NFL bond and reveal the partially and unlabelled insulin 
molecule. (C) For calibration purposed the analyte was mixed with calibration mixture 3 and 
the insulin and apomyoglobin + 2  peaks are labelled, insulin peaks tagged with one and with 
two FITC are also visible.
M arkers with natural spectral absorbance different to that o f  serum were therefore 
chosen, as these will be stable. H ence cytochrom e C and vitam in B12 were each 
spiked into hum an serum  sam ples before UF (Figure 4.1 b). The m arkers were chosen 
in order to m im ic m edium  size proteins suspected to pass through the m em brane 
(cytochrom e C) and sm aller serum  peptides (e.g. vitam in B12 has a sim ilar m ass to 
fibrinopeptide A). Both m arkers have a unique absorbance at 413 nm and 361 nm, 
respectively; allowing their specific quantitation in serum sam ples due to absorbance
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spectral differences between un-spiked serum and the two marker proteins. Three 
filters were loaded with spiked serum and one un-spiked serum sample was processed 
simultaneously for use as a blank and a control. This was repeated for cytochrome C 
and vitamin B12. Recovery of the marker in the filtrate was quantitated relatively by 
photo spectrometry for their unique absorbance, which had been determined by 
scanning o f the pure marker in the photo spectrometer for the wavelengths where the 
molecule absorbs the maximum light. Recovery o f both markers showed excellent 
reproducibility (Figure 4.6 and Table 4.3). Although 50% of cytochrome C passed 
through the filter when in the relatively simple marker mixture, only 30% were 
recovered in the filtrate when spiked into serum. In addition, when cytochrome C was 
filtered through the membrane in denaturing buffer alone, 80% of the protein passed 
through the filter after only one filtration. These results suggest that the more complex 
the sample, the lower the recovery of cytochrome C in the LMW filtrate. This 
confirmed the theory o f a filter cake or gel layer that causes blockage of the 
membrane, where proteins aggregate, especially as the sample concentration 
increases. Cytochrome C may be prone to that due to its amphiphilic properties. 
However, vitamin B12 passed through the membrane with 90% efficiency, as in the 
simple mixture. Both the marker mixture and the markers spiked into serum suffered 
from an unaccounted loss, which may also be explained by the formation o f a gel 
layer on top o f the membrane, where molecules bind to the filter or become lodged in 
the pores. The precise mechanism of this action however is still a matter o f debate 
[13-15]. Nevertheless, UF of small proteins and peptides (<10 kDa) did not suffer 
from insufficient recovery (Figure 4.3).
Table 4.3: Marker recoveries in serum. The yield of markers in the filtrate of LMW serum was 
dependent on molecular weight, the C.V. of recovery across three replicate filtrations showed 
high reproducibility. *To asses the effect of sample complexity cytochrome C was filtered in 
buffer alone at a concentration of lmg/ml, this showed high recovery.
Serum__________________________
________________________ Filtrate yield (%) Replicate CV (%)
90 08"
30 1.8
Vitamin B12 
Cytochrome C
Cytochrome C in Buffer* 80
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Figure 4.6: Recovery o f markers spiked into human serum after centrifugal ultrafiltration. The 
marker recovery o f the combined LMW filtrates and the HMW was determined by 
absorbance. (A ) The total LMW protein recovery of cytochrome C was reproducible with a
C.V. of 1.8%. (B) Vitamin B12 recovery in the LMW filtrate across 3 filters in reproducible 
(C.V. = 1%). Less than 1% of vitamin B12 remains in the HMW retentate.
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4.3. Serum Protein Analysis for Reproducible Recovery from UF
Finally, the reproducibility o f UF was further shown analysing un-spiked LMW serum 
proteins (from combined filtrates) by SDS-PAGE, MALDI-ToF MS and LC-MS/MS. 
It was important to confirm that native serum proteins also behave reproducibly 
during UF. This was complicated by the limitations MS techniques encounter. A 
combination o f all three visualisation methods provided a more complete picture. 
MALDI-ToF MS is not strictly quantitative as hotspots in the matrix can influence the 
peak intensities across an entire spectrum. However this can be improved by 
acquisition of a large number o f spectra and replicate analyses of the same sample. 
Although the chromatography across replicate LC-MS/MS separations should be 
identical, variations due to column pressure, solvent splitting, carry over and factors 
unknown can occur. Standardisation o f the peak intensity in the basepeak 
chromatogram to the same scale, can to a certain extent remove basepeak intensity 
variation. SDS-PAGE showed to be the most reproducible and robust method for 
visualisation and comparing protein concentrations across replicate protein samples. 
However, only relatively abundant and large proteins are visualised well by SDS- 
PAGE.
4.3.1. MALDI-ToF MS and SDS-PAGE
Analysis and comparison of the serum proteins from the three replicate filters by 
MALDI-ToF MS and SDS-PAGE demonstrated that the ultrafiltration step was 
reproducible for all proteins passing through the filter (Figure 4.8 and Figure 4.7). 
Whilst acknowledging that MALDI-ToF MS is not truly quantitative, it is encouraging 
that the same protein peaks (i.e. no additional or missing peaks) were present in the 
spectrum of each o f the replicate filtrates and that the peaks were at similar relative 
intensity between samples. The third spectrum appears to have an overall lower peak 
intensity, making it look as if  the spectra were not reproducible, however the same 
peaks are present just at lower intensity.
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Figure 4.7: Serum protein analysis by MALDI-TOF. Three replicate filtrates of serum were 
analysed to show reproducibility o f the centrifugal ultrafiltration procedure.
The same three LM W  serum  sam ples, separated by SD S-PA G E, showed identical 
protein bands at equal intensity  across the three filtrates. Small proteins ionize easier 
during M A LD I-ToF MS and so no peaks are visible for proteins larger than 12 kDa, 
where in the SD S-PA G E these proteins bands are clearly visible. A very strong band 
was visible at 15 kDa and again at 28 kDa. A lternatively these proteins m ay not bind 
well to C l 8  Z ip-T ips, w hich were used for desalting o f  the LM W  proteins. This gave 
emphasis to the reason w hy we used m ore that one visualisation tool to assess the  UF. 
Furtherm ore this also showed that different m ethods will give com plem entary results 
for protein identifications and quantitation. This is in agreem ent w ith the findings by 
Anderson et al. [16] com paring different proteom e analysis technologies.
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Figure 4.8: Recovery o f LMW proteins after centrifugal ultrafiltration of serum. Serum 
protein analysis by 17% tricine SDS-PAGE, stained with colloidal Coomassie blue. The 
separation of the three replicate LMW filtrates shows reproducibility of the ultra filtration 
procedure. Band intensities are comparable between lanes 3 to 5.
4.3.2. LC-MSMS Protein Profiling of Replicate Serum Filtrates
LC-M S/M S analysis o f  the three replicate LM W  filtrates w as perform ed in duplicate 
to account for run-to-run variation during the peptide identification. The scale o f  the 
peak intensity axis o f  the basepeak chrom atogram s were standardised to 2.0 x l 0 ; for 
3000 xg and 3.0 x lO 9 for 750 xg peak intensity, respectively (Figure 4.9). The spectra 
were sim ilar except for one replicate in each sam ple group (3000 xg: 2b and 750 xg: 
3b). A lthough there w as som e variation betw een the basepeak chrom atogram s o f  each 
o f  the 3 filtrates, the sam e, if  not m ore variation could be seen betw een the two 
replicate LC-M S separations o f  the sam e LM W  sample. N evertheless, sufficient 
reproducibility was observed and confirm s the usefulness o f  the UF process.
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Figure 4.9: Basepeak chromatograms for the three replicate filtrates separated by RP-LC- 
MS/MS. Each filtrate was separated twice by LC-MS/MS for the samples centrifuged at 3000 
xg (A) and 750 x g in (B) .
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Analysis o f the peak intensity o f two individual peaks confirmed the results shown by 
the basepeak chromatograms in Figure 4.9. The peak intensity across the replicates 
was reproducible except for the “outlier” 750_3b shown in Figure 4.10. 
Standardisation of the spectra against the average o f the peak intensity could be used 
to adjust for low overall signal variation. Furthermore by using a large number of 
technical replicates, outliers could be excluded. Reproducibility across the three UF 
was shown despite some variation introduced during the LC-MS analysis.
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Figure 4.10: The extracted ion chromatogram for individual peaks is shown across the 3 
LMW replicates and their RP-separation replicates. Two examples, m/z 733.2 (A) and m/z 
604.2 (B) are shown.
Chapter 4: Reproducibility and efficiency o f centrifugal ultrafiltration 123
The human FASTA database using Sequest was searched for matches with the tandem 
MS spectra from the LC-MS/MS experiment as described in Chapter 3 (section 3.3.2) 
and the Materials and Methods (section 2.8). The results from the two replicate RP- 
separations were combined and each replicate compared against the others. The 
overlap of protein matches from LC-MS/MS analysis was 50% across all three 
replicate filtrates centrifuged at 750 xg (Figure 4.11). Hence half the proteins were 
found in all three replicate filtrations. It is widely accepted that the overlap o f protein 
matches across replicate LC-MS/MS analysis is low [17, 18]. Zheng [18] only found a 
15% overlap between 3 replicate LC-MS/MS analysis o f the same serum sample 
analysed using an LTQ-FT MS. In this study, the processing of the same serum 
peptide sample in duplicate by LC-MS/MS resulted in a o f 61% overlap of protein 
identifications from two replicate LC-MS/MS runs, hence an overlap in protein 
identifications o f 50% across three filtration experiments can be considered as an 
acceptable indicator o f reproducibility.
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Figure 4.11: Protein identifications from LC—MS/MS analysis. Proteins identified after 
bottom-up protein profiling from three replicate ultrafiltrations. The Venn diagrams illustrate 
the overlap of protein identifications across three replicates centrifuging the filters at 3000 xg 
and 750 xg. An increase of protein identifications was observed in UF filtrates using the lower 
spin speed protocol. The Venn diagram shows a 50% overlap between all three centrifugal 
filters for the samples centrifuged at 750 xg.
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The presence o f a much reduced proportion o f some highly abundant HMW proteins 
in the filtrate was to be expected as UF is a dynamic process and the shape o f a 
molecule can cause it to slip through the pores o f the membrane. However, albumin 
and other HMW proteins were removed satisfactorily, allowing the detection o f other 
less abundant proteins during MS or electrophoresis (Table 4.5). Serum albumin was 
only detected in one o f the three filtrates from the 3000 xg and 750 xg UF, and only 
with 3 and 2 peptides, respectively. In conclusion, no extra variation was introduced 
during the UF step, confirming the usefulness o f this pre-processing technique to 
reduce the complexity o f serum for MS analysis. Furthermore it could be concluded 
that more than one LC-MS/MS experiment was necessary to ensure reproducible 
detection of proteins in each sample, similar to the results previously reported by 
Scherl, A. [19].
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Table 4.4: Proteins detected by RP-LC-MS/MS. Each of the three replicate filtrates at 3000 xg 
is shown for comparison for the reproducibility. The results from the replicate LC-MS/MS 
runs were merged. This data is complementary to the Venn diagram in Figure 4.11.
SwissProtID Protein
Accession
no
Protein
probability
Molecular
mass
Matched
peptides
UF membrane 1
APOA4 Apolipoprotein A-IV precursor P06727 5.65E-13 45371.5 6
FETIJA Alpha-2-HS-glycoprotein precursor P02765 7.88E-13 39299.7 2
SCYB7 Platelet basic protein precursor P02775 8.32E-10 13885.4 2
APOL1 Apolipoprotein-L1 precursor 014791 3.35E-09 43900.0 1
FI BA Rbrinogen alpha chain precursor P02671 5.91 E-09 94914.3 2
APOC3 Apolipoprotein C-lll precursor P02656 1.04E-08 10845.5 2
APOA1 Apolipoprotein A-l precursor P02647 1.92E-08 30758.9 5
A1AT Alpha-1-antitrypsin precursor P01009 6.79E-07 46707.1 1
C04A Complement C4-A precursor P0C0L4 7.84E-06 192649.5 1
THRB Prothrombin precursor P00734 2.38E-04 69992.2 1
APOA2 Apolipoprotein A-ll precursor P02652 5.34E-04 11167.9 1
UF membrane 2
FETUA Alpha-2-HS-glycoprotein precursor P02765 4.85E-13 39299.7 2
APOA4 Apolipoprotein A-IV precursor P06727 2.99E-11 45371.5 9
C03 Complement C3 precursor P01024 3.13E-11 187045.3 3
APOC3 Apolipoprotein C-lll precursor P02656 8.22E-10 10845.5 2
SCYB7 Platelet basic protein precursor P02775 1.20E-09 13885.4 2
FIBA Rbrinogen alpha chain precursor P02671 2.04E-09 94914.3 3
THRB Prothrombin precursor P00734 5.07E-09 69992.2 1
AF’OAI Apolipoprotein A-l precursor P02647 7.74E-09 30758.9 1
APOL1 Apolipoprotein-L1 precursor 014791 8.24E-09 43900.0 1
ALBU Serum albumin precursor P02768 1.85E-08 69321.6 3
A1AT Alpha-1-antitrypsin precursor P01009 2.58E-08 46707.1 1
UF membrane 3
FETUA Alpha-2-HS-glycoprotein precursor P02765 8.22E-14 39299.7 2
APOA4 Apolipoprotein A-IV precursor P06727 1.09E-10 45371.5 8
FIBA Rbrinogen alpha chain precursor P02671 1.97E-09 94914.3 7
A1AT Alpha-1-antitrypsin precursor P01009 2.33E-09 46707.1 1
APOC3 Apolipoprotein C-lll precursor P02656 2.58E-09 10845.5 2
SCYB7 Platelet basic protein precursor P02775 4.40E-09 13885.4 1
APOL1 Apolipoprotein-L1 precursor 014791 1.37E-07 43900.0 1
B2MG Beta-2-microglobulin precursor P61769 1.49E-07 13705.9 1
THRB Prothrombin precursor P00734 3.28E-07 69992.2 2
KNG1 Kininogen-1 precursor P01042 8.62E-05 71900.1 1
APOA2 Apolipoprotein A-ll precursor P02652 1.91E-04 11167.9 2
C04B Complement C4-B precursor P0C0L5 2.23E-04 192671.6 1
C04A Complement C4-A precursor P0C0L4 2.23E-04 192649.5 1
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Table 4.5: Proteins detected by RP-LC-MS/MS. Each of the three replicate filtrates at 750 xg 
is shown for comparison for the reproducibility. The results from the replicate LC-MS/MS 
runs were merged. This data is complementary to the Venn diagram in Figure 4.11.
SwissProt ID Protein
Accession
no
Protein
probability
Molecular
mass
Matched
peptides
UF membrane 1
APOC3 Apolipoprotein C-lll precursor P02656 1.20E-12 10845.5 3
APOA4 Apolipoprotein A-IV precursor P06727 3.22E-12 45371.5 13
SCYB7 Platelet basic protein precursor P02775 2.49E-11 13885.4 2
APOA1 Apolipoprotein A-l precursor P02647 1.36E-10 30758.9 9
FETUA Alpha-2-HS-glycoprotein precursor P02765 5.86E-10 39299.7 3
A1AT Alpha-1-antitrypsin precursor P01009 8.54E-10 46707.1 2
FIBA Fibrinogen alpha chain precursor P02671 6.21 E-09 94914.3 8
C 0 3 Complement C3 precursor P01024 5.79E-08 187045.3 2
CFAB Complement factor B precursor P00751 1.39E-07 85478.6 1
THRB Prothrombin precursor P00734 1.55E-07 69992.2 2
LAC Ig lambda chain C regions P01842 2.30E-06 11229.5 1
APOC2 Apolipoprotein C-ll precursor P02655 4.13E-05 11276.8 1
RETBP Plasma retinol-binding protein precursor P02753 7.18E-05 22995.3 1
KNG1 Kininogen-1 precursor P01042 1.01E-04 71900.1 1
ALBU Serum albumin precursor P02768 1.22E-04 69321.6 2
APOA2 Apolipoprotein A-ll precursor P02652 7.91 E-04 11167.9 1
APOC1 Apolipoprotein C-l precursor P02654 9.52E-04 9326.1 1
UF membrane 2
APOA4 Apolipoprotein A-IV precursor P06727 4.71E-13 45371.5 10
FETUA Alpha-2-HS-glycoprotein precursor P02765 1.88E-12 39299.7 2
APOA1 Apolipoprotein A-l precursor P02647 1.13E-11 30758.9 9
FIBA Fibrinogen alpha chain precursor P02671 2.62E -11 94914.3 4
APOC3 Apolipoprotein C-lll precursor P02656 2.32E-10 10845.5 3
SCYB7 Platelet basic protein precursor P02775 1.38E-09 13885.4 1
A1AT Alpha-1-antitrypsin precursor P01009 7.06E-09 46707.1 3
LAC Ig lambda chain C regions P01842 9.88E-09 11229.5 1
CFAB Complement factor B precursor P00751 1 .55E-06 85478.6 1
APOA2 Apolipoprotein A-ll precursor P02652 3.43E-06 11167.9 2
C 0 3 Complement C3 precursor P01024 1.44E-05 187045.3 2
APOC2 Apolipoprotein C-ll precursor P02655 1.65E-05 11276.8 1
A2AP Alpha-2-antiplasmin precursor P08697 2.17E-05 54531.2 1
TTHY Transthyretin precursor P02766 2.68E-05 15877.1 1
KNG1 Kininogen-1 precursor P01042 8.09E-05 71900.1 1
RETBP Plasma retinol-binding protein precursor P02753 1.25E-04 22995.3 1
THRB Prothrombin precursor P00734 2.38E-04 69992.2 1
UF membrane 3
APOA4 Apolipoprotein A-IV precursor P06727 5.90E -11 45371.5 12
APOA1 Apolipoprotein A-l precursor P02647 1.21E-10 30758.9 9
THRB Prothrombin precursor P00734 2.05E-10 69992.2 2
SCYB7 Platelet basic protein precursor P02775 9.48E-10 13885.4 2
C 0 3 Complement C3 precursor P01024 1.30E-09 187045.3 3
A1AT Alpha-1-antitrypsin precursor P01009 2.15E-09 46707.1 1
TTHY Transthyretin precursor P02766 4.60E-09 15877.1 1
APOC3 Apolipoprotein C-lll precursor P02656 9.61 E-09 10845.5 3
FIBA Fibrinogen alpha chain precursor P02671 1.01E-08 94914.3 4
FETUA Alpha-2-HS-glycoprotein precursor P02765 1 .04E-08 39299.7 2
APOL1 Apolipoprotein-L1 precursor 0 14791 1.02E-06 43900.0 1
CFAB Complement factor B precursor P00751 3.00E-06 85478.6 1
APOA2 Apolipoprotein A-ll precursor P02652 7.11 E-04 11167.9 2
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4.4. The Use of Multiple Filtrations Improving Protein Recovery
The advantage o f using multiple consecutive filtrations for increased protein recovery 
had already been shown using the marker mixture. This was further investigated, 
analysis the consecutive filtrates o f serum by MALDI-ToF MS. Figure 4.12 shows the 
different protein peaks present in each o f the filtrates. In the second filtrate protein 
peaks additional to the first filtrate are clearly visible. The third round o f UF did not 
significantly improve protein recovery (Figure 4.12). The change in protein peaks 
detected by MALDI-ToF MS can be partly explained by the fact that as the protein 
concentration in the retentate decreased by re-dilution, LMW proteins were 
dissociated from each other and then pass through the filter. Although only a small 
percentage o f serum proteins filtered through the membrane, the equilibrium of 
proteins binding to each other may have changed and proteins trapped the first time, 
may have had the opportunity to pass through the filter during the second filtration.
It was not by coincidence which proteins pass through the membrane the first and 
which the second time as the recovery of proteins across three replicate was 
reproducible, even for individual filtration steps.
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Figure 4.12: Consecutive LMW filtrations of serum. Each filtrate was analysed separately 
(LI, L2 and L3) for a low (A) and a higher mass range (B). Different proteins were detected in 
each of the filtrates.
To investigate any concerns regarding in vitro degradation o f  the serum proteins 
during the extended sam ple preparation, crude serum left at 4°C for 24 hours was 
com pared with an aliquot o f  the same sam ple kept frozen. Each sam ple was analysed 
by SD S-PA G E and M A LD I-ToF M S, i f  proteolytic degradation was present, we 
would expect to see m ore LM W  peaks and less or broader bands in the HM W  region. 
How ever the SD S-PAG E in Figure 4.13 for the serum  sam ples incubated at 4°C for 24 
and 0 hours looks alm ost identical, no evidence o f  degradation is visible. This was 
further confirm ed by M A LD I-ToF MS analysis o f  the sam e sam ples (Figure 4.14). 
This is in agreem ent with reports by W est-N ielsen et al. [20] and Traum  et al. [21],
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investigating serum  sam ple preparation and the effects o f  sam ple storage on protein 
degradation. Their results showed that storage o f  serum at 4°C for 24 hours does not 
cause significant degradation o f  serum  proteins, how ever room  tem perature had an 
effect after only 4 hours.
A dditionally, the effect o f  addition o f  ACN was dem onstrated, to prove that this has 
no detrim ental effect on the proteom e (Figure 4.13 and Figure 4.15). The effect o f  
A C N  in the sam ple is visible before and after 24 hour incubation in the loss o f  a band 
at approxim ately 200 kDa, m arked with an arrow (Figure 4.13). Furtherm ore the 
M A LD I-ToF spectra in Figure 4.15 show a larger num ber o f  LM W  peaks than the 
serum  sam ples incubate w ithout the addition o f  ACN. This m ay be due to dissociation 
o f  protein-protein interaction or the denaturing o f  a protein dim er which results in 
sm aller m asses, confirm ing the denaturing effect o f  ACN.
24  hours 24  hours 
A C N
Marker Marker 0 hours 0  hours 0  hours 
A C N
3 .5
Figure 4.13: SDS-PAGE of crude serum (from the same aliquot) diluted in denaturing buffer 
(25 mM NH4 HCO3 , 20% ACN) and in non-denaturing 25 mM NH4 HCO3 . The serum samples 
were incubated for 0 and 24 hours at 4°C. 24 hour storage at 4°C has no noticeable effect on 
the serum proteins the presence of ACN in the sample appears to affect one band at -200  kDa, 
marked with an arrow. This band is also visible in the 0 hour incubation without ACN.
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Figure 4.14: MALDI-ToF MS spectra o f serum samples in NH4 H C 03; showing that there is 
no noticeable difference between a fresh serum sample (A) and after 24 hours at 4°C (B).
10206,33
100
90
80
>. 70
c 600)
c 50
3? 40
0 hours + c
V oyager S p e c  #1=>M C =>TR =>SM 7=>NR (2.00)[BP
6617 67
9413.31
= 6617 .1 , 5407]
20% ACN
28132.37
«■- |
18600 24300 30000
M ass (m/z)
« 2 4  HOURS 20ACN _ 0 0 0 1 »  V oyager S p e c  #1=>TR =>N R (2.00)=>SM 7[BP = 6623 .2 ,
662302 24 hours +
9406 .15  !6£
20% ACN
13880,99 
\  114369.01
10168,34
28023 68
3000012900 2430018600
M ass (m/z)
Figure 4.15: MALDI-ToF MS spectra of serum samples in denaturing buffer; showing that 
there is no noticeable difference, after addition of 20% ACN, between a fresh serum (A) and 
after 24 hours at 4°C (B).
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4.5. Discussion and Conclusions
The reproducibility and robustness of the MWCO filters was tested and showed to be 
satisfactory. This was shown using a simple marker mixture where all markers passed 
the filter in a reproducible manner. This also showed that filtration is dependent on 
MW but also on pH, solubility and shape of the molecule. This was particularly 
obvious in the case of cytochrome C for shape and lysozyme for pH. Furthermore, the 
choice of marker was critical as solubility, stability and retention are important for 
quantitation. Spiking of cytochrome C and vitamin B12 into serum further showed the 
significance o f the marker choice as vitamin B12 was not affected by the 
concentration o f the sample but filtration of cytochrome C was reduced from 50 to 
30% in complex serum. However, the C.V.s of the markers in serum were less than 
2%, showing that despite some marker loss, recovery was consistent and reproducible. 
For LMW serum proteins, reproducibility of the recovery was assessed using MALDI- 
ToF MS, SDS-PAGE and LC-MS/MS. The three methods showed to be 
complementary each showing additional data to support the results. MALDI-ToF 
analysis was particularly good for visualising small proteins and peptides; however 
there is variation in the spectra, therefore it will be important for a large number of 
replicates and accumulation of many shots and spectra. Coomassie stained SDS- 
PAGE is known to be quantitative and showed good reproducibility of medium and 
larger serum proteins. The basepeak chromatograms of the LC-MS separation did not 
appear as robust as the other methods however looking at individual peptides in the 
extracted ion chromatograms showed that peptide recovery was reproducible. Hence 
the variation was not due to irreproducibility in the UF process. Variations in the 
basepeak intensity could be reduced by statistical standardisation and large numbers 
of technical replicates. It can be concluded that no further variation was introduced 
during this sample processing step and that UF of small proteins and peptides (<10 
kDa) did not suffer from insufficient recovery (Figure 4.3), and so these results are 
encouraging and show that UF can enrich the LMW sub-proteome for MS analysis. In 
this chapter we furthermore confirmed that serum preparation on ice or at cold 
conditions does not cause significant degradation o f the serum proteins. This is in 
accordance with findings more recently published [20-22]. In summary we have 
shown that UF is a robust sample pre-processing method to enrich the LMW sub- 
proteome for subsequent biomarker discovery in serum.
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CHAPTER 5
Biomarker Discovery using MALDI-ToF MS
Serum proteomics has generated considerable amount of excitement among 
oncologists and analytical chemists in recent years [1-5], with the promise of 
developing high-throughput blood tests for breast cancer, through mass spectrometry- 
based profiling and biomarker discovery. Using the sample preparation method 
optimised in chapter 4, the LMW sub-proteome from a cohort o f breast cancer patients 
was used for protein profiling using MALDI-ToF MS. Most data published studying 
biomarkers from serum has been generated using SELDI-ToF MS, which, in contrast 
to MALDI-ToF MS, was specifically designed for biomarker discovery. The SELDI- 
ToF equipment comes with a spectra alignment program as well as statistical analysis. 
This however is not available for MALDI-ToF analysis. Hence spectral alignment 
appeared to be the most challenging problem in terms of signal processing and a 
program was therefore developed especially for this purpose. In this chapter, MALDI- 
ToF MS was optimised for protein profiling, comparing breast cancer serum proteins 
with those from non-cancer controls. The use o f MALDI-ToF is cheaper in 
consumables and faster in analysis than SELDI-ToF MS and additionally the mass 
analyser is more sensitive with greater mass accuracy, which may provide greater 
confidence in the results.
As described in the Introduction (section 1.5), few published studies are available 
discussing biomarker discovery from intact proteins, using MALDI-ToF MS. 
However, during the course o f this thesis, Villanueva and his co-workers have 
published some studies that focused on the use o f magnetic beads for serum
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peptidom e analysis [6-9]. The use o f  m agnetic beads w as shown to enable sam ple 
clean-up and rem oval o f  album in in one step. The beads were coated w ith a reverse- 
phase chrom atographic resin that binds polar proteins and peptides. A nother paper by 
Callesen et al. [10] used M A LD I-ToF MS for protein profiling o f  breast cancer serum. 
The serum  sam ples were desalted and the peptidom e isolated using SPE cartridges. In 
their study three “m arkers” were detected (Figure 5.1). A lthough m arkers o f  the same 
m ass (m/z 4.3, 8.1 and 8.9 kDa) had been convincingly discovered using SELD I-ToF 
MS by  Li et al [2, 11]; and again in a independent study also using SELD I-ToF MS
[12], closer inspection o f  the results by Callesen et al. [10] left some doubt as to the 
d iscrim inatory capacity o f  these m arkers (Figure 5.1). The overall spectrum  intensity 
o f  the control sam ple (Figure 5.1 b) appears lower. In our results two o f  the peaks 
were also present but rem ained unchanged betw een breast cancer and control spectra 
(Figure 5.2). W e therefore had to develop the technique for b iom arker discovery using 
M A LD I-ToF MS on serum  sam ples effectively from basic principles due to a lack o f  
previously published/established techniques.
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Figure 5.1: MALDI-ToF spectra were taken frorm Callesen et al. [1 0 ], showing a breast cancer 
serum sample in (a) and a control sample in ( b) .  The peaks with m/z ratios of 4.3, 8.1 and 8.9 
kDa were reported as biomarkers in this study; however the overall intensity across all peaks 
appears lower in the control spectrum. The “markers” do not appear convincing compared to 
results obtained in our study.
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Figure 5.2: MALDI-ToF spectra from two breast cancer and two control samples. The peaks 
for m/z 4.3 and 8.9 kDa (marked *) were unchanged between the two cohorts in our results. 
No mass peak was observed at a mass o f 8 .1 kDa in any of the spectra.
In this chapter LM W  proteins from breast cancer patients and control serum  sam ples 
were com pared for protein profiling  using M A LD I-ToF M S. In the first com parative 
experim ent, only one replicate o f  LM W  filtrates per serum  sam ple w as used; from 
these results a num ber o f  potential m arkers were retrieved and areas w here the 
technique could be im proved w ere highlighted. This sam ple set was nam ed “ S I ” . A 
second profiling study was perform ed on a largely overlapping set o f  sam ples, but 
using LW M  filtrates from trip licate ultrafiltrations o f  the sam e serum  sam ple. These 
results were potentially  validating the SI results how ever, as m any factors o f  the 
sample preparation were changed, the results are m ore com plem entary than fully 
confirm atory. The second sam ple set and experim ent are term ed “S2” throughout the 
rest o f  the thesis. Som e potential m arkers were discovered from both sam ple sets and 
encouragingly som e overlapped. The discovery o f  these m arkers is exciting  and 
identification was attem pted using M A LD I-ToF-ToF peptide fragm entation. From 
this, we were able to get peptide identifications w ith hom ology to three proteins.
Chapter 5: Biomarker Discovery using MALDI-ToF MS 138
5.1. Protein Profiling using MALDI-ToF MS: Sample Set 1 (S1)
Serum  sam ples from breast cancer patients w ere collected and the LM W  sub- 
proteom e was analysed using M A LD I-ToF MS. Specim ens were linked to database 
records but were anonym ised. Blood collection, serum preparation, storage and 
handling, UF and m ass spectrom etry were carried out in exactly the same w ay for 
breast cancer patient sam ples as for the control sam ples. In fact, in each experim ent, 
the 8  m etastatic breast cancer and 8  control sera w ere ultra-filtered and analysed 
sim ultaneously. Each breast cancer sam ple was m atched w ith a control o f  a sim ilar 
age. The age distribution o f  both sam ple cohorts for sam ple set 1 (SI )  is shown in 
Figure 5.3.
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Figure 5.3: Age distribution of healthy controls and breast cancer patients in experiment SI. 
Equal numbers of patients and controls were used from each sample cohort which were 
individually age-matched. Black horizontal lines represent medians for each group.
All sam ples from both cohorts were prepared using the un-optim ised/original UF 
m ethod, as described in the M aterials and M ethods (section 2.3.2) and Chapter 3 
(section 3.3.2), collecting one single filtrate from serum , which had been diluted 1:5 
and filtered at a centrifugation speed o f  3000 xg using a 30 kD a M W CO m em brane. 
For M A LD I-ToF MS, each LM W  serum sam ple was Z ip-T ipped as three aliquots
Breast Cancer (8) Controls (8)
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(Figure 5.4). The eluted fraction were dried and spotted with oCHCA and the spectra 
were analysed in linear mode using a Voyager STR DE (Applied Biosystems, 
Warrington, UK), as described in the materials and methods.
For each set o f triplicate samples, 8 spectra were accumulated in a mass range of 
1000-7000 Da. Each spectrum was recorded in automatic mode and, before every 
sample, the mass spectrometer was externally calibrated from an adjacent spot, using 
Cal Mix 2 (angiotensin I m/z 1297.51, ACTH clip 1-17 m/z 2094.46, ACTH clip 17-39 
m/z 2456.66, ACTH clip 4-38 m/z 3660.19 and insulin m/z 5734.59) from Applied 
Biosystems.
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Se r um s a mp l e  (500 ul)
I
Di lut i on 1:5 wi th 2 5 m M  
N H 4H C 0 3, 20% A C N
L M W  UF 3000 xg 
3 0 k D a  MW CO f i l ters
Sp e e d  vac  and desa l t i ng  
using C1 8  Z i pT i ps  (150 pg) .
I I 1
M A L D I - T o F  ma s s  s p e c t r o m e t r y
I
Sp e c t r u m ana l ys i s
I
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Protei n ID
A n t i b o d y - b a s e d  Va l i da t i on
D i ag no s t i c  tool  d e v e l o p m e n t
Figure 5.4: Experiment flowchart for protein profiling of LMW serum samples. Serum 
samples were prepared by centrifugal ultrafiltration and LMW serum proteins were profiled 
by MALDI-ToF MS. Mass spectra were manually calibrated, baseline-corrected, noise was 
removed and the spectra were smoothed before the centroid peak intensities were exported. 
For profiling, the peaks were standardised by total ion signal and peak intensity ratios of the 
averages of cancer and control were compared as well as /-tests performed on individual peak 
intensities. The target proteins were identified by MALDI-ToF MS/MS. Potentially, following 
identification, antibodies could be developed for validation of the biomarkers.
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Each spectrum  was checked visually and two spectra (VI 3b and V I 3c) had to be 
rem oved prior to further analysis, as these spectra were em pty (Figure 5.5). The 
reproducibility  o f  the rem aining triplicate MS spectra can be seen in two exam ples 
(Figure 5.6) and the full data are shown in Appendix B.
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Figure 5.5: Three aliquots o f sample V13 were each cleaned using Zip-Tips and analysed by 
MALDI-ToF MS. The data for the bottom two spectra were removed as the spectra appear to 
contain no peaks.
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Figure 5.6: Two representative examples of MALDI-ToF MS spectra from LMW serum 
sample o f the SI sample set. The replicate Zip-Tip eluates analysed by MALDI-ToF MS are 
shown in one figure for each sample. The spectra have undergone baseline subtraction, noise 
removal and Gaussian smoothing.
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Using the Data Explorer™ software (Applied Biosystems, Warrington, UK), each 
spectrum was manually calibrated (m/z 1873, 3094, 5022), baseline-corrected, the 
peaks were centriod and the peak detection performed as described in the materials 
and method (section 2.7.1). Peaks with a minimum intensity and area o f 1 and that 
were detected above a signal to noise threshold of 100, were labelled and defined as a 
mass peak. The sequence of spectrum processing can be seen in Figure 5.7. The 
centroid peak intensities were exported as these contain the information of the peak 
intensity as well as o f the peak area. Especially in larger molecular weight peaks this 
is important where the peak width may be increased. Manual calibration is essential 
as, despite external calibration, the mass accuracy o f the Voyager STR DE was 
relatively poor. A mass accuracy o f 10,000 ppm was observed, which means that a 
small mass peak of, for example 1873 Da, could be displayed at anything between 
1850 and 1890 Da, or for a higher mass o f 5080 Da, values could be recorded between 
5030 and 5130 Da. Without manual calibration many peaks which are in fact different 
would be recorded as the same peak, or a peak that is essentially the same in two 
samples recorded as two different peaks, creating false peaks.
MALDI-ToF MS
1
Baseline correction, noise removal ( StDev removed: 2) 
and Gaussian smooth (filter width: 7), centroid
i
Manual calibration (m/z 1873, 3078, 5022)
i
Peak detection threshold (noise threshold: 100, max 
intensity: 1 and max peak area: 1)
i
Export peak intensities in ASCII format
Figure 5.7: MALDI-ToF MS spectrum processing and peak detection in Data Explorer ™.
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A fter m anual calibration in Data Explorer1 M, the m ass accuracy was significantly 
im proved (Figure 5.6). Interestingly, v isualisation o f  the m ass accuracy in Figure 5.8 
show ed that the precision increased w ith m olecular weight. Low m ass peaks showed a 
m ass accuracy o f  approxim ately 5000 ppm  w here as m ass values greater than 4000 Da 
show ed a m ass accuracy o f  2000 ppm  and better. This is unexplained since the 
calibration file covered all the m asses in the spectrum . The peak intensities were 
exported in the form o f  ASCII files for further analysis and biom arker detection.
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Figure 5.8: Correlation of mass accuracy against m/z of individual mass peaks. The mass 
accuracy appears to increase with increasing mass.
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5.2. Data Standardisation to Remove Variation in the Spectra
Prior to any data analysis, the peak intensities for each spectrum were standardised; 
this is important since, as can be seen from Figure 5.9, the overall spectrum intensity 
can vary between spectra. For example the spectrum for OP1 has a lower intensity 
than that o f sample OP2, rows one and two of the breast cancer spectra in Figure 5.9. 
This variation could have been introduced by a number of factors including, but not 
limited to, hotspots in the matrix that produce higher peak intensities, pipetting errors 
and application o f different volumes or concentrations o f sample [13, 14]. Finally the 
clean-up process using Zip-Tips may also introduce variations in the amount of 
protein eluted. However these variations should be minor, and not biologically 
significant. The standardisation described below can remove such differences. Any 
standardisation technique relies on making some assumptions: that the average 
number o f proteins expressed is the same across all samples being standardised, and 
that the number of proteins whose expression levels change is small relative to the 
total number o f protein peaks in the spectra. These assumptions should hold true for 
these samples, since the total number o f peaks is very large, and the samples are 
biologically similar. The “Total Ion Current” (TIC) standardisation was used, which 
measures peak intensities of all peaks in each spectrum and calculating a 
“normalisation factor” (NF) that is used to bring the data closer together [15].
First the average o f all peak intensities across each spectrum was calculated. Secondly 
a “normalisation coefficient” was calculated which takes an average across all the 
results from step 1 (similar to a grand average). Finally the NF for each spectrum was 
calculated by dividing the “normalisation coefficient” by the average peak intensity 
from step 1 for each spectrum. This is a standard automated procedure for other 
techniques (e.g. Ciphergen Biomarker Wizard software for SELDI-ToF MS analyses), 
but has to be performed manually in Excel for MALDI-ToF data.
The NF for each spectrum was then used to multiply each peak intensity value within 
the standardisation range. At this point it is worth mentioning again that the analysis 
(Zip-Tipping and MALDI-ToF MS) was performed in triplicate to minimise the 
effects o f variation.
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Figure 5.9: MALDI-ToF MS spectra of all LMW serum samples from SI. The triplicate 
spectra have been averaged using Data Explorer™.
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5.3. Peak Alignment and Data Analysis: A New Software Tool
One o f the most challenging aspects o f protein profiling using MALDI-ToF MS is the 
lack o f mass alignment tools to compare peak intensities o f particular m/z values 
across all the spectra recorded. This is especially “tricky” since the m/z values for the 
same mass peak can differ from one spectrum to the next, as explained above with 
regards to mass accuracy. For statistical analysis the peak intensities for all peaks 
across all spectra had to be combined in one data sheet.
At the start o f the project, there were no software packages for quantitative analysis of 
MALDI-ToF MS peaks commercially available. The complexity o f the data recovered 
from serum, even just for the LMW fraction, is very large and requires an automated 
method for the alignment o f peaks across all spectra to be able to compare the same 
peaks across all spectra analysed. I therefore created a peak alignment tool in 
Microsoft Visual Basic for Applications (VBA) for Excel; which was later named 
“mzAlign”. As a first step, a range for each m/z value was generated, with a value of 
2500 ppm above and below the m/z value, in the reference mass list of the 
“mastersheet”. In Excel the mastersheet is the spreadsheet where all masses from 
across all spectra are combined as the reference mass list (Figure 5.10). Using a VBA 
code, the mass list o f each spectrum was then searched for a “match” in the m/z ranges 
of the reference mass list. If this was not present, the mass range of the “new” m/z 
value was added to the reference list. In this way, a mass list of all masses across all 
spectra could be compiled, but without duplicate m/z values. As this method is not 
completely foolproof and some mass ranges overlap or other mass ranges are too 
large, m/z values could be missed or could appear in more than one m/z range. The 
mass range was therefore increased in this second round for all m/z values in the 
newly compiled reference mass list to 5000 ppm. Using an “if  clause” [=if 
(B3<=C2,C2+0.1,B3)] in Excel, the range was now changed only if  an overlap 
occurred. As a control, a second programmed code was created using the reference 
mass list to align the m/z value from each spectrum in the mastersheet. This alignment 
was manually checked and, if  necessary, the m/z ranges corrected. This step is labour- 
intensive and could be improved. A third code then searched through all the spectra as 
before and added the standardised peak intensity value for each peak next to the 
reference mass list in the mastersheet. The full code for each o f the actions possible in 
mzAlign is shown in Appendix A.
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A screenshot o f the mzAlign program is shown in Figure 5.10. The second column 
shows the reference mass list (m/z) combined from across all spectra, the third and 
fourth column show the lower and upper mass boundaries, and the remaining columns 
show peak intensities that were filled in from across all spectra. Finally the buttons 
that can be pressed for creation of the reference mass list (Master List), alignment of 
the m/z values (m/z values) and alignment of either the raw or “normalised” peak 
intensities can also be seen. The performance of razAlign can be monitored, using the 
two progress bars for both the number of lines completed in the reference mass list 
and the number of sheets (sample/spectra) searched. The progress bars were included 
to allow the user to monitor the analysis process as this can be lengthy. Once all the 
peak intensity values from each spectrum have been aligned in the mastersheet next to 
their corresponding m/z value, statistical data analysis can be performed.
Chapter 5: Biomarker Discovery using MALDI-ToF MS 149
m / z lower
Master Normalised 
upper m/z Values List Intensity
.in se tm R le \  Edit View Data Window Help
- ii jytS5% - -  1 0 / -  B /  u  SF UL_1
(CD Snaglt
A B C D E F 3" T p r > / J K Z I  L i ____ « ____ N
1 1 / /
2 sample Centroid M Lower Bot Upper Bound OP1a1 OP1c1 OP3a1 <lp3b1 OP3c1 / 0P6a1 O P 6 b l/  OP6c1 OP7b1 OP7c1
3 V25b 1010 1007 475 1012 525 T / 74 OP7c 1036 1033.41 1038.59 / /
5 OP1a 1043 1040.393 1045.6075 11895131 987554 1012559 |  617036 / /  1159081.7
8 OP6a 1051 1048.373 1053.6275 45435 244 t- 1967858 41
7 V25b 1057 1054.358 1059.6425 158565.54 / / 10525033.9 283817.775
8 V2Sb 1062 1059.743 1064.655 440947.39 1381598 / E
9 OP1a 1068 1065.33 1070 67 409115.69 ▼ / 18046 0317
10 V2Sb 1077 1074.308 1079.6925 95150 m/z values I / i 5 1328544.71
11 OP1a 1088 1085.28 1090.72 1622171 # nnrm intensity486801 ■
12 V25b 1099 1096 253 1101 7475 839972.89 264131 i 253582 594
13 V25b 1104 1101.848 1106.76
14 V2Sb
15 V25b
1113
1120
1110.218
1117.2
1115.7825
1122.8 37511 649
24962 Master List 3
16 V25b 1124 1122.9 1126.81 350381.9
17 ]V25b 1127 1126.91 1137.8375 106602.51 181674 raw intensity 7 742166.514
1145 1142138 1147 8625 14268301 182268 I 294226 981la  w s c
19 OPIa 1160 1157.1 1162.9 37799.108 master sheet lines. 4 1 > Label3
20 IV2Sb 1167 1164 083 1180 945 84850.478 21567 2
21 V25b 1187 1184,033 1189.9675 77390 data sheets a » Label4 22732 318122OP1c 1201 1197.998 1204.0025 21993
( 23 V26b 1211 1207 973 1214.0275 2 589846.513
24 Op9b 1219 1215 953 1222.0475 521022.883
25 V25b 1227 1223.933 1230.0675 81164
26 V25b 1234 1230.915 1237.085 42191.359 154326 7 61641.7928
27 V25b 1241 1237.898 1244.1025 143256.39 286277.454
28 V25b 1248 1244.88 1251.12
29 V25b 1256 1252.86 1259.14 49510 246748 280433 78666 3559 289985 875
30 V25b 1262 1259.24 1268.1625 186994.19 359666 208202 59472 72323 8799 128135.951 120434.093
31 OP3b 1272 1268.82 1275 1 8 36269 15385 245 11735 31
32 V25b 1279 1275 803 1282.1975 41064,202 52137 133887 100524.63 182484.715 89200.6179 41513.249 84523 3498
33 V25b 1290 1286.775 1293 225 80038 3901 53476.02 12426 2773
34 V25b 1295 1293 325 1298 2375 41246 94 67529 12217 31183.2523 43596 5081
35 V25b 1309 1305 728 13122725 82335.171 186712 161450 313338 196508 107554.292 135012.015 806681.113
36 V25b 1316 1312.71 1319.29
37 V25b 1324 1320.69 1327 31 228390 1 9 116644 160814 61492 238519 07 86225 6443 55723.4014 177903 327
38 V25b 1335 1331 663 13383375 113975 26 81659 35151 4803
I 39 OPIa 1344 1340.64 1347.36 37329.694
, 40 V25b 1353 1349,618 1356 3325 361876 47 163742 280523 219119 162912.98 244059 1 35 349144 368
\O u tp u t " ( n o r m a l ) /  O p la lo ^ m o T /O P lc _ 5 2 _ O O Q l  /  OP3a_04_0Q01 /  OP3b_34_OOQl /  OP3c_54_OODl /  OP6a_05_0001 /  f |  <
Ready
Figure 5.10: The “mastersheet” of the mzAlign program created in VBA for peak alignment 
from MALDI-ToF spectra. The first part of the program creates a reference mass list of all 
masses across all spectra (seen in column B). The other programs search through all spectra 
using the reference master list and will add a value for either m/z value, raw intensity or the 
normalised intensity, where necessary.
For the analysis o f  M A LD I-ToF MS spectra and com parison o f  peak intensities 
mzAlign proved to be invaluable, enabling autom ated, h igh-throughput analysis o f  all 
m ass spectra acquired as part o f  an experim ent. In this way, 272 m/z values were 
com bined from SI into one table. A fter alignm ent the data could be further analysed 
in Excel or exported into another statistical softw are package such as SPSS. Later in 
the project, we obtained an evaluation softw are package from A pplied Biosystem s, 
called M arkerview  (M V ), which perform s a sim ilar alignm ent to wzAlign. In this 
program , the m ass tolerance for creation o f  a reference m/z list can be defined during 
im port o f  the spectra. How ever, corrections o f  the individual m asses in the reference
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list cannot be performed after peak alignment. A mass tolerance o f 2000 ppm was 
recommended, however this resulted in the generation of too many peaks and did not 
correctly align masses that were the same between spectra. The mass accuracy across 
all the spectra was earlier calculated to have an average o f 4000 ppm after manual 
calibration (Figure 5.8). Furthermore, use o f this latter mass tolerance setting in 
Markerview resulted in a reasonable number of mass peaks and was most similar to 
the mass list generated using /wzAlign. Using Markerview and this mass tolerance 
setting, 274 m/z values were aligned into one table.
As a first step of statistical analysis, the data was tested for normality using the 
Kolmogorov-Smimov test in SPSS. The vast majority o f the data was found to be 
normal. As advised by a statistician from the library information service centre 
(University o f Wales, Swansea) during an SPSS one-on-one course, since >90% of the 
data was normal, the entire dataset could be regarded as normal for further analysis. In 
fact, it would be expected for a large normal dataset to contain some data points that 
deviate from normality. A Student’s /-test, for that reason, was then performed on the 
data. To simplify, the order o f events involving data analysis using mzAlign and 
Markerview is described in Figure 5.11.
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MALDI-ToF MS
I
Baseline correction, noise removal ( StDev removed: 2) 
and Gaussian smooth (filter width: 7), centroid
Manual calibration (m/z 1873, 3078, 5022)
Peak detection threshold (noise threshold: 100, max 
intensity: 1 and max peak area: 1)
Export peak intensities in ASCII format
Markerview import (4000 ppm)
Export to Excel for “NF” 
calculation
Standardisation in Markerview
1 1
Export to Excel to calculate f-test
averages
I
f-test and fold-changes
i
Import into Excel 
Standardisation
i
Create reference mass list and 
remove overlaps in mzAlign
i
Align peak intensities
I
Calculate averages
i
f-test and fold-changes
Figure 5.11: Data analysis and spectra processing. The data was analysed using our custom 
VBA alignment tool (mzAlign) and the commercially available Markerview software. Both 
software programs use alignment to generate a reference mass list and to align all peak 
intensity values in rows for downstream statistical analysis. Prior to alignment, a 
“normalisation factor” (NF) was calculated in Excel for both tools, to correct for variations in 
each spectrum.
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5.3.1. Biomarkers discovered in Sample Set S1
For biomarker discovery, the standardised data was analysed, comparing control and 
breast cancer samples. Before statistical analysis could be performed, all missing data 
points in the averaged dataset were replaced with a value of “1”. This was justified by 
the assumption that if  no peak is present in any o f the three replicate spectra from the 
same sample, then it could be assumed that this protein peak is not present in the 
particular serum sample. Missing data points were replaced with a value o f 1, and not 
zero, as the statistical algorithms cannot deal with the value o f zero, as it causes 
division by zero errors. The value o f “1” is significantly lower than the intensity 
values for “present” peaks. Values that are missing across all the technical replicates 
are therefore accepted to be “zero” but were replaced with “1”. However the 
datapoints that are only missing in one or two of the three replicate spectra are instead 
combined as a single averaged value, reflecting the fact that they are present in at least 
one sample, meaning that there is in fact a compound present.
Principal components analysis (PCA) is a statistical technique that is used to show 
clustering or grouping o f samples dependent on biological variation between two 
sample cohorts, without prior knowledge of the identity o f each sample. Un­
supervised PCA analysis of the technical replicates for SI revealed two separate 
groups with the controls and breast cancer samples in separate clusters. Furthermore it 
showed that the replicates are actually relatively close together and that most o f the 
variation therefore results from the biological samples, rather than from the technique 
itself (Figure 5.12).
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Figure 5.12: Un-supervised principal components analysis of MS-based serum protein 
profiling data derived from healthy controls and metastatic breast cancer patients.
The variance for each o f  the protein peaks com bined in the reference peak list was 
exam ined. For this, all technical replicates from each LM W  serum  sam ple were 
averaged and an un-paired S tudent’s /-test w as perform ed as described in the 
M aterials and M ethods (section 2.9.2). The Student’s /-test com pares the peak 
intensities from the control and breast cancer serum sam ples and a /?-value was 
calculated for each protein com parison. Prior to the /-test, the F-test statistic was 
calculated for each m/z value, to determ ine w hether the two sam ple groups have equal 
variances. I f  equal variance w as observed, a type II /-test was perform ed; i f  the 
variance w as not equal, a type III /-test was used. This was com puted in Excel as part 
o f  an “i f ’ statem ent. U sing a cu t-o ff value o f  p  <0.05, 12 significantly  different 
proteins were retrieved from the averaged sam ple sets (Table 5.1 and Table 5.2).
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Table 5.1 shows the m/z value of each peak found to be different between breast 
cancer and control samples. Columns 2 and 3 show the number o f spectra in which 
this peak was found, numbers in red indicate that this peak was found in less than 25% 
of spectra from each cohort. Table 5.1 shows the significant /7-values for peaks from 
the un-averaged data, and, for comparison, the m/z peaks that were found to be 
discriminant using the averaged data. However, only differential peaks (p <0.05) from 
the averaged data (shown in Table 5.2) are further discussed and the spectra analysed. 
Finally the results from alignment using Markerview followed by statistical analysis 
in Excel and in Markerview alone are shown in both tables, and the reasons for these 
different forms of analysis are discussed below.
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Table 5.1: Protein peaks found to be differentially expressed in sample set SI. In columns two 
and three, the number of spectra (n Cancer and n Control) in which each peak was found is 
shown. If this number is shown in red then this peak was found in less than 25% of spectra 
from each cohort. In the last column, the results from the ‘7-test” in Markerview are shown. 
The software does not provide a fold-change value; therefore up- or down-regulation of the 
breast cancer samples (C) is documented. C down: peak intensity lower in breast cancer 
samples compared to controls and C up: peak intensity higher in breast cancer samples 
compared to controls.
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The M arkerview  softw are was m ainly used for peak m/z alignm ent and the /-test was 
calculated separately  in Excel. H ow ever the far right colum n shows ^-va lues retrieved 
from a /-test perform ed as part o f  the M arkerview  analysis process. Interestingly, 
M arkerview  show s statistically significant peaks for m/z values that have no data 
points for one o f  the two groups (e.g. m/z 5897: peak absent in all cancer sam ples, but 
present in 4 controls). Despite the claim  to be using a /-test, this indicates that 
M arkerview  m ust be using another form o f  statistical test or norm alisation, since a /- 
test cannot be perform ed on groups w here one arm has no values. In addition, when 
exporting the peak intensities aligned using M arkerview , m issing values were 
replaced w ith  a “ 0 ” by the software, which w ould again m ake a /-test im possible.
Table 5.2: Statistical analysis of discriminating peaks derived from the averaged peak 
intensities from serum protein profiling of breast cancer patients and healthy controls. Aligned 
using mzAlign and Markerview, number of spectra (n Cancer and n Control) in each cohort 
shown in red were found in less than 25% of spectra.
A l i g n m e n t  V B A ,  
t - t e s t  e x c e l
A l i g n m e n t  M V iew ,  
t - t e s t  e x c e l
Centroid n Cancer n Control p-value fold- p-value fold-
Mass (24) (22) averages change averages change
1064 10 8 0 .019 1.7 0 .0 1 4 2 .9
1185 11 9 0 .023 1.4
1313 14 9 0 .0 3 5 1 .9
1341 13 11 0 .0 2 8 1 .9
1378 11 10 0 .0 4 5 2 .4
1391 1 6 0 .0 4 8 -7 .0
1591 18 14 0 .0 4 7 1.6
1776 10 10 0 .0 0 2 2 .0 0 .0 4 0 1 .9
2 5 5 6 18 19 0 .0 4 0 -1 .7
2 8 2 6 20 22 0 .0 3 0 -1 .5
2 9 2 5 13 12 0 .0 3 8 1.5
2 9 9 5 19 21 0 .022 -3.1 0 .0 1 5 -3 .6
3 8 5 0 21 21 0.021 -1 .6
5101 10 6 0 .0 2 2 3 .0 0 .0 4 3 2 .7
5 8 9 7 0 4 0 .0 3 8 - 2 6 1 4 1 0 .0 2 0 - 1 0 .0
6 2 7 8 6 1 0 .0 3 6 11.1 0 .0 3 6 1 1 .9
696 2 2 3 0 .0 0 2 1.7
The M arkerview  softw are can also provide an interesting alignm ent control option, 
where individual peaks can be visualised across all sam ples, as well as visualisation o f  
the peak intensities across all spectra (Figure 5.13). Further evidence for using the 
averaged data for statistical analysis was provided by the peak intensity visualisation
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w hich forms part o f  M arkerview . This clearly showed that use o f  the averaged results 
w as im portant to rem ove potential variation introduced by single outliers. For 
exam ple, as seen in Table 5.1, the peak for m/z 5101 w as calculated to be down- 
regulated in breast cancer sam ples from the non-averaged data, w hereas the averaged 
data shows this peak to be significantly up-regulated in breast cancer. Looking at the 
individual spectra them selves and the M arkerview  visualisation, this protein peak m ay 
be up-regulated in breast cancer, but is certainly not dow n-regulated (Figure 5.13 and 
Figure 5.14).
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Figure 5.13: Markerview visualisation of the peak intensities across all spectra aligned for m/z 
5101, showing skewing of the result by outliers (marked *).
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Figure 5.14: MALDI-ToF MS spectra aligned in Data Explorer from all samples across each 
clinical cohort. The absence of a peak for m/z 3850 and the discriminating peaks for m/z 5101 
and 5897 are boxed in red.
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These graphs further highlight the im portance o f  calculating averages across replicates 
to reduce variation. Peak m/z 1608, in Figure 5.15 for exam ple, was originally 
retrieved on the basis o f  having a significant p -value after calculating the variance 
taking into account all the data points (after alignm ent in M arkerview ), but was not 
significant w hen the averaged data w as used. Figure 5.15 shows that 17 peak 
intensities w ere aligned w ith m/z 1608 in the cancer group, o f  which only four had 
elevated peak intensities. The rem aining 13 peaks had roughly the sam e intensity as 
those aligned from the control spectra. A veraging rem oved the variation introduced by 
these outliers. Furtherm ore analysis o f  the spectra in D ata E xp lo re r IV1 in Figure 5.16 
showed that m/z 1608 has a peak intensity that is too low to be seen in the spectra.
m /z  1608 4
2.0e5
13
o p5  t
OP3b.txt
1  \ OP5a.txt; V
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V
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V25b.txt
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Figure 5.15: Markerview visualisation of the peak intensities across all spectra aligned for m/z 
1608. In the breast cancer cohort, shown in blue (OP1 -  OP9), four peaks have a greater 
intensity than any of the controls; however the remaining 13 peaks had a similar peak 
intensity to the controls (V5 -  V25). The line shows the intensity of the highest control peak.
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Figure 5.16: MALDI-ToF MS spectra aligned in Data Explorer from all samples across each 
clinical cohort. The mass range of m/z 1500 to 1850 shows that m/z 1776 was significantly up- 
regulated and m/z 1591 significantly reduced in the breast cancer samples.
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In total, from the averaged data, using both alignment tools, 17 discriminating peaks 
were detected (13 using mzAlign and 9 using Markerview). Of these, four were the 
same between mz Align and Markerview (Table 5.2). To verify the significance of 
discriminating peaks, each o f the 17 protein peaks was visually inspected as described 
for m/z 5101 above (Figure 5.14 to Figure 5.19). It was shown that some peaks differ 
dramatically between the two groups (m/z 1064, 1776, 2556, and 2995) whereas 
others show more subtle differences (m/z 1391, 1591, 1925, 5101 and 5897), and yet 
others have a very low signal-to-noise ratio and are probably not significant (m/z 
1185, 1313, 1341, 1368, 2826, 3850, 6278 and 6962). The peaks in this last category 
were too small (low intensity) to perform tandem MS analysis for identification and 
may therefore not be robust enough to classify as potential markers. Two examples are 
shown in Figure 5.15 and Figure 5.19, but the peaks are actually too low to be 
detected and are therefore not boxed, but the areas where the peaks would be can be 
seen in the figures.
The discriminant peaks will now be discussed in order o f increasing molecular weight. 
Looking at the discriminant peaks for m/z 1064 and 1391, an overall greater intensity 
was observed in the breast cancer samples. Although the intensity of most peaks in the 
spectrum <1400 are variable across samples within the breast cancer and control 
groups, the peaks at m/z 1064 and 1391 are significantly and visually different, 
whereas the intensity of the non-discriminating neighbouring peak (m/z 1082) was the 
same between the breast cancer and control groups (Figure 5.17).
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Figure 5.17: MALDI-ToF MS spectra from all samples in the mass range 1010-1400 Da.
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Figure 5.18 shows the alignm ent o f  a truly discrim inatory peak, m/z 2995. Here a 
significant num ber o f  m ass peaks in the control sam ple group w ere o f  greater intensity 
than those from the breast cancer cohort. The M arkerview  graph is sim ilar to what 
w as observed in the spectra in Figure 5.19; although the peak is present in the breast 
cancer spectra, it occurs m ore frequently in the control sam ples and has a higher 
intensity. The sam e is true and can be seen for m/z 2556 (Figure 5.19). Also seen in 
Figure 5.19; although m/z 2826 has a significant p-value, the peak intensity is too low 
for visualisation. Furtherm ore, the peak at m/z 2925 does not look convincingly 
different betw een control and breast cancer sam ples, which was possibly to be 
expected as the groups were only 1.5-fold different in their peak intensities.
OPib.txt 0P2c.txt OP4a.txt OPQa V15b.txt V5a.txt \J9c txtV11b.txttxt
Figure 5.18: Markerview visualisation of the peak intensities across all spectra aligned for m/z 
2995. In the control cohort (V5 -  V25), shown in red, 9 samples show a higher peak intensity 
for m/z 2995 than the control samples in blue (OP1 -  OP9). A line shows the intensity of the 
highest breast cancer peak.
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Figure 5.19: MALDI-ToF MS spectra aligned in Data Explorer from all samples across each 
clinical cohort. The mass range of m/z 2500 to 3100 is shown, the peaks for m/z 2995 appear 
to be more convincingly discriminating than the other peaks in the mass range.
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Some discrim inating peaks were only retrieved from the averaged data. Som e o f  these 
were present/absent calls, i.e. expressed in one clinical cohort only (e.g. Figure 5.20 
and Figure 5.21). The peak for m/z 6278 was increased in 6  breast cancer sam ples but 
in only one o f  the controls at a low intensity. For these peaks the m issing values in the 
averaged data had to be replaced w ith “ 1” and a type III t-test was calculated allow ing 
for unequal variance.
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Figure 5.20: Markerview analysis of m/z 6278 shows protein peaks that are different between 
the two clinical sample cohorts. This peak is an example of peaks with a / 7-value that could 
not be calculated using a /-test in Excel, due to no peaks aligned from the control group, but 
was identified as significant using Markerview.
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Figure 5.21: MALDI-ToF MS spectra aligned in Data Explorer from all samples across each 
clinical cohort. The mass range of m/z 6020 to 7000, showing m/z 6278 only to be present in 
some of the breast cancer samples and that m/z 6962 may not be a real peak.
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During the course o f this experiment, a number of issues were highlighted that could 
be further optimised. Although the results were interesting and may be useful, as the 
centrifugal ultrafiltration (UF) was only performed once, we could not be clear 
whether potential markers were found as a result of a clinical difference between the 
sample groups or due to the sample preparation step. The UF step therefore needs to 
be performed in triplicate. Furthermore, although the sample clean-up had been tested 
and optimised; and the LMW serum samples were desalted and concentrated using 
Zip-Tips from the same volume o f LMW filtrate as for SELDI-ToF analysis, the 
actual capacity of the Zip-Tips had not been defined. This was tested in the following 
section.
In addition, the spectra generated in this experiment showed a lower number o f peaks 
than expected, with surprisingly few low molecular weight peaks present. A thorough 
check o f the specifications of the MWCO filters revealed that actually only 10% of 
proteins with a molecular weight >12 kDa are expected to pass through a 30 kDa 
MWCO filter, despite their name. Hence, as described previously (Chapter 3), the UF 
step was optimised and in the remainder o f the experiments 50 kDa MWCO 
membranes were used. Finally, using the larger MWCO filters, larger proteins were 
recovered in the filtrate and therefore a different matrix than oCHCA may have to be 
used. The optimal matrix composition was determined in the next section.
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5.4. Optimisation of the Sample Preparation Procedures
5.4.1. Optimisation of Sample Concentration
To analyse human serum by mass spectrometry, the sample first has to be desalted, as 
salt interferes with the ionization process. For this, C l8 chromatography in the form 
of Zip-Tips is often used: the Cl 8 chains bind proteins and peptides and allow salts to 
be washed off with acidified water. C l8 Zip-Tips have a binding capacity of 
approximately 5 pg of protein. For larger sample quantities, SPE cartridges, also 
packed with C l8 reverse-phase silica, are recommended. Here the binding capacity of 
C l8 Zip-Tips as well as SPE cartridges was investigated to find the optimal conditions 
for salt removal and protein concentration.
Different amounts o f LMW protein were Zip-Tipped and directly applied onto a 
MALDI-ToF plate using the sandwich preparation method, where matrix, sample and 
then matrix again are applied separately and each layer is left to dry before the next is 
applied, using sinapinic acid as matrix (although it was later discovered that mixing 
sample and matrix 1:1 before spotting provides better results). The Zip-Tip flow­
through (FT) and the TFA wash o f each sample were collected and desalted using 
Millipore membrane discs before MALDI-ToF MS analysis. The membrane discs 
remove salts through a different process than C l8 chromatography: the sample is 
spotted onto the “filter paper” which floats on a water bath. The salts pass through the 
paper by osmosis leaving the purified sample behind. This provides an alternative 
method for desalting than the C l8 chromatography for the proteins that passed 
through the Zip-Tips without binding.
To check the optimal binding capacity o f the C l8 Zip-Tips, a LMW filtrate with a 
protein concentration o f 85 pg/ml was Zip-Tipped from a range o f volumes (500, 250, 
100 and 10 pi), as described in the Materials and Methods (section 2.5), to give 
varying final protein amounts o f 42.5, 21.25 pg, 8.5 and 0.85 pg. The bound peptides 
were eluted in 3 pi o f acidified water and spotted with sinapinic acid. The spectra are 
shown in Figure 5.22 a-c; they are very similar and no peaks appeared to be lost when 
smaller volumes were concentrated. The results show that the protein recovery did not 
improve with protein amounts greater than 20 pg (Figure 5.22). This may therefore be 
the maximum capacity o f the 10 pi Zip-Tips. At the lower end o f the volume
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spectrum , after concentrating 100 pi (i.e. 8.5 pg o f  protein), the same protein peaks 
w ere v isib le in the spectrum , ju st at a slightly lower intensity, whereas, in the filtrate 
taken from lOpl o f  serum , i.e. 0.85 pg o f  protein, m any peaks were lost and the 
spectrum  show ed different peaks. It was therefore determ ined that 8.5 pg o f  protein is 
the optim al protein am ount for loading, taking into account the lim ited sam ple 
availability.
A 3 2 8 8 .3 4
\4M*U1V,JL
6 3 9 3 .5 5  9 4 5 1 .2 3
7 7 0 8 .9 1  , 1 0 6 8 3 .2 5 1 3 9 2 5 .6 0
1.5E+4
42 pg
B 3 2 8 5 .4 5 1.2E+4
21 p g
6 3 9 8 .0 1 9 4 5 7 .4 0
1 3 9 3 2 .4 4
c
1.2E+4
8.5pg
6 4 0 0 .2 4
7 7 0 7 .2 8 1 0 6 9 1 .3 5 1 3 9 3 4 .9 2
1 6 .4 9 2.2E+4
3 2 9 1 .2 2
0.8 pg
5 9 4 1 .0 4  7 7 0 9 .0 1
1999.0 5599.2 91 99 .4 12799.6 16399 .8 20000.0
M ass (m/z)
Figure 5.22: MALDI analysis of different volumes of Zip-tipped LMW serum. A: 500pl of 85 
pg/ml LMW filtrate, B: 250 pi, C: 100 pi and D: 10 pi of sample.
W hen analysing the FT and the 0.1%  TFA wash, it becam e apparent that m any 
proteins, especially  those o f  larger m olecular weight, did not actually bind to the Zip- 
Tips. O verloading m ay be the reason w hy proteins that were also present in the eluted 
fraction also appeared in the FT (Figure 5.23). Larger proteins especially serum 
album in do not bind well to C l 8  chrom atography (Figure 5.24).
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Due to this poor binding capacity  o f  album in to C l 8  Z ip-T ips and SPE cartridges have 
actually  been used for album in depletion in the past [ 1 0 ]; (personal com m unication 
M atharoo-B all, B. 2006) and also in form o f  m agnetic beads covered in C 8 -oligo 
silica [6 , 8 ]. H ow ever throughout this study we used C l 8  Z ip-Tips purely for 
desalting.
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Figure 5.23: MALDI-ToF MS analysis of proteins after Zip-Tip clean-up. Panel A  shows 
peaks from the eluted fraction of the Zip-Tip and panel B shows proteins in the FT that were 
not bound to the C l 8  Zip-Tips.
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Figure 5.24: MALDI-ToF analysis (mass range 15- 70 kDa) of the FT of C l 8  Zip-Tips. 
Larger molecular weight proteins bind poorly to the C l 8  Zip-Tips and are present in the FT. 
The eluted faction of the Zip-Tips contains no proteins and produced an empty spectrum (not 
shown).
5.4.2. Comparison of C18 Zip-Tips with C18 SPE cartridges
Here, 1 ml o f  the sam e LM W  serum  sam ple (85 pg/m l) as used previously  was 
desalted using C l 8  SPE cartridges from E m pore1M (3M , Bracknel, UK) for direct 
com parison w ith C l 8  Zip-Tips. A nalysis o f  the eluted fraction from these cartridges 
by M A LD I-ToF MS did not produce the sam e num ber o f  peaks as w hen these sam ples 
were desalted w ith C l 8  Z ip-Tips (Figure 5.25). In particular, no peaks w ere detected 
in the 7-70 kD a m ass region (Figure 5.25b). M any proteins did not bind to the SPE 
cartridges but instead appeared in the FT, which leads to the conclusion that the SPE 
cartridges did not bind protein as well as the Z ip-T ips tested. C onsidering the fact that 
C l 8  m aterial is used in both devices, it is possible that the m ake o f  this particular type 
o f  cartridge w as inferior. It was therefore decided that the E m pore l v 1  SPE cartridges 
were not suitable for desalting LM W  serum sam ples, and C l 8  Z ip-T ips from 
M illipore (W atford, UK) were chosen for further analysis.
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Figure 5.25: MALDI-ToF analysis o f the eluted fraction from SPE C l 8  clean-up. The 
fractions show fewer peaks than after C l 8  Zip-Tip concentration, when analysed by MALDI- 
ToF MS. The mass range between 2000 and 5000 Da is shown in A and larger molecules in B.
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5.4.3. MALDI-ToF Matrices
One of the most important aspects o f MALDI-TOF MS is good sample preparation 
[16, 17]. Many variables influence the integrity of a good, homogeneous MALDI 
sample and this includes, but is not limited to, the concentration o f the matrix and 
analyte, choice o f matrix, analyte sample history (i.e. exposure to strong ionic 
detergents, formic acid), the sample/matrix application and solubility and 
compatibility of matrix and analyte solutions. A number o f different matrices are 
available for MALDI-ToF MS analysis. Not all samples work well with every 
MALDI-ToF matrix since each peptide/protein has a unique structure. Additionally 
each matrix compound has its own unique physical properties and interacts with the 
analyte molecules in a unique manner. In addition, to select a matrix to obtain good 
qualitative spectra, it is important to produce a homogeneous spot, in order to get 
reproducible spectra, especially during automated acquisition of mass spectra. In this 
section, commercially available matrices and their mixtures (Table 5.3) were tested 
for the optimisation of a matrix for analysis of intact LMW proteins for protein 
profiling. Critical qualities examined were homogeneity of spread o f the 
matrix/analyte mixture, homogeneity o f intensities across the spot (i.e. no hotspots), 
good signal intensity at low laser energy and a high signal-to-noise ratio. The matrices 
tested and their applications are described in Table 5.3.
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Table 5.3: MALDI-ToF MS matrices tested to find the optimal matrix for quantitative protein 
analysis from I,MW serum. Sinapinic acid (SA), a-cyano-4-hydroxycinnamic acid (CHCA), 
2,5-dihydroxybenzoic acid (DHB) and L-(-)-fucose (6 -deoxy-L-galactose) (fucose) were 
prepared at different concentrations and as mixtures.
Matrix No Matrix Cone Solvent
1 SA 10m g/m l 30/70 ACN, 0.1%  TFA
2 SA 30m g/m l 50/50 MeOH
3 SA - fu c o se 8m g/m l e a c h 50/49/1 0 .1%  TFA ,A C N ,A cetone
4 CHCA 10m g/m l 50/50 ACN, 0.1%  TFA
5 C H C A - FA 10m g/m l 70/30 ACN, 5%  FA
6 CHCA - fu co se 8m g/m l e ac h 50/49/1 0.1%  TFA ,A C N ,A cetone
7 DHB 20m g/m l 30/70 ACN, 0 .1%  TFA
8 DHB - fu c o se 8m g/m l e ac h 50/49/1 0.1%  T FA ,A C N ,A cetone
9 fu c o se 10m g/m l 50/50 ACN, 0 .1%  TFA
14 DHB-CHCA 1:1 (v:v) m atrix 7 an d  4
15 DHB - CHCA - 
fu c o se
1:1 (v:v) m atrix 7 an d  6
11 SA  - CHCA 1:1 (v:v) m atrix 1 and  4
12 SA - CHCA 1:2 (v:v) m atrix 1 an d  4
13 SA  - CHCA 2:1 (v:v) m atrix 1 an d  4
Each m atrix (Table 5.3) was evaluated for suitability with LM W  serum proteins by 
analysing a low (2-5 kDa) and a high (5-16 kDa) m ass region. Digital photographs 
were also taken o f  the m atrix spots to show how well each m atrix/analyte m ixture 
spread across the M A LD I plate w hen spotted (Figure 5.26); additionally each spot 
w as exam ined for spot appearance, hom ogeneity  o f  the peak intensity across the spot 
and the optim um  laser intensity required to produce good m ass spectra (Table 5.4). 
The results show ed that, to produce the sam e peak intensity, SA required a higher 
laser intensity than either oC H C A  or DFIB, m aking these latter two the better choices. 
H ow ever DHB did not produce a hom ogeneous spot (Figure 5.26: m atrix 7). Addition 
o f  L -(-)-fucose (6 -deoxy-L-galactose) to other m atrices had previously been reported 
to im prove hom ogeneity  o f  the spot [18-20]. How ever when fucose was added to each
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of the three matrices, these results could not be confirmed, as none of the mixtures 
showed improved spot homogeneity (Table 5.4 and Figure 5.26: matrices 3, 6 and 15).
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Table 5.4: MALDI spot properties for different matrices in respect of production of protein 
peaks, homogeneity of matrix and optimum laser intensity required for good peak intensity at 
low and high MW ranges. Each matrix was prepared as explained in Table 5.3, matrix 1 
(sinapinic acid) and matrix 4 (oCHCA) were applied mixed with the analyte before 
application to the plate (m) and by the sandwich method (s) where matrix is applied then 
analyte and then matrix again.
Matrix No Matrix
Spot
appearance
Intensity
homogeneity
Laser intensity 
(low/high m /z )
1m SA good 3031 / 3202
1s SA worse than mix 3067 / 3209
2 SA no spot
3 SA - fucose 3102 /3245
4m CHCA homogeneous good 2289 / 2353
4s CHCA worse than mix worse than mix 2183 /2318
5 CHCA- FA 2225 / 2340
6 CHCA - fucoS' funny bubbles good 2389 / 2546
7 DHB crystals outside worse high MW 2781 / 2924
peaks
8 DHB - worse than 7 worse than 7 3138 /3138
FUCOSE
9 fucose no peaks
14 DHB-CHCA not good peaks 2297 / 2632
homogeneous
15 DHB- CHCA less bubbles less peaks than 2746 /3174
FUCOSE than 6 6
11 SA - CHCA good very good 2232 / 2389
12 SA - CHCA worse than 11 worse than 11, 2318 /2389
sharp peaks
13 SA - CHCA good very good 2460 / 2746
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Figure 5.26: Digital photographs of MALDI matrices mixed with LMW serum proteins and 
peptides. Top row, SA; middle: CHCA; and bottom row: DHB matrices and mixtures.
To investigate the different m atrices further, the signal-to-noise ratio (S/N) o f  a 
selection o f  protein peaks was calculated using Data E xplorer IN1 (A pplied 
Biosystem s). To obtain the S/N ratio, a peak was highlighted and the noise level was 
calculated au tom atically  from an area in the spectrum  that has a flat baseline and no 
obvious peaks. The results are shown in Table 5.5 and Figure 5.27. In the low m ass 
region, m atrix 11 (SA -oCH CA ) produced a good clean spectrum , sim ilar to those seen 
with oC H C A  alone (Figure 5.27). H ow ever, the S/N ratio was better for m atrix 11 
than for oC H C A  alone. A dditionally, it was observed that, for the m ixture, the peak 
intensity increased the longer the laser w as applied; which was not observed in any o f  
the other m atrices. This is im portant when accum ulating a large num ber o f  shots in 
autom ated fashion, to retain a reproducible m ass spectrum. This m ixture also 
perform ed w ell w ith proteins o f  higher m olecular weight, how ever SA alone m ixed 
before application gave a m ore hom ogeneous spot and the S/N ratio o f  the peaks in 
the high m olecular w eight were higher than the other m atrices (Table 5.5). A ccording 
to these results, for analysis o f  LM W  proteins recovered from 50 kD a M W CO  filters, 
where m ore high m olecular w eight peaks are present, SA appears to be m ore suited. 
Although proteins < 3000 Da had low er S/N ratios using SA, protein peaks with a m/z 
greater than 5000 appeared to ionize better using SA. The peak intensity was kept
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relatively similar for all spectra acquired for direct comparison, however, it was not 
possible to obtain a good peak intensity for the <5000 Da peaks using SA. As this is 
conflicting with the results obtained for spot homogeny and S/N ratios, a mix of 
oCHCA and SA may be the right choice. The mixture performed well with small and 
medium sized proteins. For the mixture the .bic file settings in the Voyager software 
were set to the default for oCHCA and SA to test the best conditions. The oCHCA 
setting produces sharper peaks and better S/N ratios than the SA setting, this could be 
expected, as the spectra look more similar to the spectra produced by oCHCA alone. 
In conclusion, SA-CHCA produced the best spectra for the higher mass range and 
should be used for future MALDI-ToF analysis.
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Figure 5.27: MALDI-ToF MS spectra of LMW serum with different matrices chosen 
according to their signal-to-noise ratio from Table 5.5. In the upper panel (A), SA, CHCA, 
SA-gCHCA and DHB-oCHCA are shown for the mass range m/z 2000 -  5000 Da. In the 
lower panel (B), for the mass range m/z 5000 -  16000 Da, SA, oCHCA, DHB-oCHCA, and 
SA-gCHCA are shown.
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5.5. Protein Profiling on Sample Set S2
In light o f  the sam ple preparation im provem ents m ade above, we carried out a second 
experim ent (S2), using a lower sam ple concentration w ith 20 pg  o f  protein, and the 
sam ple w as m ixed in the tube with aC H C A -SA  m atrix m ixture. Due to lim ited sample 
availability, in the second sam ple set, two different cancer and 5 different control 
serum  sam ples w ere used com pared to sample set SI (Table 5.6).
Table 5.6: Samples used in each of the two experiments, SI and S2. Not enough serum was 
available to repeat the analysis using exactly the same samples.
S1 S2 S1 S2
Cancer OP1 OP1 Control V5 V5
Cancer OP2 OP2 Control V6 V6
Cancer OP3 OP3 Control V9 -
Cancer OP4 - Control - V10
Cancer OP5 OP5 Control V11 -
Cancer OP6 - Control V13 -
Cancer OP7 OP7 Control V15 V15
Cancer OP9 OP9 Control - V17
Cancer - OP10 Control - V19
Cancer - OP11 Control - V20
Control V22 -
Control V25 V25
It is also notew orthy that the sam ples were analysed using a slightly different UF 
protocol to incorporate the optim isations described above. The differences in sam ple 
preparation betw een sam ple sets SI and S2 are outlined in Figure 5.28 and the 
protocol is described as the optim ised UF protocol in C hapter 3 (section 3.3.2). 
Briefly, the serum  sam ples were diluted further to avoid blockage o f  the m em brane, a 
50 kD a M W C O  was used at a low er centrifugation speed (750 xg) to allow  m ore 
proteins to be recovered and finally the HM W  retentate was re-suspended and filtered 
again to increase the recovery o f  proteins norm ally found bound to HM W  carrier 
proteins. U sing 50 kD a M W CO  filters resulted in the presence o f  peaks o f  a higher 
m olecular w eight in S2 than in S I. To gain m ore confidence in the results, the UF 
process w as perform ed in triplicate and because Z ip-Tips have a low binding capacity, 
20 pg o f  LM W  protein is sufficient for analysis and was used in this sam ple set. 
A lthough these changes do not allow  a direct com parison o f  the two experim ents, it
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was considered important to show all the results especially since many o f the 
differential protein peaks were retrieved from both experiments. To allow the analysis 
of proteins >5000 Da, minor differences in the MS analysis were made, these are 
shown in Table 5.7. Additionally the spectra were externally calibrated using Cal Mix 
3 (insulin m/z 5734.59, thioredoxin m/z 11674.48, apomyoglobin m/z 16952.56) 
during automatic acquisition. Spectra processing and data analysis were the same as 
described for sample set S 1.
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Serum sample (500 ul)
S1
Dilution 1:5 with 25mM 
NH4HC03i 20% ACN
LMW UF 3000 xg 
30kDa MWCO filters
Speed vac and desalting 
using C18 ZipTips (150 pg).
Dilution 1:20 with 25mM 
NH4HC03, 20% ACN
LMW UF 750 xg 
50kDa MWCO filters
LMW UF 500 xg 
50kDa MWCO filters
Pool, lyophilize and desalting 
using C18 ZipTips (20 pg).
I i I
MALDI-ToF mass spectrometry
Spectrum analysis
Peak alignment and 
statistical analysis
MALDI-ToF MSMS sequencing
Protein ID
Antibody-based Validation
S2
Diagnostic tool development
Figure 5.28: Experiment flow chart for protein profiling of LMW serum samples. Serum 
samples were prepared by UF and LMW serum proteins were profiled by MALDI-ToF MS. 
Mass spectra were manually calibrated, baseline-corrected, noise was removed and the spectra 
were smoothed before the centroid peak intensities were exported. For profiling, the peaks 
were standardised by total ion signal and peak intensity ratios of the averages of cancer and 
control samples were compared as well as f-tests carried out on individual peak intensities. 
Target proteins were then identified by MALDI-ToF MS/MS. Upon identification, antibodies 
could be developed for validation of the biomarkers.
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Table 5.7: Additional MALDI-ToF instrument settings to those described in the materials and 
method (section 2.8.1), these settings for automated acquisition of spectra were used for S2, 
compared to SI. The settings were slightly different to allow MS analysis of m/z peaks up to 
20 kDa recovered from UF using 50 kDa MWCO membranes.
S1 S 2
A c q u i s i t i o n  m a s s  r a n g e 1 0 0 0 - 7 0 0 0  D a 1 0 0 0 - 2 0 0 0 0  D a
L a s e r  i n t e n s i t y 2 4 0 0  -  2 6 0 0 2 4 0 0  -  2 6 0 0
C a l i b r a t i o n  m a t r i x a - C H C A S A  a n d  a - C H C A  m i x
L o w  m a s s  g a t e 7 0 0  D a 1 0 0 0  D a
M i n  i n t e n s i t y 1 0 0 0 0 3 0 0 0 0
M a x  i n t e n s i t y 5 5 0 0 0 5 0 0 0 0
The m ajority o f  the cancer sam ples were the sam e betw een SI and S2. As before in 
S I , the control sam ples were chosen to create a m atch from a volunteer o f  a sim ilar 
age. The m edian age o f  both groups was m uch closer in this second sam ple set, 
com pared to S I, an extra reason w hy the two experim ents could not be directly 
compared. The age distribution o f  both breast cancer patients and controls for S2 can 
be seen in Figure 5.29.
9 0
8 0
7 0
5 0
4 0
3 0
B r e a s t  C a n c e r  ( 8 ) C o n t r o l s  ( 8 )
Figure 5.29: Age distribution of healthy controls and breast cancer patients in experiment S2. 
Equal numbers of patients and controls were used from each cohort and were individually 
age-matched. Black horizontal lines represent medians for each group.
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The M A LD I-ToF M S spectra for each sample from S2 are shown in the A ppendix 
(D). An exam ple o f  one triplicate m ass spectrum  is shown in Figure 5.30. Despite 
som e variation in the peak intensities, the spectra are com parable and show good 
reproducibility. Spectra that were different from the m ajority o f  the spectra and 
especially from the other replicates o f  the sam e serum sam ple w ere identified as 
outliers and 5 spectra were rem oved from the analysis. In addition, in the case o f  VI 5a 
shown in Figure 5.31, the calculated NF o f  this spectrum  was m ore than tw ice the 
average NF, due to an overall low er spectrum  intensity (1.4 x 104  com pared to 3.0 x 
104) and was therefore rem oved from further analysis. The other spectra and replicates 
showed good m ass accuracy after m anual calibration and reproducible peak intensity 
betw een the replicates o f  each serum  sample.
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Figure 5.30: An example o f the reproducibility across three filtrates from the same serum 
sample. Each serum sample in S2 was prepared and analysed in triplicate.
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Figure 5.31: Outlier removal. During normalisation, VI5a showed up as an outlier, as its 
normalisation factor (NF) was more than twice the average NF. Hence this spectrum was 
removed from subsequent analysis.
Consistent with S I , the m ass accuracy o f  the individual peaks across all replicates was 
found to increase with m ass (Figure 5.32); this was even m ore pronounced for this 
sample set than for S I. This could be due the m anual calibration peaks used (m/z 
3822, 8920, 13552). In the case o f  S2, this can be further explained by the use o f  Cal 
M ix 3 for external calibration. The sm allest peak in that calibrant is insulin at m/z 
5734.59. Due to this difference, staggered m ass tolerances w ere used during alignm ent 
in wzAlign: <2000 Da, 5000 ppm ; 2000-5000 Da, 3300 ppm ; and for peaks greater 
than 5000 Da, 1300 ppm . This greater m ass tolerance for the low m asses dealt 
effectively with the low m ass accuracy.
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Figure 5.32: Correlation of mass accuracy against m/z of individual mass peaks. The mass 
accuracy again appears to increase with increasing mass.
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5.5.1. Biomarkers Discovered in Sample Set S2
V ery sim ilarly as for S I , PCA analysis revealed two separate groups w ith the control 
and breast cancer sam ples in separate clusters. A dditionally the replicates from each 
sam ple are tightly clustered together, as dem onstrated by V I 7 and O P 6  (Figure 5.33). 
OP7c appear to be a bit further aw ay from the rest o f  the cluster: w hen inspecting the 
spectra for OP7 closer in Figure 5.34, it becam e obvious that the overall peak intensity 
o f  the spectrum for OP7c is higher than, for exam ple, OP7b or the spectra from other 
sam ples. How ever it is not significantly different to be flagged up in the outlier 
identification when calculating the norm alisation factors. N evertheless this shows the 
usefulness o f  the PCA analysis in highlighting sim ilarities w ithin the sam ple groups.
V^17D /
yfTsl 17sr1
O^P7c4
SELDI 2 filled 1 M 1 (PCA-X) ■  career
t[C om p. 1]/t[Comp. 2] ■  con™
C olo red  acco rd in g  to O bs ID (1)
R2 X [ 1 ]  = 0 . 1 3 1 7 0 4  R2 X[ 2 ]  = 0 . 0 9 4 5 9 1 6
Figure 5.33: Un-supervised principal components analysis (PCA) of MS-based serum protein 
profiling data derived from healthy controls and metastatic breast cancer patients in S2.
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Figure 5.34: MALDI-ToF MS spectra for the three replicates of OP7. The spectrum of OP7a 
was removed from data analysis since the spectrum is almost empty. Furthermore OP7c 
appeared to be distant from the other breast cancer in the PCA plot. The spectrum also 
appeared slightly different from the other samples; however it was not excluded from the 
sample set.
Using wzAlign, 505 m/z values were aligned in one table, com pared to 452 m/z values 
in M arkerview. The sim ilarity is not quite as tight as for S I; how ever in M arkerview  
we were not able to stagger the m ass tolerance during import. N evertheless, the results 
from both alignm ent tools are very similar.
After alignm ent in wzAlign and M arkerview , the p-values and fold-changes for each 
peak in the spectra w ere calculated in Excel. Peaks with significant ^ -va lues can be 
seen in Table 5.8; the table layout is the sam e as for S I. All discrim inant peaks are 
again shown from the averaged and non-averaged data, also shown, for further 
confirm ation o f  the results are the results from the log-norm alised data. F inally  in the 
last 3 colum ns the results from the data aligned in M arkerview  are shown. Ten peaks 
were significantly different betw een the two cohorts calculated from the averaged data 
(better seen in Table 5.9), 5 o f  those (m/z 1184, 2018, 2730, 8771 and 9647) w ere also 
found to be significant after norm alising the data. These peaks could be considered as 
m ore robust.
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Table 5.8: Significantly different intensity values of m/z peaks between breast cancer serum 
samples and control samples, p-values were calculated after standardisation with 1. VBA peak 
alignment in Excel; 2. Markerview peak alignment and t-test in Excel and 3. Alignment and t- 
test in Markerview. The average was also calculated in Excel. The peak numbers in red are 
those which were detected in less than 25% of samples through alignment.
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Table 5.9: Statistical analysis of discriminating peaks derived from the average peak 
intensities from serum protein profiling of breast cancer patients and healthy controls in S2. 
The first /-test was performed on the data aligned in VBA and the second using data that was 
aligned using Markerview. Both /-tests were done in Excel. Peaks that were discovered in less 
than 25% of spectra are marked in red.
A lignm ent VBA A lignm ent MV
C e n t r o i d  n  c a n c e r n  c o n t r o l p - v a l u e p - v a l u e f o l d -
m a s s  ( 1 9 ) ( 2 1 ) a v e r a g e f o l d - c h a n g e a v e r a g e s  c h a n g e
1 0 6 4 1 0 8 0 . 0 3 1 8.1
1 1 8 4 2 8 0 . 0 2 7 -6.5
1 2 7 2 1 0 1 0 0 . 0 0 6 -2.8
1 8 3 8 1 7 0 . 0 4 2 -9.4
1 9 3 2 9 1 4 0 . 0 4 9 -2.0
2 0 1 8 5 6 0 . 0 4 9 3.5
2 3 9 7 7 5 0 . 0 2 1 6.3 0 . 0 4 3 2.7
2 4 6 1 6 2 0 . 0 2 0 5.2
2 7 3 0 6 2 0 . 0 0 3 8.1 0 . 0 2 3 3.3
2 8 2 3 0 5 0 . 0 1 4 BC dow n
2 8 3 2 8 7 0 . 0 2 9 3.2
2 8 9 2 8 1 2 0 . 0 2 9 -3.1
3 2 9 3 2 7 0 . 0 1 3 -7.2
8 7 7 1 1 9 2 1 0 . 0 2 0 -1.9 0 . 0 1 5 -2.2
9 3 6 8 1 5 1 4 0 . 0 1 8 1.9
9 6 4 7 1 9 2 1 0 . 0 2 6 1 . 6 0 . 0 2 7 1 . 6
Furtherm ore these peaks also had significant /^-values after perform ing a /-test on the 
M arkerview-aligned data. As discovered during the analysis o f  S I , visual inspection 
o f  the discrim inant peaks can prove m ore valuable than the statistics and therefore 
spectra for each peak from the averaged data are shown below.
In total, 15 “m arkers” were discovered from the averaged data, 10 aligned with 
wzAlign and 9 with M arkerview . O f  these, four “m arkers” were discovered from both 
datasets. Variation in fold-change results o f  the VBA and M arkerview  aligned data 
can be explained by the difference in peak alignm ent. The m/z values that had m any 
peaks aligned to, such as m/z 8771 and 9647 show sim ilar fold-change results for data 
from both alignments. Shown in order o f  m olecular weight, each differential peak was 
visually inspected for signal-to-noise ratio and w hether there is a true difference 
visible between the two sam ple cohorts (Figure 5.34 to Figure 5.39). O f  the 15 peaks 
with significant p-values, five peaks were actually large enough to see (m/z 1184, 
2730 ,2832 , 8771 and 9647).
As seen in Figure 5.35, the breast cancer spectra showed no peaks for m/z 1184 
whereas at least 6  sam ples have a visible peak in the control group M arkerview
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alignment has also retrieved a significant /?-value for peak at m/z 1064, however due 
to the poor S/N ratio this cannot be identified as a real peak although the Markerview 
visualisation looks convincing (Figure 5.36). This was disappointing because m/z 
1064 was convincingly different in the SI results. The reason for this is in part that the 
S2 spectra were shot with too high levels o f laser intensity; however repetition was not 
possible, because as the samples were re-analysed, it became apparent that they had 
degraded and the original MALDI target plate had not been preserved.
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Figure 5.35: MALDI-ToF spectra for the m/z range 1000-1700 Da, showing one replicate of 
each breast cancer sample in the upper panel and one of the control samples in the lower 
panel. Peaks with significant /7-values are shown boxed.
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Figure 5.36: Markerview visualisation o f m/z 1064 and 1272. Peaks from all samples and 
replicates were aligned using Markerview.
Both m/z values 2730 and 2832 have significant ^ -values but show peaks with low 
S/N ratios (Figure 5.37). No peaks are seen in the control sam ples for m/z 2730 or 
2832. The M arkerview  visualisation also showed that relatively few peaks from across 
all the sam ples were detected. N evertheless both (m/z 2737 and 2832) appear to 
having discrim inatingp-values.
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Figure 5.37: MALDI-ToF spectra for the m/z range 2500-3300 Da, showing one replicate of 
each breast cancer sample in the upper panel and one of the control samples in the lower 
panel. Peaks with significant /7-values are shown boxed.
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Figure 5.38: Markerview visualisation of m/z 2730. Peaks from all samples and replicates 
were aligned using Markerview.
Only three peaks (m/z 1184, 8771 and 9647) from this sam ple set w ere convincing 
enough, statistically  and visually, to be considered as potential m arkers and to be 
taken forward for identification using tandem  MS. Peak m/z 1184 was described 
above (Figure 5.35). Both, m/z 8771 and 9647, have good S/N ratios and m/z 8771 is 
consistently  dow n-regulated in the breast cancer cohort w hereas m/z 9647 has an 
increased peak intensity  across all breast cancer sam ples com pared to the control 
sam ples (Figure 5.39). The M arkerview  visualisation for either is not very com pelling 
but a clear trend is visible (Figure 5.40). It is encouraging that the peaks were changed 
in opposite directions, w hereas m/z 9427 rem ained unchanged betw een the breast 
cancer and the control sam ples.
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Figure 5.39: MALDI-ToF spectra for the m/z range 8500-10000 Da, showing one replicate of 
each breast cancer sample in the upper panel and one of the control samples in the lower 
panel. Peaks with significant p-values are shown boxed.
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Figure 5.40: Markerview visualisation of m/z 8771 and 9647. Peaks from all samples and 
replicates were aligned using Markerview.
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5.5.2. Tandem MS Analysis for Identification of Potential Markers
For marker identification, the peaks with statistically- and visually-significant p- 
values from SI (m/z 1064, 1776, 2556, and 2995) and from S2 (m/z 1184, 8771 and 
9647) were further analysed. Identification of mass peaks is possible by fragmentation 
within a mass spectrometer containing a ToF/ToF*. Here the selected precursor 
masses were held in the first mass analyser and fragmented using a collision gas 
before the fragment ions were released into a second ToF tube for detection o f their 
m/z ratio. A collaboration with Matthias Gluckmann from Applied Biosystems in 
Germany was set up and some of the samples from the S2 set were Zip-Tipped and 
spotted with oGHCA matrix on a MALDI target plate for tandem MS analysis. In 
Germany, a 4700 MALDI-ToF/ToF mass analyser (Applied Biosystems, Darmstadt, 
Germany) was used for fragment ion identification. The fragmentation spectra were 
searched against the peptide database using MASCOT (MatrixScience, UK). The 
significance of the results from MASCOT is graded depending on the number of 
fragment ions matched to predicted ions from the peptide matched. An ion score of 
>28 indicates peptides with significant homology and a ion score o f >55 indicates 
identity or extensive homology (p <0.05). Unfortunately, only two (m/z 1062 and 
2832) MS/MS spectra from the potential markers produced an ion score >28, 
indicating homology to a protein in the human database. However, one other precursor 
(m/z 1932) for a significantly different peak in the S2 set produced a fragmentation 
spectrum. Both markers, m/z 1932 and 2832, were determined to be significantly 
different from the averaged data, aligned by mzAlign and Markerview. The peak for 
m/z 1064 was significantly up-regulated in the breast cancer samples, calculated from 
the MV aligned data. The fragmentation spectra are shown for m/z 1064 (ion score 36, 
11/13 b and y  ions matched) with homology to RPPGFSPFR from kininogen 
precursor (Figure 5.41), m/z 1932 (ion score 7, 8/32 b and y  ions matched) with some 
homology to SLAELGGHLDQQVEEFR from apolipoprotein A-IV precursor (Figure 
5.42), and the spectrum for m/z 2839 (ion score of 38, 16/52, b and y  ions matched) 
identifying a peptide sequence with homology to AHYDLRHTFMGVVSLG- 
SPSGEVSHPR from alpha-2-HS-glycoprotein precursor (Figure 5.43). Although the 
peak intensity difference for m/z 2832 was not as obvious as the others, there was a 
noticeable increase in intensity in the breast cancer samples (Figure 5.37).
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* Tandem  MS was perform ed by our collaborators at Applied Biosystems (Darm stadt, Germany)
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Figure 5.41: Tandem mass spectrum of m/z 1064 acquired using MALDI-ToF/ToF MS. Data 
base searching matched the peptide sequence RPPGFSPFR from kininogen precursor.
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Figure 5.42: Tandem mass spectrum of m/z 1930 acquired using MALDI-ToF/ToF MS. Data 
base searching matched the peptide sequence SLAELGGHLDQQVEEFR from apolipoprotein 
A-IV precursor.
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MS/MS spectrum for m/z 2832
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Figure 5.43: Tandem mass spectra of m/z 2832 acquired using MALDI-ToF/ToF MS. Data 
base searching matched the peptide sequence AHYDLRHTFMGW SLGSPSGEVSHPR from 
alpha-2-HS-glycoprotein precursor. The precursor was fragmented and identified from two 
separate spectra (A and B).
More in depth investigation o f  the peptide m atches revealed that m/z 1064 identified 
the amino acid sequence (from 381 to 389) coding for bradykinin. A ccording to the 
U niProtK B/Sw iss-Prot entry, bradykinin occurs in plasm a and is released from 
kininogen by plasm a kallikrein, and shows a variety o f  physiological effects: ( 1 ) 
influence in sm ooth m uscle contraction, (2) induction o f  hypotension, (3) natriuresis 
and diuresis, (4) decrease in blood glucose level, (5) it is a m ediator o f  inflam m ation 
and causes (6 ) increase in vascular perm eability, (7) stim ulation o f  nociceptors ( 8 ) 
release o f  other m ediators o f  inflam m ation (e.g. prostaglandins), (9) it has a cardio 
protective effect (directly via bradykinin action, indirectly via endothelium -derived 
relaxing factor action). The peptide (m/z 2832) identified for the alpha-2-H S- 
glycoprotein precursor was m atched to an am ino acid sequence coding for the 
connecting peptide betw een the A and B chain o f  the protein. A lpha-2-HS- 
glycoprotein itself, secreted into plasm a, prom otes endocytosis, possesses opsonic 
properties and influences the m ineral phase o f  bone. Furtherm ore alpha-2-H S- 
glycoprotein shows affinity for calcium  and barium  ions. The am ino acid sequence 
contains 3 phosphoserine sites. Finally m/z 1932 was m atched to an am ino acid 
sequence that codes for repeat 12 w ithin apolipoprotein A-IV. The protein itse lf is
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described in UniProtKB/Swiss-Prot to be secreted into plasma, and responsible for 
lipid transport and removal o f superoxide radicals. Although MASCOT appeared to 
label the majority of fragment ions, the spectra have relatively low intensity and 
identification from them is slightly unconvincing.
5.6. Comparison of the S1 and S2 Sample Markers
Very few discriminatory peaks (m/z 1064 and 1184) were found in common from the 
results o f the averaged data of both experiments (SI and S2). Therefore we have 
chosen to show all the results including /^-values from un-averaged data and from 
peak intensities aligned using Markerview. Some protein peaks, m/z 1064, 1184, 1272, 
1313, 1608, 1776, 1932, 2018, 2717, 2826, 3338, 4457 and 6962, were discriminatory 
in both SI and S2. The m/z value is not identical, due to the use of different peaks in 
the calibration file. Furthermore using the larger MWCO membranes, different 
proteins were recovered in the filtrate. And finally, many of the differential peaks in 
SI were of a MW <1700 Da, which was too small to produce good signal-to-noise 
ratio spectra in the S2 set (Figure 5.37).
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5.7. Discussion and Conclusions
Global protein profiling for biomarker discovery from serum using MALDI-ToF MS 
was widely untested prior to this study. During the course o f the analysis a couple of 
studies were published using MALDI-ToF MS for biomarker discovery [6, 8-10, 21]. 
Quantitation o f intact proteins has been mainly performed using SELDI-ToF MS, 
which makes use of chemical surfaces to separate proteins; however the mass 
spectrometry is the same as MALDI-ToF. We hypothesised that MALDI-ToF should 
therefore be able to perform quantitative analysis o f proteins as well. Using the LMW 
serum fraction reduced the complexity of serum sufficiently to avoid ion suppression. 
The present type of MALDI-ToF MS instrument can cause irreproducibility o f the 
peak intensity due to the presence of hotspots in the matrix [14]. Furthermore mass 
accuracy of the individual peaks was not accurate enough for straightforward 
comparison of individual spectra [22, 23]. And finally for a global proteomic approach 
using MALDI-ToF MS, comparing multiple spectra, an alignment software tool was 
required. These problems were addressed in this chapter by mixing of the analyte and 
matrix prior to application to the target plate to reduce the occurrence of hotspots in 
addition to accumulating at least 8 spectra for every samples spot on the plate [14]. To 
further neutralise any variation occurring due to sample preparation o f MALDI-ToF 
MS analysis, three replicates were analysed. In our study we addressed the lack of 
mass accuracy (despite external calibration) by manually calibrating each spectrum to 
bring the m/z values closer together and by using a comprehensive alignment 
algorithm coded in VBA to automate alignment. The program was called mzAlign and 
proved to be invaluable for automated profiling. A standard protocol was developed to 
compare 8 breast cancer with 8 control serum samples. The use o f replicates and the 
use of wzAlign enabled semi-quantitative analysis for marker discovery. We also 
tested a commercially available software tool called Markerview for peak alignment 
and marker discovery. In comparison to our mzAlign, Markerview performed good 
alignment o f protein peaks, very similar to ours, however it was difficult to see how 
the software actually calculates p-values. Moreover, alignment could not be 
individually adjusted for individual peaks or mass ranges but was fixed for the same 
mass tolerance across the entire mass region. In mzAlign the alignment for every mass 
peak can be individually checked and adjusted if necessary. Markerview has a 
visualisation option to show alignment of the mass peaks. Visual inspection o f the
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spectra was important to detect the presence o f outliers that may have skewed the 
data. This was recently addressed by Villanueva et al. [22], who published software 
for viewing and colour-coding of spectral overlays. Ideally wzAlign could be 
improved to contain an option for alignment visualisation.
Protein profiling was performed twice to incorporate improvements made to the UF 
protocol; this resulted in the two sample sets to be quite different and therefore the 
results had to be analysed separately. The results, as expected, were not directly 
comparable, due to the different membrane pore size used. However some o f the 
markers were the same between SI and S2. Those proteins that were significantly 
different in the SI and the S2 sample set could be considered as more robust, 
especially those visually confirmed. We wanted to identify all o f them using MS/MS 
fragmentation o f the intact proteins/peptides but were only able to get peptide 
identifications from three of the potential markers. In fact only two were “identified” 
with MASCOT scores indicating homology to the suggested protein in the database. 
For better confidence in the identifications and if  we had more time, the larger 
proteins could be isolated by SDS-PAGE or selective chromatography and identified 
through tryptic digests and fingerprinting o f the peptides. To become a useful marker, 
each protein would have to be validated by Western blotting or ELISA for the ones 
where antibodies are available; otherwise antibodies could be raised. Additionally, it 
would be interesting to see if the markers also exist in tissue by paraffin 
immunohistochemistry staining or tissue microarrays and whether it is changed there 
due to cancer growths. Furthermore these markers could then be quantitated in serum 
from patients with other cancer types to see if  they are indicators for illness o f the 
breast cancer specifically and finally if  they occur in metastatic cancers only or could 
be found in early onset patients.
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CHAPTER 6
Biomarker Discovery using SELDI-ToF MS
LMW markers may be small proteins or fragments of larger proteins arising due to the 
process o f cancer proliferation [1-3]. SELDI-ToF MS is particularly suited for LMW 
protein analysis [4] and has been widely used to find biomarkers in serum, from 
patients with many diseases including breast cancer [5-9]. ProteinChip technology is 
using surface enhanced laser desorption/ionization time-of-flight mass spectrometry 
(SELDI-ToF-MS) analysis and allows purification and concentration o f subsets of 
proteins in a automated fashion prior to MS analysis, enabling the discovery of highly 
specific biomarkers for early detection of cancer. The mass spectrometry applied is 
essentially the same as in a MALDI-ToF instrument. The difference lies in the sample 
preparation and the use o f surface-enhancing arrays for protein binding.
In this chapter a proof-of-principle experiment is described to determine whether 
SELDI-ToF MS could be developed for biomarker discovery from LMW protein 
serum samples obtained in a clinical setting. To initially investigate the technique and 
to identify which ProteinChips are most suited for our samples, a pilot study was 
performed on a small subset o f the samples across all array surfaces. Additionally to 
the different arrays the LMW proteins were pre-fractionated using a weak anion 
exchange (WAX) resin to determine whether pre-fractionation could increase the 
number o f peaks as well as “biomarkers” discovered even further. For both 
experiments I spent some time at the Ciphergen research laboratories in Guildford 
(UK). The LMW serum samples used were exactly the same as in Chapter 5, in fact 
the SELDI-ToF analysis was performed before MALDI-ToF MS and a different 
aliquot o f the same LMW filtrate was used. The results were encouraging and so the 
remaining samples (SI) were analysed in a different lab at Cardiff University. 
However these results were disappointing, so the experiment was repeated on a fresh 
set o f LMW serum samples S2. Unfortunately this experiment failed and the results
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were even worse than from SI. Therefore the main part of this chapter will focus on 
the results gathered during the pilot study in Guildford and some experiments 
investigating the problems that occurred after.
6.1. Introduction to Chromatographic Chip Surfaces
A number o f arrays with different chromatographic chemistries are available which 
enable the binding o f different proteins; additionally each array can be processed 
using different binding and wash buffers (Figure 6.1). The chemistry on the arrays 
binds proteins with particular chemical properties (e.g. polar or hydrophobic proteins) 
but others are washed off. Using washes o f different stringencies ensures only proteins 
with the specific properties favoured by each of the surfaces are retained on the chip. 
The use of a number of different arrays has the potential to collectively bind and 
analyse more proteins than uncoated chips (NP20) or MALDI plates alone [10]. This 
reduces the complexity of the proteome analysed and therefore enables analysis of 
proteins that occur at low abundance. For this experiment four arrays (hydrophobic 
(H50), anion exchange (Q10), cation exchange (CM10) and metal affinity capture 
(IMAC-Cu+)) and two different stringencies for Q10 and CM 10 chips were tested 
(Figure 6.2). Effectively 6 different ProteinChips were tested to determine which 
chromatography binds the most proteins but also which is able to detect the maximum 
number of potential markers. Within this chapter the term “marker” is used loosely; 
these markers are merely peaks which were discriminating within our experiment and 
identification, validation on larger sample sets would be necessary for “identification” 
and validation of a potential marker.
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Figure 6.1: The SELDI-ToF MS systems could provides a “3-dimensional” separation system, 
different ProteinChips bind different proteins, using different binding and wash conditions can 
increase the magnitude of separation and finally proteins are separated according to their m/z 
ratio within the ToF analyser. (Diagram taken from Ciphergen SELDI-ToF MS Handbook).
Surfaces by Chemistry: Chromatographic Surfaces
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Figure 6.2: ProteinChip chemistries and their binding properties. Reverse-phase binding 
(H50), weak cation exchange (CM 10), strong anion exchange (Q10), immobilised metal 
affinity chromatography for copper (IMAC-Cu ) and normal phase. (Diagram taken from 
Ciphergen SELDI-ToF MS Handbook).
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Using a bioprocessor (Ciphergen Biosystems Ltd), for preparation of the Protein 
Chip® arrays, each of the arrays were equilibrated twice with binding buffer (Table 
6.1). LMW serum filtrates were diluted 1:10 in binding buffer and added to the arrays. 
After incubation for 30 min at room temperature the chips were washed 3 times with 
binding buffer followed by a quick rinse with deionised water. Two 0.6 pi aliquots of 
a saturated solution o f sinapinic acid (SA) matrix (12 mg/ml in 50% ACN and 0.5% 
TFA in water, v/v) were added to each and air-dried. The ProteinChip® arrays were 
then analysed, using a ProteinChip® System, Series 4000 in linear mode using the 
following settings: 150 shots/spectrum collected in positive ion mode, laser intensity 
175, detector sensitivity 9 and focus mass 5000 Da. The mass spectrometer was 
externally calibrated using the “All-in One” peptide mass standard (Ciphergen 
Biosystems Ltd., Guildford, UK) which contains vasopressin (1084.2 Da), 
somatostatin (1637.9 Da), bovine insulin /3-chain (3495.9 Da), human insulin 
recombinant (5807.6 Da), and hirudin (7033.6 Da). Data analysis was performed 
using the Ciphergen ProteinChip® software 3.2 after baseline subtraction, 
“normalisation” and peak clustering.
Table 6.1: Binding and washing buffers for different chromatographic chip surfaces.
Array Types: Binding and Washing buffers:
H50 10% acetonitrile, 0.1% TFA
Q10 low: 50mM Tris-HCI, pH 9
high: 100mM Sodium acetate, pH 6
CM10 low: 100mM Sodium acetate, pH 4
high: 50mM Tris-HCI, pH 7
I MAC 30 0.1 M sodium phosphate, 0.5 M NaCI pH 7
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6.2. Studying the Reproducibility of SELDI-ToF MS Analysis
Reproducibility is very important for protein expression analysis; hence in this 
experiment the inter- and intra-chip reproducibility was tested. A pooled control 
sample was applied to two Q10 anion exchange ProteinChip arrays (8 spots per chip) 
and washed with high stringency buffer for MS analysis. The peaks were labelled and 
the peak intensity values exported to Excel for coefficient o f variance (C.V.) 
calculation.
^  _ StDev x 100 
Mean
As seen in Figure 6.3 the peaks on both chips look very similar, in fact by eye no 
differences in different peak intensity could be seen for any of the peaks within or 
across the arrays. Statistical comparison calculating the C.V. for each peak showed 
that the majority o f peaks had C.V.s of less than 10%; especially for smaller m/z 
values <5500 Da (Figure 6.4). The average C.V. across the entire spectrum was 
calculated as 13% for all spots. From this it was concluded that the reproducibility is 
very high and that no variation will be introduced from different chips. Despite this 
finding, the breast cancer and control samples and their matched pairs were prepared 
and analysed on the same ProteinChip.
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Figure 6.3: The same pooled sample was spotted in two arrays and analysed to investigate the 
reproducibility within and across arrays.
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Figure 6.4: The coefficient of variance was calculated for the intensity for 42 detected peaks 
above signal-to-noise threshold across all spectra from both ProteinChips. The average C.V. 
peak intensity for all peaks = 1 2 .8 %.
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6.3. Breast Cancer Marker Discovery from Sample set S1
6.3.1. Optimisation of Array Type -  The 4 x 4  Study
Initially only four o f  the 8  cancer sam ples were com pared to four o f  the 8  control
sam ples (Figure 6.5). Each o f  the four ProteinChips was prepared with 4 control and 4
breast cancer LM W  serum  sam ples and analysed to determ ine which arrays w ould be 
m ost suited for b iom arker discovery o f  these samples. Furtherm ore the Q10 and 
CM 10 arrays w ere prepare under high and then again under low stringency conditions. 
As the analysis was tim e consum ing and resources were lim ited, it was decided to 
define w hich arrays w ere best before em barking on a large study, especially since 
SELDI-ToF technology was w idely untested on the LM W  proteom e. For the 
rem ainder o f  this chapter this experim ent will be referred to as the 4 x 4  study.
4x Cancer 4x Control
Different Protein Chip arrays: 
10 pi of each sample were 
used for profiling
Figure 6.5: Initially only 4 sample from each group were analysed for simplicity. Later, 8  
metastatic breast cancer sera were compared with 8  age-matched post-menopausal volunteer 
samples.
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A nalysis o f  the different array types and stringency conditions show ed that different 
proteins bind to the arrays and therefore that using a num ber o f  different chips would 
provide a m ore com plete analysis o f  the proteom e. In Figure 6 . 6  som e o f  the 
additional proteins that bind to CM  10 chips under low rather than high stringency 
conditions are boxed in red. H ow ever som e proteins actually ionize better on the high 
stringency arrays, it could be assum ed that this is due to reduced ion suppression o f  
proteins that bind strongly under low stringency conditions. Sim ilarly Figure 6.7 
shows that m ore proteins bind to the Q10 arrays under low stringency conditions and 
finally in Figure 6 . 8  it can be seen that less proteins bind to the IM A C-Cu and H50 
arrays. The num ber o f  peaks that are bound to each type o f  array can be com pared in 
Table 6.2. This actually showed that m ore proteins were detected on the Q10 and 
CM  10 ProteinChips w hen prepared with high stringency buffers. For analysis all 
spectra from each type o f  array w ere com bined in one experim ent and peaks were 
norm alised and clustered using the user-defined peaks, peaks w ith a signal-to noise 
ratio o f  3 were detected and clustered i f  they were w ithin a m ass w indow  o f  0.3%  o f  
the m/z. Peaks that have a m inim um  S/N ratio o f  3 were labelled in the first spectrum, 
then the other spectra w ere searched for that peak and labelled if  they passed the S/N 
ratio o f  2 .
Control
Low
stringencyCancer
Control
High_A_
stringencyCancer
j hJj
Figure 6 .6 : Spectra from CM 10 arrays prepared at high and low stringency. Different subsets 
of the proteome retained using different profiling conditions. Obvious differences were boxed 
in red.
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Figure 6.7: Spectra from Q10 arrays prepared at high and low stringency. Different subsets o f 
the proteome retained using different profiling conditions. Obvious differences were boxed in 
red.
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Figure 6 .8 : Using IMAC-Cu and H50 chips a lower number of peaks were observed. These 
chips appeared to bind less o f the LMW proteins.
From the results o f  the 4 x 4 study on all the different chip types it appeared that 
CM 10 and Q10 arrays prepared at high stringency detect the m ost num ber o f  proteins 
although Q10 ProteinChip prepared at low conditions distinguished the m ost m arkers 
(Table 6.2). A lthough the com plexity  o f  the sam ple needed to be reduced, once the 
proteins were binding to the chips it is im portant to use an array that allow s m axim um  
num ber o f  proteins detected. Binding the m axim um  num ber o f  proteins does not equal 
m axim um  num ber o f  peaks detected. It is m ore likely that m ore peaks are detected on
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an array that binds few er proteins. Hence w hen using one chip type only, the Q10 
chip w ould be the chip o f  preference and if  2 types the CM 10 w ould also be useful, 
preferably prepared at both binding stringencies. It was som ew hat surprising that the 
high stringency binding and w ash conditions detected m ore proteins than the low 
conditions. It w as assum ed that proteins have to be m ore specific to bind to the arrays. 
How ever if  the proteom e binding is less com plex, m ore proteins m ay reach high 
enough intensity to be detected.
Table 6.2: Number of peaks and potential markers detected by the SELDI-ToF MS 4 x 4  pilot 
experiments on all chip types.
Condition Chip No
Total peak 
count p-value <0.05
CM10 pH4 (high) 1170202693 73 4
CM10 pH7 (low) 1170202694 55 8
Q10 pH9 (high) 1230154912 73 7
Q10 pH6  (low) 1230154913 64 13
IMAC-Cu 1190177256 6 6 6
H50 1080151427 51 1
Total 352 35 (28 unique)
As part o f  the C iphergen SELD I-ToF system , sophisticated analysis softw are is 
available to perform  spectrum  processing such as baseline correction and 
norm alisation o f  the spectra to neutralise spectrum -to-spectrum  variation. The spectra 
can then be clustered; finding peaks in com m on to be com pared using the B iom arker 
W izard where M ann-W hitney /^-values are calculated for each peak in the spectrum  to 
provide statistical evidence for differential peaks. The software also provides 
visualisation o f  the protein peaks in the form o f  peak spectra and gel view s that image 
the peak intensity in form o f  different intensity  bands. A dditionally to the M ann- 
W hitney U test results, the peak intensities from each experim ent were exported into 
Excel and the variation was calculated using an unpaired Student’s /-test. The /-test is 
m ore powerful than the non-param etric test and m oreover in Excel fold-changes o f  the 
differences in peak intensity  could be calculated [11]. The results from both analyses 
for all chip types are shown in Table 6.3, the /-test appears to be m ore stringent than 
the M ann-W hitney U test and visual inspection o f  the peaks confirm ed that m any o f
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the m/z values that were significant by only the M ann-W hitney U test w ere in fact not 
actually different or o f  very  low intensity.
Table 6.3: Discriminating peaks from the 4 x 4  study, p-values were calculated using the 
Mann-Whitney U test as part of the Biomarker Wizard software and a Student’s /-test after 
exporting the data into excel.
Mann- Mann-
p - v a l u e fold- Wh i t ney p - v a l u e fold- Whi tn ey
m/z (Exce l ) c h a n g e (Ciph erg en) m/z (Excel ) c h a n g e (C iphergen )
Q10 high stringency CM 10 high stringency
1078.2 0.021 1.6 0.021 2913.3 0.021
1225.8 0.029 1.7 0.021 2993.3 0.021
1314.9 0.029 1.7 0.043 4498.6 0.016 -1.3 0.043
1402.0 0.005 1.5 0.021 8806.1 0.028 2.7 0.043
1636.5 0.043 CM10 low stringency
1936.5 0.050 -2.1 0.043 2262.8 0.430
2249.1 0.012 -1.9 0.021 2525.0 0.021
2463.5 0.030 -1.6 0.021 2994.9 0.021
2775.8 0.041 -1.9 0.021 3791.6 0.009 -1.5
2994.8 0.021 3989.8 0.029 1.2 0.021
4207.4 0.043 5026.0 0.009 -1.5
4400.8 0.021 8803.1 0.035 3.0 0.430
4514.0 0.023 1.5 0.021 14891.2 0.048 1.8
Q10 low stringency IMAC-Cu
1780.5 0.003 -2.1 0.021 1780.1 0.011 -2.3 0.021
2994.3 0.021 1802.3 0.001 -2.7 0.021
3537.3 0.010 2.4 0.043 2775.4 0.013 -2.3 0.043
3554.5 0.032 -1.4 0.021 2791.2 0.008 -2.1 0.021
3788.2 0.043 3791.9 0.026 -1.7 0.043
6381.2 0.043 4271.7 0.021
12118.9 0.043 H50
2992.6 0.037 -3 .9 none
The m ost discrim inating peaks from each type o f  ProteinChip are shown in Figure 6.9 
to Figure 6.13. The Spectra from each sam ple w ere norm alised and overlaid within the 
ProteinChip Softw are 3.1; the red lines are from the breast cancer sam ples and the 
blue lines from controls. A list o f  the m asses that were statistically and visually 
significant across all ProteinChip types is shown after all the spectra in Table 6.4.
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1620 1636
1620 1640
1380121 1402
140013801220 1240 121
224 2249 2260 2463 248022
248024602240 2260 22
19361820
1920 1940
2775 o2760
2760 2780
4500
4500 4520
2980 2995 30
2980 3000
Figure 6.9: The 9 most discriminating peaks recovered from Q10 arrays washed with high 
stringency (pH 6 ). The spectra from each sample were overlaid, in red the breast cancer 
samples and in blue control.
Some o f  the peaks w ere found to be significant on m ore than one array. The peak at 
m/z 2775 had a significant / 7-value on the Q10 (high stringency) and IM A C-Cu" arrays 
(Figure 6.9 and Figure 6.10). H ow ever the peak with m/z 2765 (m arked *) show ed no 
significant distinction betw een the two sam ple groups (Figure 6.9). The peak at m/z 
1780 was also discrim inating on two arrays (IM AC-Cu" and Q10 low) and m/z 2995 
and 3791 on even three arrays. So for IM A C -C u+, all significant peaks were also 
detected on other ProteinChip types, except for m/z 4271 which was only elevated in 
one breast cancer sam ple (Figure 6.10). Therefore the IM AC-Cu" arrays appear to add 
no further inform ation to the profiling results.
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18001780
1775 1800
3750 3791 3
38003750
2994 3025
30253000
3537 3554  357
Figure 6.10: The four most discriminating peaks recovered from IMAC-Cu arrays. The 
spectra from each sample were overlaid, in red the breast cancer samples and in blue control.
1780 1800
1775 1800
2994 3025
3000 3025
3' 3537 3554 3573788 33750 3E
3525 3550 3573750 3800 3£
Figure 6.11: The four most discriminating peaks recovered from Q10 arrays washed with low 
stringency (pH 9). The spectra from each sample were overlaid, in red the breast cancer 
samples and in blue control.
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The discrim inating peaks at m/z 3537 and 3554 in Figure 6.11 were interesting, as 
there appears to be a m ass change in the breast cancer sam ples. The intensity for the 
peak at m/z 3537 is increased but reduced for the peak at m/z 3554 in the breast cancer 
group. It is possible that due to the cancer this protein was m odified, has lost a residue 
or a fragm ent. This w ould be an interesting protein to analyse further. The peaks at 
m/z 3791 in Figure 6.11 present an exam ple o f  a peak that had a significant /?-value 
but was not v isually  confirm ed to be different betw een the two groups. In fact the 
same is true for m/z 3791 in the CM  10 (low stringency) arrays (Figure 6.13). 
Interestingly this is one o f  the only peaks that was not significantly  different using the 
M ann-W hitney U test. Since the M ann-W hitney U statistic is less pow erful, it finds 
less peaks significant that are m ore likely to be false-positives [11]. On the other hand 
it can m iss significant differences, hence it is justified  to use both tests and to verify 
the results.
29 2913 2920300
300 2910 2920
Figure 6.12: The only truly discriminating peak recovered from the CM 10 high stringency 
(pH 7) arrays. The spectra from each sample were overlaid, in red the breast cancer samples 
and in blue control.
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Figure 6.13: The four most discriminating peaks recovered from CM 10 arrays washed with 
low stringency (pH 4). The spectra from each sample were overlaid, in red the breast cancer 
samples and in blue control.
Table 6.4: The 17 most discriminating peaks recovered from all array types, which were also 
visually confirmed.
m/z A r r a y  t y p e p  - v a lu e
f o ld -
c h a n g e
1225.8 Q10 high 0.029 1.7
1402.0 Q10 high 0.005 1.5
1636.5 Q10 high 0.043 2.2
1780.1 Q10 low, IMAC 0.021 -2.3
1802.3 IMAC 0.001 -2.7
1936.5 Q10 high 0.050 -2.1
2249.1 Q10 high 0.012 -1.9
2463.5 Q10 high 0.030 -1.6
2525.0 CM10 low 0.021 -2.5
2775.4 Q10 high, IMAC 0.013 -2.3
2791.2 IMAC 0.008 -2.1
2913.3 CM10 high 0.021 5.3
2994.8 Q10 high, Q10 low, CM10 high, 
CM10 low, H50
0.021 -2.6
3537.3 Q10 low 0.043 2.3
3554.5 Q10 low 0.021 -1.4
3791.9 IMAC, CM10 low, Q10 low 0.009 -1.7
4514.0 Q10 high 0.023 1.5
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6.3.2. Pre-Fractionation of all Samples from S1 using a WAX Separation
To reduce the com plexity  o f  the LM W  proteins even further, the sam ples were 
separated using a w eak anion exchange resin. The LM W  serum filtrate (30 pi) was 
fractionated into 6  fractions by weak anion exchange (W AX) separation using a step- 
pH gradient. A 10 pi aliquot o f  each fraction was then analysed on w eak cation 
exchange (CM  10) arrays under low stringency conditions. The experim ent setup is 
shown in Figure 6.14 and Figure 6.15. For the fractionation all 8  breast cancer and 8  
control sam ples w ere used. The fractionation was perform ed in a 96 well plate on a 
Biom ek 2000 robotic sam ple-processing station (Beckm an, UK) to avoid degradation, 
the plate was cooled.
C a n ce r C on tro l
W A X  fra c tio n a tio n  o f 
40  pi LM W  se rum  
based  on pi e lu ted  in 
100 pi
P ro te in  C h ip  a rray: C M 1 0  low, 
10 pi o f each  fra c tio n  w e re  
used  fo r  p ro filing
Figure 6.14: Experiment setup of WAX pre-fractionation of LMW serum proteins. Each 
fraction was then analysed on CM 10 ProteinChips prepared at low stringency.
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3 0  ul S a m p le  
+  Urea/C H A PS/TrisH C I pH 9
BioSepra®  Q HyperD® F 
W eak  an ion  e x c h a n g e  resin
org a n ic
Vv
C ation E x ch a n g e  
(C M 10)
Figure 6.15: Weak anion exchange (WAX) pre-fractionation. The flow-through was collected 
together with the first fraction (pH 9). Each fraction was analysed on CM 10 ProteinChips.
Fractionation o f  a com plex protein m ixture prior to MS analysis can increase the 
num ber o f  protein peaks discovered, this is due to the fact that in com plex m ixtures, 
more abundant proteins m ask low er abundant proteins by ion suppression. Reducing 
the com plexity o f  the sam ple has the potential to also increase discovery o f  possible 
markers. Figure 6.16 show s that different peaks were present in each o f  the fractions. 
Boxed in red are the peaks that were am plified in the fractions but otherw ise at low 
intensity in the un-fractionated sample. In m ore detail the num ber o f  peaks retrieved 
from each fraction is show n in Table 6.5, from this it appears that m any proteins that 
do not bind to the W AX resin (i.e. cations), bind well to the cation exchange array 
(CM 10). The CM 10 chips were prepared at low stringency binding conditions (pH 4), 
where the high pH fractions (pH 9- pH 4) are positively charged and bind to the cation 
exchanger. In fraction 5 (pH 3), the proteins are negatively charged in the pH 4 
binding buffer and hence bind poorly to the array. This is reflected by the low num ber 
o f  peaks detected in fraction 5 (pH 3) (Figure 6.16).
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Unfractionated
Flow through 
pH7 
pH5 
pH4 
pH3
Organic
each fraction and
therefore peaks that are otherwise masked in the un-fractionated sample were amplified and 
could be analysed. The flow-through was collected together with the pH 9 fraction.
Table 6.5: The number of peaks retrieved from each fraction. 160 peaks of which 113 unique 
peaks were detected on CM 10 low filters compared to only 55 from the un-fractionated 
sample. And 11 unique “biomarkers” compared to only 4 on the CM 10 low chip before 
fractionation.
Fraction pH
Peaks on 
CM10 low p -value <0.05
F1 FT + pH 9 43 1
F2 pH 7 17 3
F3 pH 5 24 2
F4 pH 4 29 2
F5 pH 3 20 1
F6 organic 27 4
Total organic 160 13 (11 unique)
As before, the spectra were analysed for expression changes using the B iom arker 
W izard and the peak intensities were exported into Excel for calculation o f  p-values 
using a /-test. In this case all 8  sam ples from each cohort were analysed and so the 
results could be regarded as a confirm ation o f  the significant p -values recovered 
before. How ever it is im portant to keep in m ind that these fractions were only 
prepared on CM  10 chips at low stringency conditions. Few m arkers in the 4 x 4 study
1.5-5kDa 5-10kDa
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were actually discovered on that chip type and so only two m arkers (m/z 2994 and 
3793) from the 4 x 4  experim ent w here also found am ongst the m arkers in the W AX 
fractions (Table 6 .6 ). H ow ever m any m arkers were seen that are not on any o f  the 
chips w ithout fractionation.
In total 160 peaks were detected from all fractions, com pared to only 55 from the un- 
fractionated sample. O f those, 113 peaks were unique; furtherm ore 11 unique m arkers 
were discovered. This is m ore than double the num ber from un-fractionated LM W  
serum on CM 10 arrays in the 4 x 4 study. H ow ever m ost o f  these m arkers have 
relatively low fold-change differences betw een the breast cancer and control samples.
Table 6 .6 : Discriminating peaks from WAX fractions. Calculated by univariate analysis in 
Excel and a Mann-Whitney U test as part of the Biomarker Wizard.
Markers (f-test) Markers (Biomarker Wizard)
F r a c t i o n m/z p - v a l u e f o l d - c h a n g e F r a c t i o n m/z p - v a l u e
F 2 1 0 1 3 . 5 0 . 0 3 1 1 . 0 F 2 1 0 1 3 . 7 0 . 0 3 6
F 6 1 0 3 4 . 4 0 . 0 2 9 1 . 0 F 6 1 0 3 4 . 3 0 . 0 3 6
F 2 ,  F 3 ,  F 4 2 9 9 7 . 1 0 . 0 3 0 1 . 1 F 2 ,  F 3 2 9 9 8 . 3 0 . 0 4 6
F T 3 1 7 2 . 4 0 . 0 3 0 - 1 . 1 F T 3 1 7 5 . 4 0 . 0 4 6
F 2 3 3 0 9 . 5 0 . 0 2 9 - 1 . 2
F 3 3 3 8 4 . 7 0 . 0 2 4 - 1 . 4 F 3 3 3 8 2 . 1 0 . 0 2 1
F 6 3 7 9 3 . 7 0 . 0 1 9 - 1 . 4 F 6 3 7 9 2 . 2 0 . 0 1 6
F 5 4 2 3 4 . 3 0 . 0 4 3 1 . 0
F 4 5 1 0 7 . 9 0 . 0 2 5 - 1 . 2 F 4 5 1 0 0 . 5 0 . 0 2 9
F 6 7 6 2 6 . 6 0 . 0 1 5 - 1 . 0 F 6 7 6 2 0 . 6 0 . 0 0 9
F 6 7 9 1 1 . 7 0 . 0 2 5 1 . 1 F 6 7 9 0 0 . 4 0 . 0 3 6
Visual inspection o f  the “m arkers” in Figure 6.17 to Figure 6.22 showed that m ost o f  
the peaks appear to be convincingly different betw een breast cancer (red) and controls 
(blue) spectra. Som e o f  the higher m olecular w eight peaks such as m/z 5107 and m/z 
7900 were a bit fuzzy. One o f  the m ost convincing m arkers from the SI set in the 
M A LD I-ToF MS data was m/z 2995. This m arker was also show n to be significantly 
different, using SELD I-ToF MS.
Chapter 6: Biomarker D iscover usins SELDI-ToF MS 227
3125 3150 3175 FT 3172 *5
32253125 3150 3175 3200
Figure 6.17: The most discriminating peak recovered from fraction 1 (FT and pH 9) on CM 10 
arrays. The spectra from each sample were overlaid, in red the breast cancer samples and in 
blue control.
1000
F2 1013 & 1034
1000 1020 1040
F2 29972900 2950
2900 2950 3000
F2 33093250 3300
3250 3300 3350
Figure 6.18: The three most discriminating peak recovered from fraction 2 (pH 7) on CM 10 
arrays. The spectra from each sample were overlaid, in red the breast cancer samples and in 
blue control.
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33 F3 3384 3425
3375 3400 3425
F3 29972950 2975 3025
2950 2975 3000 3025
Figure 6.19: The two most discriminating peak recovered from fraction 3 (pH 5) on CM 10 
arrays. The spectra from each sample were overlaid, in red the breast cancer samples and in 
blue control.
F 4  2 9 9 72975 3025
2975 3000 3025
F 4  5 1 0 7  125 51755075 5150
5075 5100 5125 5150 5175
Figure 6.20: The two most discriminating peak recovered from fraction 4 (pH 4) on CM 10 
arrays. The spectra from each sample were overlaid, in red the breast cancer samples and in 
blue control.
F542344200 4300
4200 4250 4300
Figure 6.21: The most discriminating peak recovered from fraction 5 (pH 3) on CM 10 arrays. 
The spectra from each sample were overlaid, in red the breast cancer samples and in blue 
control.
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3780 F 6  3 7 9 3  8oo 3820
3780 38203800
7850 F 6  7 9 0 0 7950
7850 7900 7950 8000
Figure 6.22: The four most discriminating peak recovered from fraction 6  (organic) on CM 10 
arrays. The spectra from each sample were overlaid, in red the breast cancer samples and in 
blue control.
It was interesting to see what w hile the peak intensity for m/z 4234 in Figure 6.21 was 
slightly decreased in m ost o f  the breast cancer sam ples;, it rem ained unchanged for 
m/z 4310. This added further confidence that the change w as due to the cancer and not 
due to an overall difference in the spectrum  intensity. Furtherm ore there appeared to 
be more variation am ong the control sam ples and the breast cancer peak intensity 
values were tighter (Figure 6.23). This provided a certain am ount o f  confidence that 
the discrim inating peaks are related to the breast cancer. The control volunteers had 
very little in com m on, except for that none o f  them  should have cancer. H ow ever the 
patients all had breast cancer as a com m on factor.
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Figure 6.23: Distribution of the peak intensities for m/z 2997 in fraction F2, from the breast 
cancer (red) and control (blue) samples.
6.3.3. The Effects of Sample Pooling on Peak Recovery and Biomarker 
Discovery
There is an argum ent for pooling all sam ples to gain a representative breast cancer 
sam ple and control sam ple and to reduce biological variation to identify m akers that 
are truly different due to the breast cancer status. This w ould also m ake analysis faster 
and reduce the num ber o f  SELDI chips to be used. On the other hand there is some 
argum ent against this since small changes, possibly due to the cancer, could be 
m asked by the com m on peaks. Breast cancer is a heterogeneous disease and changes 
m ay be present in a certain clinical group, dependent on stage or for exam ple Her2- 
status. Furtherm ore, m arkers due to a certain stage in the cancer could be lost when 
pooling these particular sam ples with other cancer serum  sam ples. Pooling m ay be 
m ore appropriate for the control sam ple. H ow ever it should be better to treat both 
sam ple cohorts the same. In m icroarray analysis due to the cost o f  the chips, pooling 
has been done [12]. H ow ever specific statistical analysis and algorithm s are necessary 
to deal with pooling [13, 14].
Here the effect o f  pooling on peak detection, in com parison to un-pooled sam ples was 
investigated. A breast cancer sam ple (pooled across all 8  patient sam ples) and a 
control sam ple (pooled from all volunteer sam ples) was created. Both pooled sam ples 
were fractionated using the W AX resin and left un-fractionated. The sam ples and 
fractions w ere com pared on CM  10 arrays at high and low stringency, as well as on an 
IM AC-CW  arrays. The num ber o f  peaks detected was used as an indication if  pooling 
affects the results. The results revealed that only approxim ately h a lf  the num ber o f  
peaks was recovered from the pooled sam ples com pared to the individuals on each o f  
the array types (Table 6.7).
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Table 6.7: Recovery of the number of peaks is a good measure for suitability of the chip type. 
Here the results from the analysis of the SI samples while in Guildford is shown, the number 
of peaks detected on various array types is compared with the number of peaks detected when 
analysing the same sample by MALDI-ToF MS.
Method Profiling conditions/ peak Number Total Peak Number
MALDI 274
Arrays Low stringency High stringency
H 50 51 - 51
SELDI 4x4 Q10 65 73 138
CM10 55 73 128
I MAC 30 66 - 66
CM10 35 30 65
SELD1 pooled I MAC 30 36 -
WAX resin fractions
Pre-fractionation
+ SELDI CM10 FT + pH9 pH7 pH5 pH4 pH3 organic
low 43 17 25 28 20 27 160 (113 unique)
Although fractionation enables detection o f  som e proteins that were at very low 
intensity in the pooled sam ple, the overall peak intensity was low er (Figure 6.24). This 
showed further that pooling has a negative effect on peak recovery. H ow ever the 
spectra look very sim ilar, it can be seen that m ore peaks are present in the un-pooled, 
un-fractionated sam ple and F3 and F5 contain m ore peaks in the un-pooled fractions 
(Figure 6.24). Both sam ples were prepared and analysed on CM 10 arrays in the same 
experiment. Table 6.7 shows a sum m ary o f  the num ber o f  peaks detected from  each 
type o f  array; for com parison the pooled sam ple and the W AX fractions w ere also 
shown. Furtherm ore the num ber o f  peaks recovered by M A LD I-ToF MS (274) was 
also shown. The M A LD I-ToF results were exported w ith a low er threshold for peak 
detection than the SELD I-ToF spectra, which explains the larger num ber o f  peaks 
discovered. D uring cluster analysis for SELDI-ToF, i f  a peak passes the intensity 
threshold in one or m ore spectra, the algorithm  will find this peak in the other spectra 
and label it. This is not possible for M A LD I-ToF spectra and therefore m ore peaks 
had to be exported to ensure com plete com parison betw een all spectra.
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Figure 6.24: WAX fractionation of pooled control serum sample (A) and an un-pooled control 
sample (B). A mass range of m/z 3500-5300 is shown.
Nevertheless, som e o f  the m arkers that were discovered in the 4 x 4  study and in the 
un-pooled fractions were also visibly different com paring the pooled breast cancer and 
control LM W  serum sample.
B
1000
5 00
0
6 00
4110
0
100
O
300
200
1 00
0
1 50
1 00
50
O
20
0
400
200
n
100
75
50
25
n
10
7.5  
5
2.5  0
30
20
10
0
30
20
10
0
60
40
20
n
0
5
0
232
Chapter 6: Biomarker Discoven’ using SELDI-ToF MS 233
Due to the lack o f  replicates no statistical analysis w as perform ed to find 
discrim inating peaks. H ow ever, som e differences in peak intensity were easily seen by 
eye. Two exam ples are shown below  (Figure 6.25). It m ay be argued that the 
differences betw een breast cancer and control peaks are m ore intense in the pooled 
sam ples com pared to the spectra from un-pooled samples. H ow ever since there was 
only one replicate each, it cannot be said for certain that this has not happened by 
chance.
2800 3000 •coo
300
0
2D0
100
0
Control
Cancer
1800 1850 1900 1950 17S0 1800 1850 1900 1950
300
0
300
100
-------
1800
0
1750 1850 1850 1900 19501750 1800
Figure 6.25: Two exam ples o f  m arkers that were retrieved from analysis o f  the pooled 
breast cancer and the non-cancer control LM W  serum samples. Both exam ples were 
chosen because an un-changed peak is visible, giving evidence that the m arkers are 
not due to an overall difference in spectral intensity.
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Although the peak intensity  and resolution was decreased in the pooled com pared to 
the un-pooled sam ples, m arkers w ere still discovered. It m ight be w orth pooling if  
sample was lim ited i f  the cost had to be reduced. It m ay allow  analyses o f  larger 
num ber o f  technical replicates in an experim ent with a large num ber o f  biological 
replicates.
6.3.4. Analysis of the Remaining S1 Samples in Cardiff: The 8 x 8  Study
The 4 x 4  study was continued to analyse all o f  the 8  breast cancer and 8  control 
samples (SI in Chapter 5) on two further chips per sam ple in C ard iff using a PBS-II 
ToF ProteinChip reader (Figure 6.26). This produced three technical replicates from 
each o f  the 8  x 8  sam ples (Table 6 .8 ). Since the m ass analyser in C ard iff is an older 
version o f  the instrum ent, the chips previously prepared in G uildford were analysed 
again alongside the new chips. The arrays w ere prepared in the sam e way as before 
(section 6.1). For the new  chips a higher laser intensity (210) was requires to obtain 
peaks, how ever the laser intensity was kept at 175 for the chips prepared in Guildford.
fable 6 .8 : ProteinChip preparation. Four control and four breast cancer samples were bound 
to the arrays in Guildford. The remaining four of each group were prepared in Cardiff. 
Furthermore another two replicate chips were prepared of all 8  x 8  samples while in Cardiff. 
All chips were scanned in Cardiff on a PBS-II ToF ProteinChipR reader.
Replicate
Arrays
P repa ra tion  
S am ples  Lab
P repa ra tion  
S am p les  Lab
1 1 - 4 breast cancer Gui|dford 
1 - 4 control
5 - 8 breast cancer Qarcjjff 
5 - 8  control
2 1 - 4 breast cancer _ .... . . , . Cardiff 
1 - 4 control
5 - 8 breast cancer _
_ Q . . Cardiff 5 - 8  control
3 1 - 4 breast cancer ~ ..„  „ . x . Cardiff 
1 - 4 control
5 - 8 breast cancer ~ 
c o  Cardiff 5 - 8  control
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8x Cancer 8x Control
f t
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3x each sample Q10 
high and Q10 low 
stringency
Figure 6.26: ProteinChip preparation for the 8  breast cancer and 8  breast cancer samples on 
strong anion exchange (Q10) arrays in Cardiff. The chips were prepared in triplicates. 
However 4 cancer and 4 control chips, already prepared in Guildford, were scanned again in 
Cardiff.
The spectra from the new ProteinChips look com pletely different, the peak intensity  is 
very low and the few peaks that were detectable were broad with low resolution and 
looked asym m etrical (Figure 6.27 and Figure 6.28). For com parison the spectrum  
from the array prepared in G uildford is shown below the two new replicates. The 
spectra from the G uildford arrays look good, analysed on the older ProteinChip 
reader, which suggests that the problem  originated from either the sam ple or the 
sample preparation during chip binding. This was the same for all sam ples from both 
cohorts, two exam ples from the breast cancer group are show in Figure 6.27 and 
another exam ple from the control group is shown in Figure 6.28. A high and a low 
resolution m ass range are show n for each sample.
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Figure 6.27: SELDI-ToF MS spectra of LMW two breast cancer serum sample, OP4 (A) and 
OP5 (B) on Q10 ProteinChips with high stringency wash. Comparison of one LMW serum 
samples prepared on chip in Guildford and two in Cardiff.
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Figure 6.28: SELDI-ToF MS spectra of LMW control serum sample (V6 ) on Q10 
ProteinChips with high stringency wash. Comparison of one LMW serum samples prepared 
on chip in Guildford and two in Cardiff.
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Although the resolution o f  the chips prepared in C ard iff was o f  an inferior quality than 
the ones from Guildford they displayed the sam e m ass peaks (Figure 6.27 and Figure 
6.28). Therefore they w ere analysed using the B iom arker W izard as described before 
and the spectra data was exported into Excel (Table 6.9). For statistical analysis the 
Guildford arrays were rem oved, to avoid variation. Hence for lA  the sam ples in each 
cohort, three replicates and for the other lA  two replicates were analysed. This allowed 
calculation o f  sam ple averages in Excel. The results from a /-test and the M ann- 
W hitney test U test are shown in Table 6.9. As before it appears that the /-test 
identifies less significant peaks and even less were discovered from the averaged 
samples. Each o f  the significant peaks was inspected visually  and the ones that were 
truly discrim inative are shown in F igure 6.30 and Figure 6.29. The low resolution o f  
the peaks can be seen in the low intensity and also in the poor discrim ination betw een 
the groups.
Chapter 6: Biomarker Discovery using SELDI-ToF MS 238
Table 6.9: Discriminating peaks, of SI analysed in Cardiff, calculated using a Student’s /-test 
in Excel and a Mann-Whitney U test as part of the Biomarker Wizard in the ProteinChip 
software.
All re p lic a te s S a m p le  a v e r a g e s
All p - Mann-
va lue fold- Whitney fold- p -value fold-
m /z (Excel) c h a n g e (Ciphergen)  c h a n g e m /z  (Excel) c h a n g e
Q 10 high stringency Q 10 high stringency
1 1 3 9 .9 0 .0 4 6 2 .4 1 1 3 9 .9  0 .0 1 5 2 .4
1 7 5 6 .3 0 .0 0 6 -1 .5 0 .0 0 7 -1 .5 1 7 5 6 .3  0 .0 0 2 -1 .6
4 2 9 2 .9 0 .0 3 2 1.2 4 2 9 2 .9  0 .0 2 2 1.2
1 3 9 1 1 .4 0 .0 2 7 7.1 0 .0 3 5 7 .0 1 3 9 1 1 .4  0 .0 2 5 7 .0
Q 10 low  stringency Q 10 low stringency
2 0 9 6 .9 0 .0 2 4 1.4 2 0 9 5 .9  0 .0 2 7 1.3
2 2 2 3 .9 0 .0 1 9 1.3
2 2 7 3 .0 0 .0 4 4 1.3
2 3 7 1 .8 0 .0 4 8 3.4
2 3 8 4 .3 0 .0 0 8 1.3
2 4 9 0 .0 0 .0 0 4 1.3 2 4 8 9 .9  0 .0 1 4 1.4
2 5 9 1 .8 0 .0 2 3 1.3 0 .0 1 6 1.2
2 9 7 7 .8 0 .0 0 7 -1 .4
3 6 0 4 .0 0 .0 3 5 -2 .0
5 7 6 8 .5 0 .0 0 9 -2 .0 0 .0 0 2 -2 .5
As for the M A LD I-ToF MS data, i f  a fold-change was very large, such as 7.0 for m/z 
13911 on the Q10 (high stringency) arrays, it was usually due to one sam ple skewing 
the data with an unusually high intensity. Again this em phasises that visual validation 
o f  the m arkers is crucial, additional to statistical analysis. Four peaks w ere calculated 
to have significant /^-values from the Q10 arrays prepared at high stringency, o f  those 
only 2  peaks were visually different betw een the breast cancer and the control cohort 
(Figure 6.29).
4150 4200 4250 m/z 4292 4350
Figure 6.29: The two most discriminating peaks recovered from Q10 ProteinChips prepared at 
high stringency conditions. All spectra were overlaid, in red the breast cancer and in blue the 
control samples.
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O f the 10 significant peaks on the Q10 (low stringency) arrays seven w ere visually 
confirm ed (Figure 6.30). O nly one (m/z 2490) o f  the significant peaks from the 
averaged data was actually  different, looking at the spectra. Because the spectra 
processing and data analysis for these arrays was perform ed in Cardiff, all files were 
available. For that reason it was possible to get the inform ation on fold-changes 
calculated from the m eans obtained form the B iom arker W izard software.
m/z 2384
257 m /z  2595 2625 2650
2575 2600 2625 2650
3400 3500 m/z 3606 3700
/y*+\
j j g g
3400 3500 3600 3700
5/C0 m /z  5769 5850 59
Figure 6.30: The 7 most discriminating peaks recovered from Q10 ProteinChips prepared at 
low stringency conditions. All spectra were overlaid, in red the breast cancer and in blue the 
control samples.
V isually the m ost obvious peak with a significant difference betw een breast cancer 
and the control sam ple w as m/z 1756 detected from the chips prepared at high 
stringency. Because o f  the poor resolution o f  the peaks this is not visualised as well in 
the overlaid peak view. Figure 6.31 shows the difference m ore convincingly. 
However, here only 3 sam ples from each cohort were chosen, to not overcrow d the 
spectra.
2450 247 m /z  2490 2525 2550
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Figure 6.31: Alternative visualisation of the mass spectra from breast cancer and control 
samples. The peak at m/z 1756 is significantly decreased in the breast cancer cohort where as 
the peak at m/z 1600 retained the same peak intensity in both cohorts.
6.4. SELDI-ToF MS Analysis of Sample Set S2
After the failure o f  the analysis o f  the SI sam ple set with m ore replicates in C ard iff 
and discussion w ith Ciphergen, it was suggested that the ProteinChips had expired and 
therefore a w hole new sam ple set o f  LM W  serum  (S2) was prepared as described in 
Chapter 5 (section 5.5). Brand new chips and buffers w ere used for this analysis. The 
samples were prepared and analysed on Q10 and CM 10 ProteinChips. H ow ever as can
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be seen in Figure 6.32 and Figure 6.33 the resolution o f  the m ass peaks in the SELDI- 
ToF spectra is very low and the individual peaks were not defined but had m erged into 
broad lumps. These spectra w ere too poor to be analysed for b iom arker discovery. 
Suggestions that this m ay be due to degradation were refuted as the M A LD I-ToF MS 
analysis was perform ed a few w eeks after the SELD I-ToF M S analysis on an aliquot 
prepared at exactly the sam e time. A num ber o f  experim ents were preform ed to 
investigate the reason behind this how ever no explanation could be found and in the 
interest o f  saving tim e and resources SELD I-ToF MS analysis was abandoned.
Voyager Spec «1->BC->NR(2.00)[BP — 9420.8. 38870]
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Figure 6.32: Comparison of MALDI-ToF and SELDI-ToF MS of the same sample. The LMW 
serum sample was Zip-Tipped for MALDI-ToF and prepared on a Q10 array at low 
stringency. The whole mass range 1000- 20000 Da (A) and a narrow range highlighting the 
peaks between 9000 and 11000 Da (B) are shown.
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Figure 6.33: Comparison of MALDI-ToF and SELDI-ToF MS of the same sample. The LMW 
serum sample was Zip-Tipped for MALDI-ToF and prepared on a CM 10 array at low 
stringency. The whole mass range 1000- 20000 Da (A) and a narrow range highlighting the 
peaks between 9000 and 11000 Da (B) are shown.
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6.4.1. Possible Explanations for the Unsuccessful Experiments
A num ber o f  different reasons were explored to investigate w hy the SELD I-ToF 
analysis failed and to explain the low spectrum  resolution. A fresh aliquot o f  neat 
serum w as analysed un-fractionated m ixed w ith different am ounts o f  m atrix on NP20 
arrays (Figure 6.34). For all experim ents above 2x 0.6 pi o f  SA m atrix w ere used per 
spot; using m ore m atrix (2 x 1 pi) did not im prove the spectra but m ade them  worse, 
especially for the low m ass range. The num ber o f  peaks detected was few er than 
expected for a com plex m ixture such as neat serum. Therefore the serum sam ple was 
fractionated using W AX resin and each fraction was analysed on N P20 arrays, this 
type was chosen as it w ill bind all proteins sim ilar to a M A LD I-ToF target plate. As 
visible in Figure 6.35 few peaks were present in each o f  the fractions and the peak 
widths were broad. This shows that the problem s were not related to the ultrafiltration 
but occurred with all sam ples tested and furtherm ore that the com plexity  o f  the serum 
is not the hindering factor since W AX fractionation could not im prove the spectra. In 
any case, the LM W  filtrates have a m uch low er com plexity  and are free o f  album in, 
which has been a lim iting factor in the past.
40000 600002000 3000 4000 5000 61 20000000
6652,8+H1208.2+H
1 ul neat + 2x 0.6ul matrix
449.5+H
i4195.1 +H1854.0+H I8954.6+H
1281548h
,6654202 2+H
1 ul neat + 2x 1 ul matrixI3853.4+Hl1 519.4+H 12383.1+H
[5124.2+H 6658 9+H
i28167.9+H
,14071.7+H
000 2000 3000 4000 5000 6! 20000 40000 60000
Figure 6.34: Neat serum from a different source was analysed on NP20 chips. The sample was 
prepared with different volumes of matrix. Very few peaks are present in each spectrum.
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Figure 6.35: Neat serum fractions separated on WAX resin columns. The fractions along with 
some un-fractionated serum were prepared on NP20 arrays.
W e already knew that the ProteinChip reader was functional, since the analysis o f  the 
sam ples prepared in G uildford was successful. N ew  chips and buffers w ere used for 
preparation o f  the S2 set, furtherm ore these sam ples had been freshly prepared a day 
before the SELD I-ToF M S analysis. Also another aliquot o f  the same filtrates was 
analysed by M A LD I-ToF MS a couple o f  w eeks later and the spectra show ed no 
evidence o f  degradation or reduced peak resolution. As shown in Figure 6.33 o f  the
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previous section. In conclusion no explanation could be found for the problems and 
therefore SELDI-ToF analysis was abandoned and all samples from the S2 set were 
analysed with MALDI-ToF MS only. At the time o f the experiments, very little 
information was available on biomarker discovery using MALDI-ToF MS; however 
in Chapter 5 we managed to develop a robust protocol for protein profiling. A 
comparison of the two techniques is described in the next section.
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6.5. Comparison of SELDI-ToF with MALDI-ToF MS
Direct analysis o f serum is limited by the complexity o f the proteome and the great 
range o f protein concentrations within the sample. Analysis o f all serum proteins 
results in detection of the high abundant proteins only (e.g. albumin, immunoglobulins 
and transferrin). During mass spectrometry, ion suppression causes the highly 
abundant proteins, that ionize very well, to dominate the spectrum and the lower 
abundant proteins cannot be seen. The same is true for gel electrophoresis. Therefore 
serum was fractionated by UF and the LMW proteome, free from albumin and 
immunoglobulins was analysed. During the UF salts, small enough to pass through the 
membrane, may accumulate. To remove these the sample is washed with buffers on 
the SELDI ProteinChips (this is the standard protocol for ProteinChip preparation) 
and for MALDI-ToF each sample was Zip-Tipped on C l8 tips (this is also standard 
for serum protein preparation for MALDI-ToF MS). Each type of the ProteinChip 
arrays has a different chromatographic surface, binding specific proteins, in the same 
way C l8 Zip-Tips bind polar proteins. Hence slightly different proteins may be 
detected on the MALDI-ToF Chips compared to any o f the ProteinChips. In Figure 
6.36 a spectrum of a H50 array (C8 chromatographic surface) was compared to the 
MALDI-ToF spectrum o f the same sample. The spectra show comparable numbers of 
peaks and some of the major peaks are the same, some peaks however occur in only 
one or the other spectrum. In the SELDI-ToF spectrum a peak for m/z 1756 is 
observed and also demonstrated to be a significant marker, this peak is widely absent 
or of very low intensity from all MALDI-ToF spectra. Another example from a 
different sample analyzed by MALDI-ToF and on Q10 arrays at high and low 
stringency is shown in Figure 6.37. A small mass shift was observed, which may be 
due to different calibration files during manual calibration. For example m/z 1441 in 
the SELDI-ToF spectrum is the same peak as m/z 1469 in the MALDI-ToF spectrum. 
The SELDI-ToF spectra in Figure 6.36 was taken from the good Chips prepared in 
Guildford, whereas the spectra in Figure 6.37 were taken from the poor SI chips 
prepared in Cardiff. However both exhibit the mass shift and the presence o f m/z 
1756.
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Figure 6.36: Compare MALDI-ToF and SELDI-ToF spectra from the same sample. For 
MALDI-ToF MS the sample was cleaned using C l 8  Zip-Tips and for SELDI-ToF MS a H50 
array was used.
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Figure 6.37: Comparison of MALDI-ToF MS spectrum with spectra from Q10 SELDI-ToF 
arrays.
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For reasons described above different peaks were detected by MALDI-ToF and 
SELDI-ToF MS and therefore different significant markers were detected on each 
platform. In Table 6.10 m/z values that were found to be significantly different on both 
platforms are shown. These values were taken from across all the SELDI-ToF arrays 
and from the entire results table including all data (i.e. un-averaged, averaged and 
Markerview results) o f the MALDI-ToF results. However the results from the 
averaged MALDI-ToF MS results were marked in bold, as these could be considered 
more robust (Table 6.10). SELDI-ToF “markers”, listed in the first column of the 
table, that were visually confirmed from the spectra above, were also marked in bold. 
It is worth mentioning again that all the results shown from SELDI-ToF and MALDI- 
ToF MS analyses in this chapter were generated from the SI sample set.
Identification o f the discriminating peaks was attempted using MALDI-ToF/ToF by 
our collaborators at Applied Biosystems in Germany. Three peptide identifications 
were obtained and the proposed amino acid sequences are shown in Table 6.10. This 
was described in more detail in Chapter 5 (section 5.5.2). Although the database 
results only suggest homology to the protein matches. It is exciting to know that three 
potential markers were detected using SELDI-ToF and MALDI-ToF MS, and that 
they were also identified by MS/MS fragmentation.
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Table 6.10: Discriminating m/z values retrieved from both SELDI-ToF and MALDI-ToF 
analysis. The peaks in bold from the SELDI-ToF results are peaks that were visually 
confirmed to be different and in the MALDI-ToF set the peaks marked in bold are m/z values 
that where significant in the averaged dataset in the Excel data. Three peptides were identified 
using MALDI-ToF/ToF and the retrieved ammo acid sequence is shown.
Markers from SELDI -ToF MS Markers from MALDI -ToF MS
m/z p-value
fold-
change m/z p-value
fold-
change peptide ID
1034 0.036 1.0 1064 0.014 1.5 R P P G F S P F R
1226 0.029 1.7 1 2 7 3 0 . 0 2 7 1 . 8
1402 0.005 1.5 1 4 0 0 0 . 0 4 4 1 . 8
1636 0.043 2.2 1 6 0 8 0 . 0 2 2 1 . 6
1757 0.021 -2.3 1776 0.008 1.0
1936 0.050 -2.1 1932 0.014 -1.3 A H Y D L R H T F M G W S L G S
P S G E V S H P R
2464 0.030 -1.6 2 4 4 1 0 . 0 1 9 C  d o w n
2525 0.021 -2.5 2556 0.037 -1.6
2791 0.008 -2.1 2832 0.021 -2.1 S L A E L G G H L D Q Q V E E F R
2 9 1 3 0 . 0 2 1 5 . 3 2 2 9 2 5 0 . 0 3 8 1 . 5
2997 0.007 -2.6 2995 0.002 -1.9
3309 0.029 -1.2 3 3 3 8 0 . 0 2 3 C  d o w n
3555 0.021 -1.7 3 5 9 4 0 . 0 2 4 C  d o w n
5108 0.025 -1.2 5 1 0 1 0 . 0 1 6 - 1 . 1
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6.6. Discussion and Conclusions
Although the majority o f the SELDI-ToF MS analysis was unsuccessful, the results 
obtained from the experiments in Guildford determined that using multiple array 
chemistries and binding conditions can increase the number of proteins and potential 
markers discovered; the best ProteinChip types were Q10 and CM 10. The study 
further showed that pooling o f the sample reduces the number of peaks recovered and 
may therefore mask small changes when comparing two clinical groups. However 
potential markers were visible. The benefits o f fractionation and selective array 
chemistry, to reduce the sample complexity, were demonstrated; as significantly more 
proteins and markers were discovered from the WAX fractions.
The preliminary study showed that SELDI-ToF MS technology is reproducible and 
quantitative, however repeating the experiment in a separate laboratory failed. 
Unfortunately it was not possible to repeat the experiment with more replicates to get 
better statistical confidence. In the same way as for the MALDI-ToF study, analysis of 
the S1 samples provided some interesting results and could recover markers that were 
significantly discriminating between breast cancer and control serum samples. 
However each serum sample was only prepared once by UF; any “outliers” or spectra 
pushing the data either way may be due to a biological difference but could just as 
well be due to a difference introduce during the UF process. Although the UF showed 
to be a robust and reproducible method in Chapter 4, using replicates can minimise 
any variation and confirm the biological significance o f “outliers”. Repeating the UF 
on new serum samples in triplicate yielded good filtrates that were successfully 
analysed using MALDI-ToF MS (see chapter 5), however the SELDI-ToF analysis, 
despite brand new ProteinChips and reagents failed completely. Nevertheless the 
results that were recovered from the SI samples were compared to the markers 
retrieved from the MALDI-ToF analysis and encouragingly many of the markers 
overlap. It can be assumed that markers that are recovered from two completely 
different forms of analysis are more convincing and maybe regarded as a confirmation 
of the MALDI-ToF results.
Ideally, for protein identification, all samples would be separated by SDS-PAGE, 
corresponding molecular weight bands excised and digested with trypsin for 
identification using LC-MS/MS. However the proteins with significant /7-values were 
very small, more like peptides and therefore visualisation on SDS-PAGE is not
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straightforward. Alternatively these peaks can be analysed by MALDI-ToF/ToF, as 
was done with some success, for the markers recovered from MALDI-ToF analysis in 
the previous chapter. With more time and resources, this would be done for all 
potential markers. Furthermore each marker, if  an antibody is available, should be 
validated using Western Blotting or ELISA. In the literature three potential markers 
for breast cancer (m/z 4.3, 8.1 and 8.9 kDa) discovered using SELDI-ToF have been 
described by Li et a l [ l , 15]; and again in a independent study by Mathelin et al. [16]. 
These proteins were not changed in our breast cancer samples. No proteins were 
discovered in the 8-9 kDa mass range.
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CHAPTER 7
Biomarker Discovery using LC-MS/MS
The ability to quantitatively measure relative protein abundance between different 
clinical samples is essential for identifying candidate protein biomarkers; however as 
described above, most of this work has previously been done using intact proteins, by 
SELDI-ToF MS analysis. The use o f LC-MS/MS for human serum or plasma 
profiling using enzymatically digested proteins was initiated by the first global 
shotgun proteomics study of human serum published in 2002 by Adkins et al. [1]. An 
explosion o f LC-MS/MS-based applications in human serum and plasma soon 
followed due to the great interest in finding disease-related proteins [2-7]. Shotgun 
proteomics, where the proteins are digested prior to MS analysis, has now also been 
used in conjunction with isotopic (160 / 180 ), chemical (ICAT) or metabolic labelling 
for a global quantitative approach, quantifying relative protein abundance in plasma or 
serum [6, 8, 9]. This approach has been successfully used for pairwise comparisons 
where each sample is labelled with a different isotopic tag, however it can often be 
challenging to compare multiple samples or to use replicates due to the limited 
number o f available labels.
Label-free quantitation instead makes use o f the peak area or peak intensity as a 
measure for quantitation. This approach might be considered to introduce the least 
variation during sample preparation. Additionally, “label-free” direct quantitation 
provides greater flexibility for comparing multiple samples and for sample processing. 
This approach has been published quantitating peak-intensities [9-11]. However, in 
these papers, experiments were only used on small sample numbers or peptide
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standards for method development. We therefore tried to take this approach further 
and apply it to serum samples, in a comparison o f breast cancer and control samples.
In this chapter, our attempts to optimise and develop a LC-MS/MS-based protocol for 
protein profiling are described. As has been reported in a number of publications, the 
dynamic range o f the sample is a key factor for successful analysis [12-16]. Hence the 
LMW sub-proteome (containing only 1% of the total serum proteins) appeared to be 
an ideal source for detection of potential markers. As a first step, the column 
reproducibility was assessed and the separation gradients and sample concentrations 
optimised. In a first attempt at quantitation, all samples from the SI sample set (8 
breast cancer and 8 control LMW serum samples) were trypsin-digested and separated 
by LC-MS/MS twice. The experiment setup is shown in Figure 7.1.
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Figure 7.1: Experiment setup. Serum samples were prepared by centrifugal ultra-filtration, the 
filtrate was digested with trypsin and the peptides separated using a C l 8  pulled tip reverse- 
phase column spraying directly into the source of the ion-trap for MS/MS analysis. The 
fragmentation spectra were matched to peptides in the human FASTA database.
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7.1. Optimization of Sample Preparation and HPLC separation
Although LC-MS/MS has been used extensively in the literature for peptide 
identification, we still thought it important to optimize the technique for quantitative 
analyses, especially since any experimental irreproducibility could introduce 
additional variation and influence the results.
For peptide separation using reverse phase C l8 columns, fused silica capillaries were 
pulled into a tapered tip and packed with PepMap C l8 reverse-phase stationary phase 
(Dionex, Camberley, UK) into 10 cm long columns (75 pm ID x 10 cm, 300 A, 3 
pm), as described in the Materials and Methods (section 2.8.1). Initially 20 pm porous 
particles were used as packing material; however, as seen in Figure 7.2, the peak 
resolution for these is not as good as when using 3 pm particles. The resolution was 
tested using a peptide mix of four peptides standards (bradykinin (m/z 531), Leu-ENK 
(m/z 556), GluFib (m/z 786) and angiotensin II (m/z 524)). Only in the separation 
using the columns with 3 pm porous particles were all four standard peptides eluted in 
separate peaks.
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Figure 7.2: RP-LC-MS/MS separation of a test peptide mix: bradykinin (m/z 531), Leu-ENK 
(m/z 556), GluFib (m/z 786) and angiotensin II (m/z 524) using (A) 20pm and (B) 3pm porous 
particle C l 8  packing.
The use o f  small porous particles, small inner diam eter colum ns and nano-electrospray 
interfaces has allowed m ore efficient separations with higher peak capacities [17]. By 
reducing the inner diam eter o f  the colum n the flow -rate can be reduced and the 
analyte is concentrated as it elutes from the colum n. To reduce costs, all “nano” 
colum ns w ere packed by hand into pulled-tip  capillaries. D uring the packing  process,
• (R)it was noted that although the M etaG uard C l 8 -packing m aterial (Polaris, Varian 
Limited, Oxford, UK) produced colum ns with good chrom atography, they  were not as 
robust as the colum ns packed with C l 8  PepM ap m aterial (D ionex, Cam berley, UK). 
Furtherm ore a heat source and constant stirring o f  the packing m aterial w as necessary 
to allow consistent packing o f  the colum ns, especially for longer colum ns and when 
the am bient tem perature was low.
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7.1.1. Column Reproducibility for Peptide Elution and Peak Area 
Detection
To investigate if  repeated runs o f  the sam e sam ple on the sam e colum n were 
reproducible, initially a tryptic digest o f  a m ixture o f  standards (250 fmol o f  BSA, 
cytochrom e C (CytC), alpha-casein, and beta-casein) was separated and analysed 
using LC-M S/M S. The digest was injected 7 tim es and eluted using a continuous 
gradient from 2% to 98%  ACN, 2% form ic acid (FA) over 6 8  m inutes (Figure 7.3).
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Figure 7.3: nRP-LC-MS/MS separation of LMW serum peptides from replicate separations. 
The basepeak chromatogram of each of the 6  replicates is shown.
The spectra were searched against the bovine FA STA database using TurboSequest, 
as part o f  the Bioworks Brow ser version 3.1, using the follow ing filter criteria for high 
stringency cross correlation (Xcorr 1+, 2+, 3+ = 1.8, 2.5, 3.2 and DeltaCn = 0.08). A 
num ber o f  peaks from the basepeak chrom atogram  were then selected for com parison 
o f  retention tim e (RT) and peak area (AA). The coefficient o f  variance (C.V .) was 
calculated for each o f  these peak values. A C.V. o f  < 20%  has been show n to be a 
m easure o f  good reproducibility. The C.V .s for retention tim e o f  each peak were
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extrem ely  reproducible and the m ajority o f  peak area values o f  the selected peaks 
show ed good reproducibility  (Figure 7.4).
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Figure 7.4: Reproducibility o f the retention time (RT) and peak area for a number of selected 
peaks, measured by coefficient of variance (C.V.), across six replicate separations o f the 
peptide digests of BSA, cytochrome C, alpha casein, and beta casein.
In Table 7.1 the am ino acid sequence for each o f  the peptides in Figure 7.4 is shown 
to dem onstrate that they were retrieved from tryptic digests o f  the standard proteins in 
the m ixture. A dditionally the confidence levels o f  peptide identification are shown in 
the form o f  a cross-correlation (Xcorr) and delta correlation (dCn). A lthough the 
peptide identifications for the peaks chosen for evaluation o f  reproducibility  do not 
show very high levels o f  confidence, how ever we know that only these proteins were 
digested in the m ixture o f  standards. Furtherm ore the peaks were m erely used to 
assess possible variations in retention tim e or peak area.
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Table 7.1: Peptide identifications of the digest mixture of standards separated by LC-MS/MS 
and identified in the bovine FASTA database using Sequest. Each m/z value was matched to 
one of the standards. Confidence levels are given in the form of a cross-correlation (Xcorr) and 
delta correlation (dCN) value.
m/z xCorr dCn ch a rge S w is s P r o t  ID S e q u e n c e
481.0 3.45 0.25 3 BSA (R)RHPEYAVSVLLR
483.0 2.30 0.04 2 CytC (R)EDLIAYLK
488.0 2.50 0.20 2 BSA (K)DLGEEHFK
501.9 2.14 0.35 2 BSA (K)LWSTQTALA
545.5 1.12 — 1 BSA (K)VASLR
569.7 2.27 0.00 2 beta-casein
572.2 2.60 0.20 2 BSA (K)KQTALVELLK
582.7 3.58 0.31 3 BSA (K)LVNELTEFAK
587.7 3.94 0.02 3 alpha-casein (K)HQGLPQEVLNENLLR
625.6 3.10 0.09 2 BSA (R)FKDLGEEHFK
634.5 1.53 . . . . 1 CytC (K)IFVQK
642.6 1.72 0.32 2 BSA (R)HPEYAVSVLLR
646.5 1.62 0.16 1 beta-casein (K)EAMAPK.H
653.7 3.10 0.33 2 BSA (K)HLVDEPQNLIK
682.7 3.98 0.02 3 BSA (R)RHPYFYAPELLYYANK
720.5 3.03 0.35 2 BSA (R)RHPEYAVSVLLR
748.4 1.07 0.16 1 alpha-casein (K)TTMPLW
756.5 2.88 0.14 2 BSA (K)VPQVSTPTLVEVSR
785.2 4.67 0.45 2 BSA (K)DAFLGSFLYEYSR
This experim ent was then extended to look at LM W  peptides from serum , separated 
by using the same m ethod as for the peptides. For quality control, the retention tim e 
was first checked using bradykinin. The LM W  serum peptides were injected and 
separated 7 tim es, and the individual spectra are shown in Figure 7.5. In Figure 7.6, 
the C .V .s for the retention tim e and the peak area for a num ber o f  selected peaks that 
occur in all spectra, are shown. The m ajority o f  peptides elute in a reproducible 
m anner with an average C.V. o f  20%  for the peak area reproducibility. As for the 
standards the reproducibility  o f  the retention tim e o f  each peak was excellent.
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Figure 7.5: nRP-LC-MS/MS separation of LMW serum peptides from replicate separations. 
The basepeak chromatogram of each of the 7 replicates is shown.
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Figure 7.6: Reproducibility of the retention time (RT) and peak area for a number o f selected 
peaks, measured by coefficient o f variance (C.V.), across seven replicate separations of the 
peptide digests of LMW serum.
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7.1 .2 . Elution G radients  for Optimal P eptide  Separation
From  the results described above, and particularly in Figure 7.5, it becam e apparent 
that the chrom atography could be im proved to allow  further separation o f  the LM W  
serum  peptides and to further im prove peptide identification. Enabling greater 
separation o f  eluted peptides m ay also reduce the effect o f  ion suppression and the 
exclusion tim e com m on to LC separations. Therefore a num ber o f  elution gradients 
w ere tested, separating LM W  serum  peptides. It was discovered that the gradient has a 
strong influence on the w ay that peptides bind and elute from the colum n. To assess 
the differences betw een the gradients, the chrom atogram s w ere visually  inspected and 
the peak resolution for a num ber o f  selected peaks was calculated. From previous 
results, it was observed that m ost peptides elute from the C l 8  colum n during the 30 
and 50%  organic phase (ACN , 2% FA). Hence it was hypothesised that the gradient in 
the phase up to 30%  ACN could be shorter and steeper to allow  m ore tim e for the 
peptides to elute at an organic phase above 30%  ACN, w ithout increasing the overall 
tim e o f  the analysis. H ow ever as shown in Figure 7.7, m ost o f  the peptides actually 
elute as soon as the steep gradient sets in. A shallow er gradient is therefore required 
from the start to ensure binding to the colum n and good retention times.
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Figure 7.7: Neat serum separated on steep gradient to increase the actual separation time 
between 30 and 50% ACN.
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Increasingly shallow  and m ore “gentle” gradients were therefore tested. As can be 
seen in Figure 7.8, where the elution gradient itse lf is show n in red, the peaks becam e 
increasingly resolved the shallow er the gradient.
steep
gentle
2
zo<
very gentle
caressing
R eten tion  T im e  (m in )
Figure 7.8: Un-diluted LMW serum separated with four different gradients. Peptides were not 
retained on the column using the steep gradient. However they were retained and separated 
out using the three more gentle gradients. The separation gradient itself is shown in red.
Additionally the peak resolution o f  three peak distances for the “gentle”, “very gentle” 
and “caressing” gradient are shown in Table 7.2.
* , = 2 ( ( 'A
The peak resolution (Rs) can be described by  the above equation, where A is the first 
o f  two peaks and B the second, which elute at tim es (tR)A and (tR)B, and W the w idths 
o f each peak.
As seen in Table 7.2 no one gradient perform ed optim ally for all peaks analysed. 
How ever the very gentle gradient on average resulted in the best peak resolution for
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the three peak ranges and produced separation chromatograms with symmetrical, 
narrow peaks. It is possible that the separation in the caressing gradient is too shallow, 
resulting in broader peaks. Therefore for future LC-MS/MS experiments, the very 
gentle gradient was chosen.
Table 7.2: Peak resolution of the three different gradients for three separate areas in the 
spectrum. In each case, two peaks that elute very close together were chosen. The greater the 
Rs value, the better the resolution.
Peaks Gentle (Rs) V Gentle (Rs) Caressing (Rs)
m/z 737 (A)-1101 (B) 1.03 0.79 0.51
m/z 1135 (A) - 1103 (B) 0.46 1.01 0.52
m/z 886 (A) 1006 (B) 0.70 0.77 0.89
7.1.3. Peptide Concentration for Optimal Loading
The chromatograms in Figure 7.8 showed signs o f column overloading, as many 
peptides eluted early at 20 minutes, when the ACN concentration is still low. 
However, the same peptides were also eluted again later in the gradient. Overloading 
of the Cl 8 columns can cause early elution o f peptides that do not bind strongly to the 
column, and also peak broadening. Finding the optimal peptide concentration allows 
binding o f as many peptides as possible to the column, while still binding enough 
sample to analyse as many peptides as possible by tandem MS and finally retain 
enough sample to perform multiple separations.
A LMW serum filtrate was therefore trypsin-digested and loaded onto the C l8 RP- 
column in a series of dilutions. The initial peptide concentration was determined by 
BCA assay to be 0.88 mg/ml and a dilution series o f 1:5, 1:10, 1:50, 1:100, and 1:500 
was created. For each sample, 7 pi were loaded onto the column and separated along 
the “very gentle” gradient, increasing stepwise from 2% to 98% B (ACN, 2% FA) in 
105 min (Figure 7.9). From the concentrated serum sample, 6.16 pg o f peptides were 
injected, whereas only 0.012 pg were loaded onto the column from the 1:500 diluted 
sample. The retention time of the concentrated sample was slightly shifted compared 
to the others, with peptides eluting earlier than in the other dilutions, additionally, a
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large and w ide peak is visible at 20 m in (Figure 7.9). These factors together indicate 
that the colum n was overloaded and these peptides were eluted at a lower percentage 
o f  organic-phase. The spectra from dilutions o f  1:5 and 1:10 looked sim ilar to each 
other and the TIC intensities were 2 .3x109, and 1 .4 x l0 9, respectively. The dilutions 
1:50 and 1:100 also looked very sim ilar, w ith m axim um  basepeak intensities o f
8 s
4.3x10' and 5.8x10 respectively, but few er peaks w ere observed in these than in the 
higher concentrations.
Injection o f  1.24 pg (1:5 dilutions) o f  LM W  peptides appeared to overcom e the effect 
o f  overloading and the peaks are m ore spread out and narrower. The dilutions o f  1:50 
to 1:500 showed a peak cluster (RT: 56 - 60 m in) that has sim ilarity to a polym er 
com m on in LC -M S/M S spectra, and the intensity o f  the serum peptides is too low to 
be visible com pared to the polym er. H ence approxim ately 0.62 pg (1:10 dilutions) 
were necessary for separation o f  the LM W  peptides w ithout interference o f  
background contam inants or elution problem s. Shen et al. [18] also reported that 
overloading o f  the colum n can reduce the num ber o f  identified proteins. They further 
stated that 0.5 -  2.5 pg o f  sam ple was optim al for peptide identification; which is very 
sim ilar to our findings.
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Figure 7.9: Whole basepeak chromatogram of a dilution series of a concentrated LMW serum 
peptide sample (cone.) separated over 105 min from 2% to 98% ACN.
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A fter LC -M S/M S separation, the num ber o f  .dta files (hence the num ber o f  peaks 
selected for M S/M S) w as used to gain a m easure o f  the efficiency o f  peptide recovery 
(Figure 7.10). Since the M S/M S analysis was perform ed in data-dependent m ode, 
excluding precursors that had been fragm ented three tim es within a given tim e 
w indow , it can be assum ed that m ost .dta files correspond to different peptides.
A lso seen in Figure 7.10 the num ber o f  peaks selected for M S/M S analysis decreased 
w ith the am ount o f  protein loaded onto the colum n: a sudden drop is observed 
betw een 1.24 pg and 0.62 pg o f  protein. W e tried to detect any peaks that were 
present in the neat LM W  serum but not in the 1:500 dilution but could not find any. 
This indicates that the sam e peak inform ation is present in the low concentration 
sam ples as in the very concentrated sam ples.
The num ber o f  M S/M S scans increased w ith every replicate separation (Figure 7.10). 
This cannot be readily  explained, how ever the spray m ay have stabilized during the 
course o f  the experim ent or the background noise could have reduced during the 
course o f  the experim ent. N evertheless, the sam e trend o f  increasing M S/M S scans 
with increasing am ount o f  peptides was observed in every run.
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Figure 7.10: The number of peaks selected for MS/MS fragmentations across three replicate 
separations. The number of .dta files increases with every replicate run, however the trend of 
the slope is the same.
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To investigate w hether the differences betw een the three replicate runs had an 
influence on retention tim e and peak area, a num ber o f  selected peaks from the 1:500 
dilution were observed for retention tim e and peak area (Figure 7.11 a and b). It 
appears that the peaks eluted earlier in the third replicate for the m ajority o f  peaks 
(Figure 7.11 a), how ever this can be com pensated for in the spectra by adjusting the 
baseline. How ever, although the num ber o f  .dta files showed a trend, increasing across 
the replicate separations, the peak area o f  the chosen peaks varied random ly across the 
three replicates and no trend is visible (Figure 7.11 b).
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Figure 7.11: Replicate separation of LMW serum peptides (12 ng/injection). A number of 
selected peptides were analysed with regards to retention time (RT) (A ) and peak area (B).
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A dditionally, w e looked at various individual peaks and observed how they perform  in
the dilutions: a decrease in peak intensity and area with increasing dilution is visible in
• 8Figure 7.12. The peak intensity  was adjusted to an absolute intensity o f  6  xlO for the
8 • • un-diluted LM W  serum  and 1 xlO  for the dilutions to visualise the decreasing peak
height o f  m/z 668.4.
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Figure 7.12: The extracted ion chromatogram of m/z 668.4 for the dilution series from 6.16 -  
0.01 pg of LMW serum. The peak intensity was adjusted to an absolute intensity of 6  x l( f  for 
the undiluted serum and 1 x 1 0  ^ for the dilutions to enable visualisation of the decrease in peak 
height.
Furtherm ore, in Figure 7.13, the relative intensity for each concentration is shown in 
the extracted ion chrom atogram  (XIC) and in this way the change in area o f  the three 
peaks that elute at different tim es in the m ass range m/z 667.9-668.9 can be seen. 
Three peaks are visible in each chrom atogram , at 24 m in (m/z 668.5), at 67 min (m/z 
668.3) and at 80 min (m/z 6 6 8 .6 ). The intensity o f  each o f  these in relation to one 
another changed with decreasing peptide concentration: a shift in the retention time
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was visible betw een the concentrated and the diluted sam ples (Figure 7.13). A change 
in the relative peak height can also be seen in the spectra as the sam ples becam e 
increasingly m ore dilute.
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Figure 7.13: The extracted ion chromatogram (XIC) of m/z 668.4 for the dilution series from 
6.16 -  0.01 pg of LMW serum. The peak intensity was adjusted to the relative basepeak, 
showing the highest peak in the spectrum at 100%. This enables visualization of the different 
peaks in the XIC of m/z 667.9-668.9.
The results showed that finding a balance betw een overloading o f  the colum n and 
recovery o f  a sufficient num ber o f  M S scans is crucial: this was achieved by injecting
1.2 pg o f  peptides onto the colum n. For separation o f  larger am ounts o f  protein, a 
larger colum n, either in term s o f  length or inner diam eter, w ould be required. 
How ever larger colum ns m ay cause the peak resolution to suffer.
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7.2. Label-Free Quantitation of Peptides for Biomarker Discovery
The effectiveness of label-free peptide quantitation was tested using peptides 
(bradykinin, LeuENK, B-glufibrino-peptide and angiotensin II) spiked into LMW 
serum samples. From the XICs, the mass peaks were detected and quantitated by 
manual integration of the peak area, as well as by using the Bioworks Browser version
3.2 (Thermo Finnigan, UK) to identify the MS/MS spectra and for automated 
quantitation o f the peak areas. An aliquot o f 3 pg of LMW serum peptides was spiked 
with a series o f concentrations of each of these standard peptides (0.5, 50, 100, 150 
and 200 fmol/ injection). Each sample was injected and separated twice and the results 
were combined. In the Bioworks Browser, the area for each peptide identified from 
the FASTA database using TurboSequest, was computed. For the standard peptides, 
since the m/z for each was known, each peak was actively searched for in the XICs for 
manual peak integration. The results using both approaches are shown in Figure 7.14. 
As shown, some of the values from Bioworks Browser are missing due to lack of 
identifications from the MS/MS spectra. All peptides show good linearity except for 
angiotensin II, this may ionize slightly better. Similar results have been shown by 
Wang G. et al. [19], where a special computer program was developed to implement 
label-free quantitation of bovine serotransferrin spiked into albumin-depleted plasma. 
In the same study, protein changes in knock-out p53‘/_ compared to wild-type cells 
were determined and four peptides present only in wild-type and a further 12 only in 
p53'/_ cells were detected.
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Figure 7.14: Quantitation o f peptides spiked into LMW serum peptides by area integration 
from LC-MS/MS analysis. In A, the area quantitation method within the Bioworks Browser 
was used to automatically detect the area for peptides that were identified by Sequest. In B, 
the area for each peptide was manually searched and integrated in the XIC within Qual 
Browser of Xcalibur1 V1 version 1.4 and the area for that peak recorded.
The results from Figure 7.14 showed that quantitation using the Bioworks B row ser 
has lim itations. A low num ber o f  M S/M S scans are perform ed due to the slow scan 
rate o f  the LCQ Deca (Therm o Finnigan, UK) com pared to a new er instrum ent such 
as the LTQ. Additional to the lim ited num ber o f  M S/M S spectra, fragm entation
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spectra that are not present in the database, such as modified sequences or post- 
transcriptional changes cannot be quantitated. In the spiked standards experiment we 
were able to directly search for the peptide peaks using the XIC, as their mass was 
known, and integrate the peak area for quantitation. However in a complex biological 
mixture o f unknown peptides, such as serum, this is not possible.
Nevertheless we did try to compare the 8 breast cancer and 8 control samples from the 
SI sample set (see previous chapters). Each LMW serum sample was trypsin-digested 
and analysed by LC-MS/MS twice before the MS/MS scans were searched through 
the human FAST A database for peptide identification. The spectra could not be 
analysed with the Bioworks Browser version 3.2, as only two files can be compared 
with each other and, as described above and seen in Figure 7.14 a, the analysis is 
limited to identifiable MS/MS spectra. Spectra were therefore compared visually for 
different sections and mass ranges highlighted in XICs across all samples with the 
intention to detect (more or less by chance) any peptides that had a different peak area 
or intensity in the breast cancer samples compared to the controls. No formal 
statistical analysis was performed.
We managed to detect one peptide that was only present in the breast cancer samples, 
in every single one, but was not present in the control samples. As seen in Figure 7.15, 
this peptide at m/z 790.2 is present and at relatively high intensity (the y-axis was 
fixed to 2.0 xlO8) only in the breast cancer samples. The same data is shown, using a 
slightly different view, in Figure 7.16: this visualization shows an even more 
convincing difference between the two sample groups.
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Figure 7.15: Extracted ion chromatogram for m/z 790.2 for all breast cancer and control LC- 
MS/MS separations. The y-axis o f the spectra was fixed to 2.0 x l0 N for the breast cancer and 
2.0 xlO for the controls (The lower intensity for the control spectra was chosen to ensure that 
the peptide is really not present.)
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Figure 7.16: A different view of the XIC m/z 790.2 of all breast cancer (red) and control 
samples the different angle and the overlaying of the spectra show the difference between the 
two clinical cohorts for m/z 790 even more clearly.
A search o f  the literature revealed no published data identifying differentially 
expressed proteins or peptides detected using label-free quantitation from serum. 
Hence this is a novel discovery. Ideally, we w ould have thoroughly analysed this 
dataset to identify any further potential m arker peptides, how ever, due to the lack o f  
available softw are program s for m ore thorough quantitation, no relative quantitation 
o f  the other peptides in the spectra could be perform ed. It is likely that other peptides 
were up- or dow n-regulated in the breast cancer samples. Since m/z 790.2 is absent in 
the control group, no relative quantitation can be calculated, how ever, this only m akes 
it m ore valuable, it represents a true absent/present m arker. To detect a peptide that is 
only present in one o f  two sam ple groups is a real treasure. Identification o f  this 
peptide could lay a path for the developm ent o f  a clinical tool or diagnostic test, given 
thorough validation. H ow ever since the peptide occurred in all breast cancer sam ples,
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despite the heterogeneity  o f  the patient group, this is an im portant first step towards 
identifying a diagnostic marker.
7.3. Tandem MS Analysis for Identification m/z 790.2 Da
All spectra w ere searched against the hum an FA STA  database; how ever no 
identification for any o f  the scans containing m/z 790.2 was obtained. Therefore the 
rem nants o f  all the breast cancer sam ples were pooled and analysed again by selective 
ion fragm entation for m/z 790.2, specifically. Here M S/M S fragm entation was 
perform ed only on scans containing m/z 790.2, reducing any effect o f  ion suppression 
or the slow scan rate o f  the ion trap. The peak intensity o f  the resulting M S/M S 
spectra was very low (NL: 1.06 xlO 3) and alm ost indistinguishable from noise (Figure 
7.17). Furtherm ore, although the zoom  scan in Figure 7.18 indicates that the peptide is 
singly charged, the fragm ent ions exceed the m/z o f  the precursor ion. The peaks in the 
zoom scan were not well defined and another peak m ay be hidden underneath. Hence 
further analyses to determ ine the charge-state o f  this peptide was required.
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F igure  7 .17: F ra g m en ta tio n  p a tte rn  o f  m/z 790 , th e  p e a k  in te n s ity  is low  and  the  frag m en t ions 
are la rg e r than  the  p re c u rso r  m ass , a lth o u g h  the  ion  is su p p o sed  to  be  s in g ly  ch a rg ed .
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Figure 7.18: A zoom scan o f the peak at m/z 790.2. The spectrum indicates that the peptide 
has a single charge.
To further attem pt to identify our potential m arker peptide, the sam ple was separated 
on a C l 8 reverse-phase colum n and analysed online by M S/M S using a Q-ToF MS 
(M icrom ass, W aters, UK) as described in the M aterials and M ethods (section 2.8.4). 
The Q-ToF has greater resolving pow er for individual m ass peaks and m ay be m ore 
sensitive than the LCQ. D irectly scanning for m/z 790 again resulted in very low 
intensity fragm entation spectra, and although M A SCOT searching (version 1.9; 
M atrixScience, London, UK) and clenovo sequencing was attem pted the fragm ent ions 
were too small and too few to get any useful identification (Figure 7.19). The 
precursor ion was still present in the spectrum ; from this at least the single charge 
state o f  the ion could be confirm ed (Figure 7.20).
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Figure 7.19: Tandem MS spectrum of the peak at m/z 790.2. The intensity of the spectrum is 
low and few fragment ions are visible, sequencing was not successful.
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Figure 7.20: Tandem MS spectrum of peak at m/z 790.2. Zooming in over the precursor 
confirmed that the peptide is singly changed.
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7.4. Discussion and Conclusions
In this final results chapter the use o f LC-MS/MS based analysis of peptides was 
tested for biomarker detection from serum. Label-free quantitation o f peptides from 
LC-MS/MS separation relies on the reproducible elution of the peptides and the 
reproducible determination of their peak areas. Using LMW serum protein digests the 
complexity o f the sample was reduced and the reproducibility o f the retention time 
and peak area detection was demonstrated on a number o f selected peptide peaks. 
Furthermore to identify a maximum number o f peptides an optimal elution gradient 
and concentration of peptides was determined to resolve peptides into separate peaks. 
Finally for high throughput analysis including data analysis, sophisticated software 
tools are required to analyse the vast amount of data produced, in a reliable and rapid 
manner. Initially we demonstrated that standard peptides spiked into LMW serum can 
be semi-quantitated, from the XICs, using peak area integration. However quantitation 
of those standards using the Bioworks Browser showed to be more complicated. The 
quantitation algorithm within Bioworks makes use of the MS/MS scans, and only 
peaks that produce a positive peptide identification are quantitated. Due to the limited 
number of MS/MS scans produced with the LCQ Deca, even from the standards some 
peaks were not identified and hence not quantitated. However a small profiling study 
was still undertaken using the SI sample set (see Chapter 5 and 6) for label-free 
quantitation. Using the optimized elution gradient and the optimal concentration of 
peptides we were able to detect a peptide that was only present in the breast cancer 
samples. Although breast cancer is a heterogeneous disease, this potential “marker” 
was present in all breast cancer samples but in none o f the controls. Discovering a 
peptide present in only one sample cohort even with the use o f statistical software, is 
rare. Even in the absence of a positive identification for the peptide at m/z 790.2, this 
could, if  validated in repeat experiments and larger sample groups, become a potential 
marker for detection of breast cancer patients. If we were able to isolate a peak at m/z
790.2 it may be possible to identify the peak, although it appeared to be difficult to 
fragment this peptide.
For a more global search for peptides o f different intensity within a complex sample 
of unknowns the use o f a high-speed 2D linear ion trap such as an LTQ or LTQ-
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Orbitrap could increase the protein coverage greatly compared to an LCQ with a 3D 
ion trap [20]. Using the LCQ with data-dependent MS/MS scans the analysis suffered 
from a limited number o f MS/MS fragmentations due to ion suppression and loss in 
the exclusion time, as only a proportion of species observed in the survey MS scan 
was selected for MS/MS fragmentation [21]. To overcome this all samples were 
analysed in MS mode only and then once differences are detected these could be 
specifically identified in a separate MS/MS experiment. However automated 
quantitation using the identification-based algorithm in Bioworks was not possible. It 
has been reported [22] that multiple sources o f variation affecting the peak intensity 
may be introduced during the analysis, such as differences in electrospray ionization 
efficiencies among different peptides and samples as well as differences in separation 
(as seen in Figure 7.10 for replicate runs and in Figure 7.14 for angiotensin II). These 
issues are often peptide dependent, resulting in differences in relative abundance in 
peptides from the same protein, making an automated approach using all peptides 
identified from one protein such as using Bioworks Browser quantitation more 
difficult. For these collected reasons we decided that the algorithm in Bioworks is not 
suitable for our data collected from the LCQ Deca analysis, and the experiment was 
not extended to analysing the S2 sample set.
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CHAPTER 8
Final Discussion and Conclusions
During the three years that this study has taken, little has changed in terms of 
biomarker discovery for breast cancer. In fact very few markers have been reported 
for any diseases, or discovered using proteomics. [1]. A review by Hu et. al. [2] 
summarizes all the markers discovered using proteomics and mass spectrometry for 
any disease from serum and they reported less than 15 for breast cancer.
In biomarker research, the focus has changed from pattern profiling and the use of 
SELDI-ToF to attempts to develop and optimise other types of mass spectrometry as 
well as studies o f the capabilities and reproducibility o f current protocols and 
techniques.
In particular, in the case o f serum it has become apparent that storage and handling is 
crucial for quantitative analyses, as much variation can be introduced to LMW 
proteins during these first steps.
8.1. Sample Preparation
There was surprisingly little in the literature about methods of standardising sample 
preparation and handling at the time this project was started. This may be due to the 
fact that researchers were caught up in the excitement of the fast development of 
mass spectrometry and new applications, discovering biomarkers. In fact, factors 
such as sample preparation and handling, for instance clotting time, storage 
temperature and time, freeze/thaw cycles and the time taken for further sample 
preparation are all very important. This is especially important when each candidate 
marker will have to be validated on large independent sample sets [3]. Recently, the
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Human Proteome Organization (HUPO) has published a meta-analysis of 
information gathered over the last 3 years on these issues [4], and a number o f other 
papers have been published on the back of the data collected [5-7],
At the beginning o f this study it was thought that serum samples could be stored in 
small aliquots at -80°C for a prolonged time. Since then there have been reports that 
serum samples may in fact be best stored in liquid nitrogen and that even here they 
may only be stable for a few months [1, 8 ]. Furthermore it may in fact be the case 
that serum may be most stable in dry form, after precipitation. In my own research, I 
have discovered that the serum samples were not stable in the -80°C freezer for long 
periods, such as 18 months, even in the absence o f freeze/thawing. The LMW 
samples, which were stored in NH4 HCO3 following centrifugal ultrafiltration (UF) 
were even less stable and appeared to degrade within 6  months. A possible 
explanation for this may be the lack o f albumin; albumin has been reported to have 
protective properties against protease activity in serum [3]. Protease inhibitors could 
be added to the sample to prevent protein degradation during storage and handling, 
however these may interfere with subsequent MS analysis or lead to formation of 
covalent bonds with other proteins [4, 9-12]. Furthermore, Villanueva et al. [13] 
reported that the use o f protease inhibitors could mask the presence of disease-related 
proteases that produce the diagnostic signature o f endogenous peptides.
From the start we were very careful to standardise all sample preparation steps and 
so the type o f serum collection tubes, clotting time, centrifugation and storage were 
kept the same for all samples. And this decision is supported by the most current 
literature. Freeze/thawing, on the other hand appears to cause less obvious changes to 
LMW proteins and peptides [3] than previously thought as long as the samples are 
kept on ice [14]. The only factor that we did not have power over was the storage 
time and, in light of the studies published recently [3, 7, 9, 14], this may be a major 
problem. In our experiment, storage time has presented as the major limiting factor, 
as we were not able to repeat any o f the experiments described in this thesis later on 
the same samples. The only possibility was to use those LMW samples that were 
stored completely lyophilized, as they were more stable than the neat serum or LMW 
samples in solution. If I was to repeat this project, I would use all serum samples 
within 6  months of freezing, and ensure that all processed samples were lyophilized 
to complete dryness. I would not use protease inhibitors or precipitation prior to
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freezing, as these may introduce additional variation or complicate future analysis. 
However this sort of change is not possible for large-scale sample collection projects 
such as serum banks started before this project. More research is clearly required into 
the effects o f storage.
8.2. Albumin Depletion
In this thesis, we set out to develop a protocol for detection o f serum markers for 
breast cancer. It quickly became obvious that serum is too complex to analyse and 
that albumin and other proteins of high abundance present in serum interfere with the 
analysis o f other serum proteins, o f low abundance. These low abundance proteins 
may have not been studied in great detail, but may be clinically most interesting. To 
study low-abundance proteins, the high-abundance species are often eliminated as 
the first step in the analytical protocol [15-21]. Removal can be achieved by affinity 
depletion through LC columns or cartridges, protein precipitation or centrifugal 
ultrafiltration.
We have tested the above methods and shown that UF is the best technique for 
removal of albumin and the enrichment o f low molecular weight (LMW) proteins. 
Using UF, recovery o f the LMW sub-proteome was possible in one single step 
without the use o f high salt buffers that would later interfere with MS analysis. The 
reproducibility o f this step is paramount and therefore an in-depths study was 
performed. The results confirmed the reproducibility o f UF and that the complexity 
of the serum proteome was sufficiently reduced by this method for quantitative 
studies. During the extensive optimisation of the UF procedure, a new protocol was 
designed, different to those previously described in the literature [22-25]. Using this 
optimised method we were able to recover a larger number of LMW proteins in a 
more reproducible fashion.
The use of UF may be further justified by the fact that the only reported marker 
discovered in the last 4-6 years, before the beginning o f this study, had been peptides 
of low molecular weight [1, 26, 27]. Markers of higher molecular weight have often 
turned out to be unrelated to the actual disease itself [13].
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In summary, we have shown that UF is a robust sample pre-processing method to 
enrich the LMW proteome for subsequent biomarker discovery in serum. 
Furthermore, UF has been shown here to be more selective at removing albumin and 
immunoglobulin from serum than affinity chromatography and precipitation without 
the loss of other proteins.
8.3. Biomarker Discovery from Intact Proteins
The aim of this project was to discover a biomarker or a protein pattern as a signature 
of breast cancer. At the start o f the thesis, very little literature was available on the 
use of mass spectrometry for quantitative proteome analysis. SELDI-ToF MS was 
the most cited technology and a number o f convincing studies had been published, 
using this technique for protein quantitation from serum. We therefore started off 
using SELDI-ToF analysis, which appeared to be optimal for the LMW sub- 
proteome, since SELDI-ToF has an optimal mass range smaller than 30,000 Da. As 
there was no SELDI-ToF mass spectrometer available on-site, I formed a 
collaboration with a group at Cardiff University. MALDI-ToF MS, on the other 
hand, was available in Swansea. Although quantitation o f all proteins in the complex 
mixture had not been reported using MALDI-ToF we also analysed all our samples 
with MALDI-ToF MS. The two sample sets (SI and S2), o f 8 breast cancer and 8 
control samples, were each analysed using both techniques. For the SI sample set an 
initial “4 x 4 study” was set up of a smaller subset o f samples analysed on all SELDI 
chip types. Also on this sample set, pre-fractionation using WAX resin was tested 
and this was termed the “8 x 8 study”. The two ToF instruments work relatively 
similarly; hence intact protein analysis should be directly comparable. The SELDI- 
ToF analysis of the first sample set (SI) produced some very interesting results, 
hinting at some potential markers. From the 4 x 4  study, 17 discriminating protein 
peaks were discovered and 11 peaks identified from the fractions of the 8 x 8  study. 
After the first experiment, it became apparent that it is essential to use multiple 
replicates through-out the whole experiment to allow for any variation occurring 
during the sample preparation or MS analysis. Therefore we could not be sure about 
the authenticity of the markers because no replicates of the actual samples were 
prepared. For this reason the experiment was repeated using new serum samples,
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prepared by UF in triplicate before MS analysis. Unfortunately, the second 
experiment using SELDI-ToF MS failed; the samples produced very low resolution 
spectra and could not be used for marker discovery. Despite extensive research into 
the cause for the low resolution spectra we were not able to resolve the problems and 
SELDI-ToF analysis was therefore abandoned. We know that the samples were of 
good quality as they were subsequently analysed by MALDI-ToF and produced good 
resolution spectra. Analysis of these SI samples on triplicate MALDI spots by 
MALDI-ToF MS resulted in 9 potential markers, of which 4 were visually 
convincing enough to be taken forward.
The results recovered from the SI samples by SELDI-ToF were compared to the 
markers retrieved from the MALDI-ToF MS analysis and encouragingly many o f the 
markers overlap. It can be assumed that markers that are recovered from two 
completely different forms o f analysis should be more convincing and may be 
regarded as a confirmation of the MALDI-ToF results.
The second sample set, S2, provided results with more confidence as three replicate 
UF from each serum sample were carried out before analysis by MALDI-ToF. Using 
alignment with razAlign and Markerview, 16 proteins with significant /^-values were 
detected. Of these, three markers were visually convincing enough to be further 
analysed in addition to four markers from the SI results using tandem MS for protein 
identification. Three markers produced MS/MS spectra with enough fragment ions to 
be matched to a peptide sequence using MASCOT. Of those, two results had an ion 
score with enough confidence to indicate homology to bradykinin and the connecting 
peptide between the A and B chain o f a-2-HS-glycoprotein. However, unfortunately 
no peptide identification was found for the most convincing peptides in the S2 
sample set. The peaks at m/z 8771 and 9647 were statistically the most significant but 
since these peptides were relatively large, no fragmentation spectra were obtained 
from the MS/MS analysis for identification. The most convincing peak from the SI 
data set is m/z 2995 but this peak was not present in the spectra from the S2 samples, 
hence no identification by MS/MS was possible.
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8.4. Data Analysis
Semi-quantitative protein profiling from serum samples had not been published when 
the project was started and so the experiment and in particular the data analysis had 
to be developed from basic principles. Peak alignment proved to be the most 
challenging aspect of the analysis, although this later also proved to be the most 
important factor when comparing multiple spectra from different samples, including 
replicates. The mass accuracy o f the present MALDI-ToF instrument was relatively 
poor and so a wide range o f masses was produced for the same peak from the spectra 
of individual samples. These first had to be aligned in order to be recognized as the 
same peak before they could then be used to calculate intensity changes. A program, 
later called wzAlign, was written in VBA for Excel to combine the masses from the 
peaks across all spectra into one reference mass list. A second sequence of the 
program aligned the peak intensities for the same peak across all spectra. To avoid 
misalignment, the mass tolerance was checked and could be adjusted in the program. 
This proved to be invaluable and one of the greatest advantages o f mzAlign over 
other commercially-available options. For example Markerview, supplied by Applied 
Biosystems, that became available later in the study (2006), was tested and compared 
to mzAlign. The application is very similar, creating a reference mass list and then 
aligning the peak intensities from across the spectra in one datasheet. Markerview 
provides more sophisticated visualization options for control o f peak alignment than 
wzAlign, but the mass tolerance for individual peaks cannot be altered, which was a 
disadvantage, resulting in some peaks being wrongly aligned from distinct peaks in 
the spectra or false peaks created. Additionally, statistical analysis using a /-test and 
principal component analysis (PCA) are possible. However using the /-test, p-values 
were found to be calculated for peaks that were not present in one o f the cohorts. 
This is statistically impossible; hence we did not use this function, but instead 
exported the aligned results into Excel to perform statistical analysis there. 
Furthermore, because o f the great variation in the results with a large number of 
missing values for each peak across all spectra, PCA analysis was not possible. In 
Markerview the scatter plots showed too much variation across principal component
1. In Excel, however, the average o f all replicates (biological and technical) for each 
patient sample could be calculated and in this way we were able to reduce the 
variation greatly. This average was then used to calculate ^-values in Excel and to 
perform PCA analysis using SIMCA-P from Umetrics (Windsor, UK). The scatter
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plot here showed that the breast cancer and control samples clustered in distinct 
groups although a lot of variation was still present.
Visual inspection of the discriminant peaks also proved to be paramount, as the peak 
intensity variation was great and significantly different results could result from 
single outliers. This was also described by Villanueva et al. [28, 29]; this group was 
the first to publish quantitative data o f serum profiling by MALDI-ToF MS. For peak 
alignment this group used the GeneSpring analysis platform (Agilent Technologies 
UK Limited, Stockport, UK), which was originally designed for microarray analysis. 
In one o f their more recent papers, a new algorithm for peak alignment was also 
proposed [28]. This program enables the user to visualise aligned peaks by 
overlaying them, very similar to what was possible in the SELDI-ToF software and 
the overlaid spectra look like those shown in Chapter 6. Ideally /wzAlign could be 
improved to contain an option for alignment visualisation in this way.
Furthermore, our analysis method could be generalized for many diagnostic and 
predictive purposes, as an in vitro phenotypic readout o f catalytic and metabolic 
activities in body fluids or tissues, utilizing either endogenous substrates or measured 
quantities o f externally assed isotopic labelled substrates followed by quantitative 
analysis.
8.5. LC-MS/MS
Shot-gun proteomics has been practiced successfully for a while now for 
identification of many proteins from serum, and is being used to identify more and 
more protein from biofluids, cells and tissue. However quantitative profiling studies 
have mainly been carried out using isotopically-labelled samples. Nevertheless label- 
free quantitation using peak intensities has been proposed in a number of studies 
which tested the application using standards [30, 31]. We therefore attempted label- 
free quantitative analysis using tryptic digest of the S 1 samples. The new version of 
Bioworks 3.2 has been designed to be able to quantitate peptides using the peak area 
of each peptide from LC-MS spectra. An experiment using standard peptides spiked 
into serum quickly revealed that a high resolution iontrap MS would be necessary for
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such analysis, as well as an instrument with a fast scan rate to minimise the effect of 
the exclusion time. Due to the exclusion time o f the LCQ, very few peptides were 
analysed by MS/MS, despite a long elution gradient. Better results were achieved 
using manual integration of the peptide peaks in the extracted ion chromatogram 
(XIC) for each of the standard peptides. However this is not possible for complex 
mixtures without the prior knowledge o f the m/z o f the peptides.
In an attempt to find a differentially expressed peptide, small mass ranges were 
selected in XICs and inspected for peaks that had different expression levels between 
the breast cancer and the control cohorts. One peptide was discovered that is 
exclusively present in the breast cancer samples, and is completely absent in the 
controls.
It was decided that for relative quantitation, more sophisticated algorithms are 
required for normalization and to calculate differences while taking into account 
variation. Especially where a large number o f replicates per sample is required. A 
number of algorithms are available commercially, such as the DeCyder MS 
Differential Analysis Software (GE Healthcare, UK) or Progenesis from Nonlinear 
Dynamics (Newcastle upon Tyne, UK), to name only a few. Johansson et al. [32] 
published a study successfully comparing levels o f integrase in E.coli using DeCyder 
MS for automated detection and relative quantitation o f unlabelled peptides in LC- 
MS/MS data. DeCyder MS generates 2D representations o f the peptide patterns from 
individual LC-MS/MS analyses which can then be matched and compared. The use 
of other algorithms has also been published for peak area comparison, such as Q- 
MEND [33].
For future research it would be useful to develop a software tool, similar to mzAlign, 
to automatically integrate all peaks in the spectra, normalize them and adjust the 
mass alignment. However, unless all samples were analysed in full scan mode, an 
instrument with a faster scan rate would be required to obtain reproducible peptide 
identifications from tandem MS spectra.
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8.6. Future Prospects
If more time had been available to take the project further there are various routes 
that could have been followed. For protein/peptide identification of potential 
markers, proteins could be isolated by SDS-PAGE or selective chromatography and 
identified through tryptic digests and peptides fingerprinting. To qualify as a useful 
marker, each protein would then have to be validated by Western blotting or ELISA 
for these where antibodies are available; otherwise antibodies could be raised. 
Additionally, it would be interesting to see if  the markers are also present in tissue 
rather than serum by paraffin immunohistochemistry staining or tissue microarrays 
and if the identified proteins were differentially present in tumour and normal tissue. 
Furthermore these markers could then be quantitated in serum from patients with 
other cancer types to see if  they are indicators for breast cancer specifically, and 
finally, if  they occur in metastatic cancers only or could be found in serum from 
patients with early stage disease.
In conclusion the use o f multiple MS platforms for biomarker discovery from breast 
cancer serum samples has highlighted the advantages and limitations of the current 
technology. The minimum requirements for a protein profiling platform suitable for 
biomarker discovery in a clinical setting, as summarized by Qian et al. [34] are (i) a 
high dynamic range to detect low abundance proteins (ii) high confidence protein 
identifications; (iii) accurate quantitation for relative protein abundances across 
different sample groups and between replicates; (iv) high-throughput that allows 
analysis of large sample numbers to provide sufficient statistical power to address 
biological variation and, finally, (v) comprehensive informatics software for data 
mining and statistical analysis. At the moment, no single one of the platforms in use 
can meet all o f these requirements for effective biomarker discovery. This therefore 
re-emphasises the need for the use of multiple platforms on the same sample set as 
was carried out in this thesis.
Development o f a standardised method for sample collection, preparation and 
handling is also crucial for serum proteome analysis. In our study, UF appeared to be 
an effective means to unmask low abundant proteins in serum. Quantitative MS 
analysis was achieved using a combination of SELDI-ToF, MALDI-ToF and LC- 
MS. However for identification of potential markers, the proteins need to be isolated
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in order to do peptide fingerprinting. Further improvements in technology will be 
necessary for biomarker discovery, especially to allow more high-throughput 
analysis. Unlike genomic analysis using microarrays, proteomics is far more 
complicated and encompasses too many options, as evidenced by the results from 
this thesis. It is critical to increase the ease o f use, throughput, speed and accuracy of 
currently available proteomics techniques to allow their more general use in a 
clinical setting. For example for more high-throughput analysis during identification 
of markers, and for label-free LC-MS quantitation, the samples were trypsin 
digested, which required a 24 hour protocol. To increase the speed o f analysis this 
step could be optimized.
The use o f microwave-assisted trypsin digestion as reported by Juan et al. [35] and 
Sun et al. [36], can improve enzymatic digestion and enable a more high-throughput 
protocol for peptide profiling experiments. Although not reported in the results, the 
efficiency o f trypsin digestion at different times in the microwave was compared 
with 6 hour-, and the most commonly used 16 hour-digestion at 37°C, without the 
use of the microwave. The results showed that overnight digestion at 37°C was 
inferior to the other methods, but a 30 min treatment of the proteins in the microwave 
produced superior results. This experiment was performed after all other experiments 
were completed. However, in any future experiments, I would perform a microwave- 
assisted trypsin digestion, to achieve better peptide coverage and increased 
experimental throughput.
As a take home message, quantitation of intact proteins using MALDI-ToF MS was 
successful using the LMW sub-proteome, however a larger number o f technical 
replicates is required for biomarker discovery. In the future I would prepare each 
serum sample in triplicate by UF and then analyse each replicate again in triplicate 
using MALDI-ToF MS analysis. For data mining, the use o f wzAlign or Markerview 
allows fast and effective alignment and analysis o f a large dataset. Markers were 
detected easily but still had to be confirmed by visual inspection of the spectra. A 
visualisation tool such as the software described by Villanueva et al. [28] would be 
beneficial, to overlay and inspect all spectra for a particular peak at once. For small 
peptides, the MALDI-ToF target plate should be saved to perform further MS/MS 
analysis on the spots containing discriminating peaks directly for identification. The
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use o f LC-MS/MS for label-free quantitation of peptides appears to be promising but 
is limited by the type of instrument used and more sophisticated alignment 
algorithms are necessary to compare multiple samples and their replicates.
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